<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="EN" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Mol Pharm</journal-id><journal-id journal-id-type="iso-abbrev">Mol Pharm</journal-id><journal-id journal-id-type="pmc-domain-id">822</journal-id><journal-id journal-id-type="pmc-domain">acssd</journal-id><journal-id journal-id-type="publisher-id">mp</journal-id><journal-title-group><journal-title>Molecular Pharmaceutics</journal-title></journal-title-group><issn pub-type="ppub">1543-8384</issn><issn pub-type="epub">1543-8392</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>ACS AuthorChoice</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11615947</article-id><article-id pub-id-type="pmcid-ver">PMC11615947.1</article-id><article-id pub-id-type="pmcaid">11615947</article-id><article-id pub-id-type="pmcaiid">11615947</article-id><article-id pub-id-type="pmid">39478434</article-id><article-id pub-id-type="doi">10.1021/acs.molpharmaceut.4c00692</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group><subject>Review</subject></subj-group></article-categories><title-group><article-title>Therapeutic Immunomodulation of Tumor-Lymphatic Crosstalk
via Intratumoral Immunotherapy</article-title></title-group><contrib-group><contrib contrib-type="author" id="ath1"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-3281-8398</contrib-id><name name-style="western"><surname>Lucas</surname><given-names initials="SN">Samuel
N.</given-names></name><xref rid="aff1" ref-type="aff">&#8224;</xref></contrib><contrib contrib-type="author" corresp="yes" id="ath2"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-4651-232X</contrib-id><name name-style="western"><surname>Thomas</surname><given-names initials="SN">Susan N.</given-names></name><xref rid="cor1" ref-type="other">*</xref><xref rid="aff1" ref-type="aff">&#8224;</xref><xref rid="aff2" ref-type="aff">&#8225;</xref><xref rid="aff3" ref-type="aff">&#167;</xref><xref rid="aff4" ref-type="aff">&#8741;</xref></contrib><aff id="aff1"><label>&#8224;</label>Wallace
H. Coulter Department of Biomedical Engineering, <institution>Georgia Institute of Technology and Emory University</institution>, Atlanta, Georgia 30332, <country>United States
of America</country></aff><aff id="aff2"><label>&#8225;</label>George
W. Woodruff School of Mechanical Engineering, <institution>Georgia Institute of Technology</institution>, Atlanta, Georgia 30332, <country>United States of America</country></aff><aff id="aff3"><label>&#167;</label>Parker
H. Petit Institute for Bioengineering and Bioscience, <institution>Georgia Institute of Technology</institution>, Atlanta, Georgia 30332, <country>United States of America</country></aff><aff id="aff4"><label>&#8741;</label>Winship
Cancer Institute, <institution>Emory University</institution>, Atlanta, Georgia 30322, <country>United States
of America</country></aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>E-mail: <email>susan.thomas@gatech.edu</email>.</corresp></author-notes><pub-date pub-type="epub"><day>31</day><month>10</month><year>2024</year></pub-date><pub-date pub-type="collection"><day>02</day><month>12</month><year>2024</year></pub-date><volume>21</volume><issue>12</issue><issue-id pub-id-type="pmc-issue-id">476317</issue-id><fpage>5929</fpage><lpage>5943</lpage><history><date date-type="received"><day>02</day><month>07</month><year>2024</year></date><date date-type="accepted"><day>17</day><month>10</month><year>2024</year></date><date date-type="rev-recd"><day>16</day><month>10</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>04</day><month>12</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>05</day><month>12</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-12-05 10:25:22.663"><day>05</day><month>12</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2024 The Authors. Published by American Chemical Society</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>The Authors</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="mp4c00692.pdf"/><abstract><p content-type="toc-graphic"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="ab-tgr1" position="float" orientation="portrait" xlink:href="mp4c00692_0004.jpg"/></p><p>Intra- and peritumoral
lymphatics and tumor-draining lymph nodes
play major roles in mediating the adaptive immune response to cancer
immunotherapy. Despite this, current paradigms of clinical cancer
management seldom seek to therapeutically modulate tumor-lymphatic
immune crosstalk. This review explores recent developments that set
the stage for how this regulatory axis can be therapeutically manipulated,
with a particular emphasis on tumor-localized immunomodulation. Building
on this idea, the nature of tumor-lymphatic immune crosstalk and relevant
immunotherapeutic targets and pathways are reviewed, with a focus
on their translational potential. Engineered drug delivery systems
that enhance intratumoral immunotherapy by improving drug delivery
to both the tumor and lymph nodes are also highlighted.</p></abstract><kwd-group><kwd>sentinel lymph node</kwd><kwd>lymphatics</kwd><kwd>immune crosstalk</kwd><kwd>cancer immunotherapy</kwd><kwd>drug delivery</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution>National Institutes of Health</institution><institution-id institution-id-type="doi">10.13039/100000002</institution-id></institution-wrap></funding-source><award-id>R01CA207619</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution>National Institutes of Health</institution><institution-id institution-id-type="doi">10.13039/100000002</institution-id></institution-wrap></funding-source><award-id>T32GM008433</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution>National Institutes of Health</institution><institution-id institution-id-type="doi">10.13039/100000002</institution-id></institution-wrap></funding-source><award-id>R01HL173943</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution>National Institutes of Health</institution><institution-id institution-id-type="doi">10.13039/100000002</institution-id></institution-wrap></funding-source><award-id>R01CA247484</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta><custom-meta><meta-name>document-id-old-9</meta-name><meta-value>mp4c00692</meta-value></custom-meta><custom-meta><meta-name>document-id-new-14</meta-name><meta-value>mp4c00692</meta-value></custom-meta><custom-meta><meta-name>ccc-price</meta-name><meta-value/></custom-meta></custom-meta-group></article-meta><notes id="spn1"><title>Special Issue</title><p>Published
as part of <italic toggle="yes">Molecular Pharmaceutics</italic><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/curated-content?journal=mpohbp&amp;ref=feature">special issue</ext-link> &#8220;Intratumoral Immunotherapy with
Nanoparticles&#8221;.</p></notes></front><body><sec id="sec1"><label>1</label><title>Introduction</title><p>Sentinel lymph node (SLN)
status has been a mainstay of clinical
cancer diagnoses and prognoses for the better part of a century; only
more recently have the numerous regulatory roles that the crosstalk
between the tumor microenvironment and the lymphatic system play in
disease progression come into focus.<sup><xref ref-type="bibr" rid="ref1">1</xref>&#8722;<xref ref-type="bibr" rid="ref3">3</xref></sup> These roles include not
only providing a pathway for spread of disease from regional to systemic
but also developing an antitumor adaptive immune response, facilitated
by peritumoral lymphatics, locally as well as in tumor-draining lymph
nodes (TDLNs), that is necessary for tumor immune surveillance and
elimination.<sup><xref ref-type="bibr" rid="ref1">1</xref>,<xref ref-type="bibr" rid="ref4">4</xref>,<xref ref-type="bibr" rid="ref5">5</xref></sup> Critically,
these TDLNs are sites where systemically active immune responses can
be modulated. Tumors can also coopt immune regulatory pathways to
modulate immune activity in the TDLN and peritumoral lymphatics in
order to evade immune surveillance and destruction.<sup><xref ref-type="bibr" rid="ref6">6</xref></sup> These immune regulatory effects are important factors limiting
the effects of cancer immunotherapies. The transformative success
of immunotherapies in the past decade thus stands to further benefit
from expanding targets to include those implicated in tumor-lymphatic
immune crosstalk.<sup><xref ref-type="bibr" rid="ref7">7</xref>&#8722;<xref ref-type="bibr" rid="ref9">9</xref></sup></p><p>The clinical advances in cancer immunotherapy
have been accompanied
by an explosion of preclinical and clinical investigations into new
immunotherapeutic modalities and targets. Yet most immunotherapies
currently in clinical use continue to be administered systemically,
despite the nature of the adaptive immune system allowing localized
immune education that yields systemic immunity. Systemically administered
therapies have relatively poor access to the tumor. Even purportedly
tumor-targeting antibodies such as antibody-drug conjugates (ADCs)
see less than 1% of the administered dose reach the tumor following
intravenous injection.<sup><xref ref-type="bibr" rid="ref10">10</xref>,<xref ref-type="bibr" rid="ref11">11</xref></sup> Access to peritumoral lymphatics,
SLNs, and TDLNs from systemic administration is even poorer, making
it easy to understand how therapeutic immunomodulation within the
regional lymphatic bed of solid tumors has long been overlooked. A
potential solution to improving the accumulation of therapeutic payload
in both tumors and their lymphatic basins is suggested by a commonly
used diagnostic technique: SLN mapping is routinely achieved by intratumoral
or peritumoral injection of contrast agent. Treating solid tumors
regionally can allow high levels of drug delivery to tumors and TDLNs
as an alternative to systemic administration. In the context of immunotherapy,
such approaches could modulate both local immunity (in the tumor)
and systemic immunity (via the TDLNs), not only controlling the treated
tumor but also generating systemic control of disease despite the
treatment being regionally applied. Indeed, such a therapeutic strategy
may be key to overcoming the historical failure of intratumoral therapy
in adequately treating distant metastases.</p><p>Developments in diagnostic
techniques and treatment protocols in
recent years increasingly fortify the relevance of peritumoral lymphatics
and the SLN as therapeutic targets. For example, lymphatic mapping,
which uses a tracer to identify the LN(s) draining a tumor basin,
is an ever more widely used diagnostic tool that could also plausibly
enable deliberate therapeutic targeting of the SLN. Complete LN dissection
(CLND), which is the preemptive surgical removal of all LNs locoregional
to an identified tumor, has dramatically decreased in prevalence due
to mounting evidence that routine CLND does not benefit most patients.
For example, randomized phase 3 clinical trials in melanoma have indicated
no difference in survival for patients with SLN metastasis who receive
CLND compared to observation.<sup><xref ref-type="bibr" rid="ref12">12</xref>,<xref ref-type="bibr" rid="ref13">13</xref></sup> Similarly, despite
its potential diagnostic value, even routine SLN biopsy (SLNB) has
not resulted in significantly improved disease-specific survival versus
observation in melanoma or breast cancer.<sup><xref ref-type="bibr" rid="ref14">14</xref>&#8722;<xref ref-type="bibr" rid="ref16">16</xref></sup> As such, debate
continues over whether LN metastasis occurs in advance or concurrently
with systemic metastasis. Thus, now and looking to the future, more
LNs are being left in patients post diagnosis, offering unique, heretofore
untapped opportunities for immunomodulation.</p><p>In parallel to
changes in clinical practices around LN management/removal,
treatment paradigms have changed (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>).<sup><xref ref-type="bibr" rid="ref17">17</xref></sup> The early
as well as more recent immunotherapies were all first approved in
the adjuvant setting (given after tumor resection/main treatment).
However, immunotherapies have been increasingly shown to demonstrate
even greater potency in the neoadjuvant setting (given before tumor
resection/main treatment).<sup><xref ref-type="bibr" rid="ref18">18</xref>&#8722;<xref ref-type="bibr" rid="ref21">21</xref></sup> Unlike neoadjuvant cytotoxic chemotherapy, which
has as its primary advantage the ability to debulk a tumor to enable
surgery, neoadjuvant immunotherapy takes advantage of increased tumor
antigen presence to enable a more potent immune response prior to
surgery that persists after primary tumor resection. As one example,
neoadjuvant immunotherapy with the immune checkpoint inhibitors ipilimumab
and nivolumab resulted in greater expansion of tumor-related T cell
clonotypes in peripheral blood than seen with adjuvant immunotherapy
in the OpACIN clinical trial.<sup><xref ref-type="bibr" rid="ref22">22</xref></sup></p><fig id="fig1" position="float" orientation="portrait"><label>Figure 1</label><caption><p>Evolving clinical
paradigms increasingly leave tumor and lymphatics
intact at the time of first immunotherapeutic treatment, creating
opportunities for intratumoral immunotherapy. The following examples
are based primarily around changes in melanoma treatment paradigms
but are emblematic of changes more broadly in cancer treatment as
well. Representative examples of A) the established paradigm for surgery
and immunotherapy sequencing including CLND/SLNB; B) the emerging
paradigm for surgery and immunotherapy sequencing with adjuvant options
dependent on neoadjuvant response; C) opportunities for intratumoral
immunotherapy to interface with the emerging immunotherapeutic paradigm
by modulating tumor-lymphatic crosstalk.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="gr1" position="float" orientation="portrait" xlink:href="mp4c00692_0001.jpg"/></fig><p>Taken together, over a widening number of cancer types and stages,
there is an increasing number of immunotherapy-eligible patients who
may possess a primary tumor at the time of the first immunotherapeutic
treatment and retain at least some degree of intact lymphatic vasculature
and TDLNs. Tumor-lymphatic crosstalk is thus clinically relevant not
only in terms of disease progression (e.g., metastasis) but also for
therapeutic manipulation of the ongoing antitumor immune response.
Deliberate modulation of this crosstalk has the potential to generate
therapeutic responses both locally and systemically to control both
treated lesions and untreated metastases. In this light, this review
will elaborate on the nature and qualities of immune system crosstalk
facilitated by the tumor-lymphatic tissue interface, detail therapeutically
actionable strategies related to these pathways, and highlight opportunities
for engineered drug delivery systems to favorably manipulate this
crosstalk in the context of intratumoral immunotherapy to improve
treatment efficacy and therapeutic outcomes. Previous cancer immunotherapy
reviews have discussed the biology of immune cell crosstalk in the
tumor, therapeutic pathways for intratumoral immunotherapy, the biology
of immune cell crosstalk in the TDLN, and possibilities for TDLN-targeted
immunotherapy, but these areas have generally been considered as largely
distinct domains rather than viewed as part of a unified tumor/lymphatic
therapeutic strategy.<sup><xref ref-type="bibr" rid="ref1">1</xref>,<xref ref-type="bibr" rid="ref6">6</xref>,<xref ref-type="bibr" rid="ref23">23</xref>,<xref ref-type="bibr" rid="ref24">24</xref></sup> Similarly, while previous reviews on drug
delivery have discussed possibilities for engineered drug delivery
systems to mitigate toxicities from intratumoral immunotherapy, to
improve therapeutic retention, and to engineer therapeutic delivery
to the TDLN, they have not explicitly connected these important questions
to an overall goal of simultaneous therapeutic immunomodulation of
the tumor and lymphatic system.<sup><xref ref-type="bibr" rid="ref25">25</xref>&#8722;<xref ref-type="bibr" rid="ref29">29</xref></sup> This review synthesizes the emerging clinical immunotherapeutic
paradigm with the rationale for therapeutic modulation of the tumor
and lymphatic system, key pathways with potential for simultaneous
modulation in the tumor and tumor-associated lymphatics/TDLNs, and
modalities and drug delivery technologies relevant to these shared
key pathways as a strategy for improving the treatment efficacy and
therapeutic outcomes of intratumoral immunotherapy.</p></sec><sec id="sec2"><label>2</label><title>Tumor-Lymphatic Immune Crosstalk</title><p>TDLNs, especially but not
limited to the SLN(s), play a critical
role in the establishment and maintenance of antitumor immunity (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>). Lymph containing
tumor antigen as well as other tumor-derived factors continuously
drain from the tumor microenvironment and surrounding tissue interstitium
via lymphatic capillaries to TDLNs. There, APCs such as dendritic
cells (DCs) that reside in the LN sample lymph-draining antigen for
processing into peptides and presentation on major histocompatibility
complex (MHC) molecules. Alternatively, migratory DCs take up antigens
in the tumor microenvironment before migrating to the TDLN via lymphatic
vessels. DCs presenting tumor antigen can then interact with T cells
to present antigen for T cell priming as well as providing important
secondary signals such as costimulation through the CD28-B7 axis and
proinflammatory cytokines to initiate effective T cell activation
and proliferation.<sup><xref ref-type="bibr" rid="ref30">30</xref>&#8722;<xref ref-type="bibr" rid="ref32">32</xref></sup> Critically, this behavior appears restricted to TDLNs,
as recent work has demonstrated that, while T cells can differentiate
in the tumor via interacting with APC niches there, tumor-reactive
T cells undergo priming and clonal expansion in the TDLNs but not
substantially in the tumor or in other lymphoid tissues such as noninvolved
lymph nodes or the spleen.<sup><xref ref-type="bibr" rid="ref33">33</xref>,<xref ref-type="bibr" rid="ref34">34</xref></sup> Because TDLNs are the
primary sites for tumor-reactive T cell activation and expansion,
they form the primary reservoir from which antigen-experienced tumor-reactive
T cells enter the bloodstream and traffic to the tumor microenvironment,
enabling tumor control. Notably, this characteristic of TDLNs is directly
impacted by upstream lymphatic function: research in both mice and
humans has linked higher relative lymphatic gene expression in the
tumor to increased tumor infiltration by lymphocytes.<sup><xref ref-type="bibr" rid="ref2">2</xref>,<xref ref-type="bibr" rid="ref35">35</xref></sup></p><fig id="fig2" position="float" orientation="portrait"><label>Figure 2</label><caption><p>Tumor-lymphatic
immune crosstalk involves an interplay between
antitumor and pro-tumor immune effects in the lymphatics and TDLNs.
TDLNs facilitate an intersection between tumor antigen, DCs, and T
cells, promoting antitumor effects including tumor-reactive T cell
priming and the formation and maintenance of an immunotherapy-responsive
stem-like T cell niche (bottom right). These effects translate to
antitumor effects within the tumor itself, culminating in effective
cancer cell killing. At the same time, tumors can coopt lymphatics
and TDLNs in order to orchestrate pro-tumor effects, increasing immune
checkpoint expression and suppressive cytokine secretion as well as
promoting DC dysfunction and T cell anergy, resulting ultimately in
tumor escape (top left).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="gr2" position="float" orientation="portrait" xlink:href="mp4c00692_0002.jpg"/></fig><p>TDLNs are also notable
in that they maintain an immunotherapy-responsive
T cell pool. Seminal work from multiple groups has demonstrated that
stem-like CD8+ T cells, an antigen-experienced CD8+ T cell subset
that retains the capacity for both self-renewal and further differentiation,
are the primary CD8+ T cell subset that responds to therapeutic immune
checkpoint blockade (ICB).<sup><xref ref-type="bibr" rid="ref36">36</xref>&#8722;<xref ref-type="bibr" rid="ref38">38</xref></sup> Subsequent work has demonstrated
that a niche of these stem-like CD8+ T cells is maintained in TDLNs
throughout tumor progression, in part due to the role played by migratory
DCs transiting from the tumor microenvironment to the lymph node via
the peritumoral lymphatics.<sup><xref ref-type="bibr" rid="ref39">39</xref>,<xref ref-type="bibr" rid="ref40">40</xref></sup></p><p>TDLNs have also
been implicated in mediating the immune response
to and the abscopal effect generated by tumor-directed radiotherapy,
which can in some ways be thought of as a classical example of intratumoral
therapy. For example, tumor-directed radiotherapy has been shown preclinically
to generate an abscopal effect that correlates with enhanced CD8+
T cell proliferation in the TDLN, but only if the TDLN itself is spared
irradiation.<sup><xref ref-type="bibr" rid="ref41">41</xref></sup> The generation of potent
immune responses in TDLNs, then, is important for eliciting systemic
immunity and treating distant tumors. Similar findings have corroborated
this in humans, with an immunostimulatory effect observed in the TDLN
in response to low-dose radiation which is abrogated when using high-dose
radiation.<sup><xref ref-type="bibr" rid="ref42">42</xref></sup> This implies that an enhanced
antitumor immune response to intratumoral immunotherapy is to some
degree contingent upon intact peritumoral lymphatics and TDLNs.</p><p>Despite the critical roles played by the TDLNs and peritumoral
lymphatics in generating and maintaining the antitumor immune response,
the presence of a tumor exerts substantial suppressive effects on
the lymphatics and on TDLNs (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>). One well-documented mechanism for this is the way
in which tumors can bias DCs toward a tolerogenic phenotype, resulting
in dysfunctional or anergic T cell priming in the TDLN. For example,
in both mice and humans, tumor-derived soluble factors such as transforming
growth factor beta (TGF-&#946;) and prostaglandin E2 (PGE2) reduce
MHC and costimulatory ligand expression and enhance immune checkpoint
ligand expression on DCs in the TDLN.<sup><xref ref-type="bibr" rid="ref43">43</xref>,<xref ref-type="bibr" rid="ref44">44</xref></sup> This has functional
consequences for T cell antitumor activity including increased CD8+
T cell anergy and induction of suppressive CD4+ regulatory T cells
(T<sub>reg</sub>s).<sup><xref ref-type="bibr" rid="ref45">45</xref>,<xref ref-type="bibr" rid="ref46">46</xref></sup> The immunosuppressive cytokine
IL-10 is also known to be increased in TDLNs with downstream consequences
for TDLN-resident APCs such as reduced costimulatory ligand expression
and downregulation of proinflammatory cytokines like IL-12.<sup><xref ref-type="bibr" rid="ref47">47</xref></sup> Similarly, tumor-derived M-CSF, GM-CSF, and
IL-6 promote myeloid-derived suppressor cell (MDSC) recruitment to
and expansion in the TDLN.<sup><xref ref-type="bibr" rid="ref48">48</xref></sup></p><p>In addition
to suppressive effects exerted by the tumor on APCs,
tumor presence can act on T cells without intermediaries in order
to inhibit T cell function and promote suppressive T cell phenotypes
in the TDLN. In addition to its well-documented effects on APCs, tumor-derived
TGF-&#946; can also directly inhibit T cell differentiation and function.<sup><xref ref-type="bibr" rid="ref49">49</xref>,<xref ref-type="bibr" rid="ref50">50</xref></sup> Furthermore, the TDLN sees preferential differentiation of tumor
antigen-specific CD4+ T cells into T<sub>reg</sub>s over effector
T cells, even at early stages of tumor growth.<sup><xref ref-type="bibr" rid="ref51">51</xref></sup> Perhaps most notoriously, tumor presence is associated
with increased expression of immune checkpoints in the TDLN. Upregulation
of the immune checkpoints programmed cell death protein (PD) 1 and
programmed death ligand (PD-L) 1 on immune cells in the TDLN compared
to other tissues and consequent increases in immune suppression of
T cell function have been extensively demonstrated.<sup><xref ref-type="bibr" rid="ref7">7</xref>,<xref ref-type="bibr" rid="ref52">52</xref></sup> Interaction
between PD-1 on T cells with its ligands, PD-L1 (expressed on a wide
variety of cells including APCs and cancer cells) and PD-L2 (expressed
primarily on APCs) affects T cell signaling downstream of the T cell
receptor (TCR) and costimulatory receptor CD28 to promote T cell inhibition
as well as disrupting TCR-CD8 cooperativity during antigen recognition.<sup><xref ref-type="bibr" rid="ref53">53</xref>,<xref ref-type="bibr" rid="ref54">54</xref></sup> Similarly, cytotoxic T lymphocyte associated protein 4 (CTLA-4),
which limits T cell activation by outcompeting CD28 for costimulatory
ligand binding, is upregulated in the TDLN. Whereas PD-1/PD-L interactions
suppress T cell function in both the TDLN and the TME, CTLA-4 is understood
to be primarily active in the TDLN due to its role in regulating T
cell priming.<sup><xref ref-type="bibr" rid="ref55">55</xref></sup> Additional research has
shown increased expression of other immune checkpoints in the TDLN
as well, such as lymphocyte activation gene 3 (LAG-3), which prevents
CD4+ T cells from interacting efficiently with MHC-II.<sup><xref ref-type="bibr" rid="ref55">55</xref>,<xref ref-type="bibr" rid="ref56">56</xref></sup></p><p>Beyond merely exerting effects on immune cells in the TDLN,
tumors
can also modulate the lymphatic endothelial cells (LECs) that make
up lymphatic vessels and LN sinuses through diverse mechanisms to
decrease antitumor immune activity. Part of this modulation involves
the induction of passive mechanisms of immune suppression or tolerance.
For example, while LECs constitutively express PD-L1 as part of their
role in maintaining immune homeostasis, PD-L1 is upregulated in tumor-associated
lymphatic vessels in comparison with nonassociated lymphatic vessels
with the result that T cells interacting with these vessels are suppressed.<sup><xref ref-type="bibr" rid="ref57">57</xref></sup> LECs can also be coopted to play an active role
in tumor-induced immune suppression: tumor-derived vascular endothelial
growth factor C (VEGF-C) induces LECs in the TDLN to promote the deletion
of tumor antigen-specific CD8+ T cells.<sup><xref ref-type="bibr" rid="ref58">58</xref></sup> LECs can affect T cell behavior once T cells have migrated to a
tumor site, as well. Multiple groups have demonstrated that, in mice,
T cells can continuously egress the tumor via peritumoral lymphatics
to the TDLN.<sup><xref ref-type="bibr" rid="ref59">59</xref>,<xref ref-type="bibr" rid="ref60">60</xref></sup> Recent investigation into this
phenomenon has shown that the LECs that comprise peritumoral lymphatics
upregulate CXCL12, influencing how different qualities of T cell are
either retained at the tumor site or induced to egress the tumor.<sup><xref ref-type="bibr" rid="ref61">61</xref></sup></p><p>The importance of the TDLN and peritumoral
lymphatics in mediating
both pro-tumor and antitumor immune activity motivates the use of
therapeutic approaches that modulate these pathways. Because intratumoral
immunotherapy can simultaneously enable greater drug accumulation
in the tumor and increase drug access to the tumor lymphatic basin
compared to systemic administration, it has a unique potential to
simultaneously modulate tumor-lymphatic crosstalk in the tumor, peritumoral
lymphatics, and TDLN.</p></sec><sec id="sec3"><label>3</label><title>Therapeutically Relevant
Targets and Pathways
for Intratumoral Immunotherapy</title><sec id="sec3.1"><label>3.1</label><title>Oncolytic Viruses</title><p>To date, oncolytic
viruses are the only intratumoral immunotherapy to receive FDA approval,
making them particularly worthy of discussion here. Oncolytic viruses
infect and kill cancer cells, inducing immunogenic cell death and
releasing tumor antigen and damage-associated molecular patterns (DAMPs),
as well as pathogen-associated molecular patterns (PAMPs) from the
virus itself, to spur an antitumor immune response.<sup><xref ref-type="bibr" rid="ref62">62</xref></sup> Talimogene laherparepvec (T-VEC) is an oncolytic herpes
virus that transduces infected cells with a gene encoding the cytokine
GM-CSF in order to enhance DC recruitment to and maturation within
the tumor and is cleared for intratumoral treatment of recurrent unresectable
cutaneous, subcutaneous, and nodal melanomas in the adjuvant setting.
More recently, T-VEC has also been investigated in the neoadjuvant
setting, demonstrating somewhat improved relapse-free and overall
survival vs resection alone (<xref rid="tbl1" ref-type="other">Table <xref rid="tbl1" ref-type="other">1</xref></xref>).<sup><xref ref-type="bibr" rid="ref63">63</xref></sup> The success of T-VEC
has inspired extensive clinical efforts toward oncolytic viruses,
and T-VEC itself may hold important design cues for subsequent effective
oncolytic viruses. Notably, the therapeutic effects seen in response
to T-VEC are likely due to a combination of immunogenic cell death
and other immunomodulatory effects rather than direct viral cancer
cell killing.<sup><xref ref-type="bibr" rid="ref64">64</xref></sup> Investigations into patients
receiving T-VEC showed that frequencies of suppressive T<sub>reg</sub>s and MDSCs were decreased in treated lesions compared to nontreated
lesions and that nontreated lesions had increased infiltration by
CD8+ T cells post-treatment, suggestive of local and potentially also
systemic antitumor immune responses.<sup><xref ref-type="bibr" rid="ref65">65</xref>,<xref ref-type="bibr" rid="ref66">66</xref></sup> However, T-VEC
has not yet been shown to significantly improve overall survival vs
standard of care or have clinically significant effects on distant
metastases to tissues such as the lung or the liver.<sup><xref ref-type="bibr" rid="ref67">67</xref></sup> Despite this, as the only FDA-approved intratumoral immunotherapy,
it sets a reasonable threshold for efficacy that other intratumoral
immunotherapies must meet if not exceed.</p><table-wrap id="tbl1" position="float" orientation="portrait"><label>Table 1</label><caption><title>Selected
Recent Neoadjuvant Intratumoral
Immunotherapy Clinical Trials</title></caption><table frame="hsides" rules="groups" border="0"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th style="border:none;" align="center" colspan="1" rowspan="1">Trial Number</th><th style="border:none;" align="center" colspan="1" rowspan="1">Trial Stage</th><th style="border:none;" align="center" colspan="1" rowspan="1">Cancer Types</th><th style="border:none;" align="center" colspan="1" rowspan="1">Disease Stage</th><th style="border:none;" align="center" colspan="1" rowspan="1">Intervention</th><th style="border:none;" align="center" colspan="1" rowspan="1">Effect</th></tr></thead><tbody><tr><td style="border:none;" align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02211131">NCT02211131</ext-link></td><td style="border:none;" align="left" colspan="1" rowspan="1">Phase II</td><td style="border:none;" align="left" colspan="1" rowspan="1">Melanoma</td><td style="border:none;" align="left" colspan="1" rowspan="1">Stage III/IV</td><td style="border:none;" align="left" colspan="1" rowspan="1">Oncolytic
virus (T-VEC)</td><td style="border:none;" align="left" colspan="1" rowspan="1">Improved relapse-free and overall survival
vs resection alone</td></tr><tr><td style="border:none;" align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02274155">NCT02274155</ext-link></td><td style="border:none;" align="left" colspan="1" rowspan="1">Phase I</td><td style="border:none;" align="left" colspan="1" rowspan="1">HNSCC</td><td style="border:none;" align="left" colspan="1" rowspan="1">Stage III/IV</td><td style="border:none;" align="left" colspan="1" rowspan="1">aOX40 mAb (MEDI6469)</td><td style="border:none;" align="left" colspan="1" rowspan="1">T cell proliferation in peripheral
blood, increased activated
TILs</td></tr><tr><td style="border:none;" align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02706353">NCT02706353</ext-link></td><td style="border:none;" align="left" colspan="1" rowspan="1">Phase I/II</td><td style="border:none;" align="left" colspan="1" rowspan="1">Melanoma</td><td style="border:none;" align="left" colspan="1" rowspan="1">Stage IV</td><td style="border:none;" align="left" colspan="1" rowspan="1">aCD40 mAb (AMX005M)
with i.v. aPD-1 mAb (pembrolizumab)</td><td style="border:none;" align="left" colspan="1" rowspan="1">Increased antigen
presentation locally, increased T cell activation
and clonal diversity locally and in distant lesions (vs aPD-1 alone)</td></tr><tr><td style="border:none;" align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02379741">NCT02379741</ext-link></td><td style="border:none;" align="left" colspan="1" rowspan="1">Phase I</td><td style="border:none;" align="left" colspan="1" rowspan="1">Solid tumors</td><td style="border:none;" align="left" colspan="1" rowspan="1">Stage IV</td><td style="border:none;" align="left" colspan="1" rowspan="1">aCD40 mAb (mitazalimab)</td><td style="border:none;" align="left" colspan="1" rowspan="1">Increased CD86+ B cells in peripheral blood</td></tr><tr><td style="border:none;" align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06205849">NCT06205849</ext-link></td><td style="border:none;" align="left" colspan="1" rowspan="1">Phase I</td><td style="border:none;" align="left" colspan="1" rowspan="1">Pancreatic
cancer</td><td style="border:none;" align="left" colspan="1" rowspan="1">Stage III</td><td style="border:none;" align="left" colspan="1" rowspan="1">aCD40 mAb (mitazalimab)</td><td style="border:none;" align="left" colspan="1" rowspan="1">Ongoing</td></tr><tr><td style="border:none;" align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02857569">NCT02857569</ext-link></td><td style="border:none;" align="left" colspan="1" rowspan="1">Phase I</td><td style="border:none;" align="left" colspan="1" rowspan="1">Melanoma</td><td style="border:none;" align="left" colspan="1" rowspan="1">Stage IV</td><td style="border:none;" align="left" colspan="1" rowspan="1">aCTLA-4 mAb (ipilimumab) with i.v. aPD-1 mAb (nivolumab)</td><td style="border:none;" align="left" colspan="1" rowspan="1">Lower toxicity i.v. vs i.t., depletion of intratumoral T<sub>regs</sub> for i.t. only</td></tr><tr><td style="border:none;" align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04695977">NCT04695977</ext-link></td><td style="border:none;" align="left" colspan="1" rowspan="1">Phase II/III</td><td style="border:none;" align="left" colspan="1" rowspan="1">Melanoma</td><td style="border:none;" align="left" colspan="1" rowspan="1">Stage III/IV</td><td style="border:none;" align="left" colspan="1" rowspan="1">TLR9 agonist (vidutolimod) with i.v. aPD-1 mAb (nivolumab)</td><td style="border:none;" align="left" colspan="1" rowspan="1">Ongoing</td></tr><tr><td style="border:none;" align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03262103">NCT03262103</ext-link></td><td style="border:none;" align="left" colspan="1" rowspan="1">Phase I</td><td style="border:none;" align="left" colspan="1" rowspan="1">Prostate cancer</td><td style="border:none;" align="left" colspan="1" rowspan="1">Stage I/II</td><td style="border:none;" align="left" colspan="1" rowspan="1">TLR3 agonist (Hiltonol)</td><td style="border:none;" align="left" colspan="1" rowspan="1">Increased TIL density
in resected sample compared to pretreatment
biopsy, TLS formation, increased T cell/NK cell response in peripheral
blood</td></tr><tr><td style="border:none;" align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06343077">NCT06343077</ext-link></td><td style="border:none;" align="left" colspan="1" rowspan="1">Phase II</td><td style="border:none;" align="left" colspan="1" rowspan="1">Prostate cancer</td><td style="border:none;" align="left" colspan="1" rowspan="1">Stage I/II</td><td style="border:none;" align="left" colspan="1" rowspan="1">TLR3
agonist (Hiltonol)</td><td style="border:none;" align="left" colspan="1" rowspan="1">Ongoing</td></tr><tr><td style="border:none;" align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06022029">NCT06022029</ext-link></td><td style="border:none;" align="left" colspan="1" rowspan="1">Phase I</td><td style="border:none;" align="left" colspan="1" rowspan="1">Solid tumors and
lymphomas</td><td style="border:none;" align="left" colspan="1" rowspan="1">Stage III/IV</td><td style="border:none;" align="left" colspan="1" rowspan="1">STING agonist (ONM-501)
with i.v. aPD-1 mAb (cemiplimab)</td><td style="border:none;" align="left" colspan="1" rowspan="1">Ongoing</td></tr><tr><td style="border:none;" align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04799054">NCT04799054</ext-link></td><td style="border:none;" align="left" colspan="1" rowspan="1">Phase I/II</td><td style="border:none;" align="left" colspan="1" rowspan="1">Solid
tumors</td><td style="border:none;" align="left" colspan="1" rowspan="1">Stage III/IV</td><td style="border:none;" align="left" colspan="1" rowspan="1">TLR7/8 agonist (resiquimod)
with i.v. aPD-1 mAb (pembrolizumab)</td><td style="border:none;" align="left" colspan="1" rowspan="1">Ongoing</td></tr><tr><td style="border:none;" align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02076633">NCT02076633</ext-link></td><td style="border:none;" align="left" colspan="1" rowspan="1">Phase II</td><td style="border:none;" align="left" colspan="1" rowspan="1">Melanoma</td><td style="border:none;" align="left" colspan="1" rowspan="1">Stage III/IV</td><td style="border:none;" align="left" colspan="1" rowspan="1">IL-2 and TNF fused to antifibronectin
mAb (Daromun)</td><td style="border:none;" align="left" colspan="1" rowspan="1">Abscopal responses in noninjected lesions</td></tr><tr><td style="border:none;" align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02938299">NCT02938299</ext-link></td><td style="border:none;" align="left" colspan="1" rowspan="1">Phase III</td><td style="border:none;" align="left" colspan="1" rowspan="1">Melanoma</td><td style="border:none;" align="left" colspan="1" rowspan="1">Stage III</td><td style="border:none;" align="left" colspan="1" rowspan="1">IL-2 and TNF fused
to antifibronectin mAb (Daromun)</td><td style="border:none;" align="left" colspan="1" rowspan="1">Improved recurrence-free
survival vs resection alone</td></tr><tr><td style="border:none;" align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03739931">NCT03739931</ext-link></td><td style="border:none;" align="left" colspan="1" rowspan="1">Phase I</td><td style="border:none;" align="left" colspan="1" rowspan="1">Solid tumors and lymphoma</td><td style="border:none;" align="left" colspan="1" rowspan="1">Stage III/IV</td><td style="border:none;" align="left" colspan="1" rowspan="1">mRNA encoding OX40L, IL-23, IL-36y (mRNA-2752)
with i.v. aPD-L1
mAb (durvalumab)</td><td style="border:none;" align="left" colspan="1" rowspan="1">Ongoing</td></tr><tr><td style="border:none;" align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05539157">NCT05539157</ext-link></td><td style="border:none;" align="left" colspan="1" rowspan="1">Phase I</td><td style="border:none;" align="left" colspan="1" rowspan="1">Solid tumors</td><td style="border:none;" align="left" colspan="1" rowspan="1">Solid tumors</td><td style="border:none;" align="left" colspan="1" rowspan="1">mRNA encoding IL-12 (JCXH-211)</td><td style="border:none;" align="left" colspan="1" rowspan="1">Increased T and
NK cell infiltrate in treated lesions, observed
abscopal response in 1 patient</td></tr><tr><td style="border:none;" align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06171750">NCT06171750</ext-link></td><td style="border:none;" align="left" colspan="1" rowspan="1">Phase 1</td><td style="border:none;" align="left" colspan="1" rowspan="1">Solid tumors</td><td style="border:none;" align="left" colspan="1" rowspan="1">Stage III/Stage
IV</td><td style="border:none;" align="left" colspan="1" rowspan="1">Aluminum hydroxide-anchored IL-12</td><td style="border:none;" align="left" colspan="1" rowspan="1">Ongoing</td></tr></tbody></table></table-wrap><p>Clinical investigations
of oncolytic viruses have often neglected
to examine in depth the effects occurring in the SLN (or other TDLNs
if the patient has undergone SLNB) and consequently oncolytic virus
candidates may not be optimized to elicit immunomodulatory effects
in both the tumor and the LN. One possibility to enhance the effects
of oncolytic viruses is to seek to engineer the virus to drive greater
antigen, DAMP, and PAMP release in order to promote a stronger antitumor
immune response both in the tumor and in the TDLN. This can in turn
drive increased DC and T cell recruitment to the treated tumor while
also enhancing antigen and DAMP/PAMP drainage to the TDLN, facilitating
greater T cell priming and increasing the pool of tumor-reactive T
cells with the potential to generate a systemic antitumor T cell response.
Combining an optimized oncolytic virus with other tumor- and TDLN-targeted
approaches such as locoregional ICB might generate substantially improved
therapeutic effects.</p></sec><sec id="sec3.2"><label>3.2</label><title>Immunomodulatory Antibodies</title><sec id="sec3.2.1"><label>3.2.1</label><title>Targeting Immune Checkpoints in the Tumor
and in the TDLN</title><p>Since their development, therapeutic antibodies
have been an important modality for cancer therapy, and their relevance
has increased only since the dawn of ICB therapy as a mainstay of
medical oncology. While their obvious advantages include antigen specificity
and long circulation times due to their ability to engage with neonatal
Fc receptors, an interesting additional feature of therapeutic IgG
monoclonal antibodies (mAbs) relevant to this discussion is that their
size (&#8764;150 kDa) is highly amenable to lymphatic uptake and
drainage to the TDLN via peritumoral lymphatics.<sup><xref ref-type="bibr" rid="ref68">68</xref>,<xref ref-type="bibr" rid="ref69">69</xref></sup> Consequently, targeting T cells in the tumor with intratumoral antibodies
can enable simultaneous targeting of T cells in the TDLN. Interestingly,
ICB mAbs currently marketed as systemic therapies are being reformulated
for locoregional delivery, with a subcutaneous version of the aPD-L1
antibody atezolizumab receiving EMA approval in 2023 after showing
noninferior drug exposure and comparable efficacy and safety to intravenous
atezolizumab and similar results for a subcutaneous version of the
aPD-1 antibody nivolumab.<sup><xref ref-type="bibr" rid="ref70">70</xref>,<xref ref-type="bibr" rid="ref71">71</xref></sup> While these formulations
are administered subcutaneously rather than intratumorally and are
not designed to target TDLNs specifically, they represent a conceptual step toward
the clinical realization of intratumoral antibody administration relevant
to this discussion.</p><p>The rationale for ensuring delivery of ICB
to the TDLN has been extensively validated in recent years. Preclinical
research has demonstrated that the TDLN is primarily responsible for
the initial immune response to ICB (whether aPD-1, aPD-L1, or aCTLA-4),
and that administering ICB mAbs to T cells in the TDLN alone has similar
immunomodulatory and therapeutic effects to administering ICB to T
cells in the TDLN and in the tumor.<sup><xref ref-type="bibr" rid="ref52">52</xref>,<xref ref-type="bibr" rid="ref68">68</xref></sup> Early in-human
data has confirmed the importance of the SLN in ICB response, with
patients who received a single low dose of the aCTLA-4 antibody tremelimumab
at the tumor resection site before SLNB exhibiting increased effector
T cell activation and reduced T<sub>reg</sub> presence in both the
SLN and peripheral blood, enhanced antigen-specific peripheral blood
T cell response upon <italic toggle="yes">ex vivo</italic> restimulation, and even
enhanced migratory DC presence in the SLN.<sup><xref ref-type="bibr" rid="ref72">72</xref></sup> Consequently, intratumoral administration of ICB mAbs, which can
increase T cell exposure to mAb in the TDLN as well as in the tumor,
has significant therapeutic potential. In addition, in light of the
upregulation of PD-L1 on LECs in peritumoral lymphatics and in the
TDLN, intratumoral administration of aPD1 or aPD-L1 has the potential
to mitigate the tumor-induced modulation of T cell activity by LECs.
Intratumoral administration is particularly interesting for targeting
immune checkpoints, like CTLA-4, whose inhibition has been well documented
to show dose-dependent antitumor effects but also dose-dependent toxicities.<sup><xref ref-type="bibr" rid="ref73">73</xref>,<xref ref-type="bibr" rid="ref74">74</xref></sup> The ability of intratumoral mAb injection to potentially increase
mAb localization to the TME and lymphatic basin and decrease systemic
tissue exposure can help navigate this complexity.<sup><xref ref-type="bibr" rid="ref75">75</xref></sup></p></sec><sec id="sec3.2.2"><label>3.2.2</label><title>TCR Agonism and Costimulatory
Receptor Agonism
in the Tumor and in the TDLN</title><p>Agonistic antibodies against
T cell costimulatory receptors have been a difficult area of exploration
ever since the serious adverse events seen in the clinical trial of
the anti-CD28 superagonist TGN1412.<sup><xref ref-type="bibr" rid="ref76">76</xref></sup> Providing
effective costimulation to T cells independently of APCs has potential
to generate significant T cell antitumor responses, but because costimulatory
mAbs are typically given systemically, they tend to come with major
side effects and may be dose-limited at a subeffective dose.<sup><xref ref-type="bibr" rid="ref77">77</xref>,<xref ref-type="bibr" rid="ref78">78</xref></sup> Increasingly, there is increased interest in administering these
modalities intratumorally rather than systemically. One T cell costimulatory
receptor that has attracted significant attention both preclinically
and clinically is the tumor necrosis factor (TNF) superfamily member
OX40, which has a variety of roles including enabling T cell survival
and regulating cytokine production.<sup><xref ref-type="bibr" rid="ref79">79</xref></sup> After
preclinical reports described the potent antitumor effects of intratumoral
OX40 agonism in mice, there are now ongoing early investigations exploring
the intratumoral administration of OX40 agonists in humans.<sup><xref ref-type="bibr" rid="ref80">80</xref>,<xref ref-type="bibr" rid="ref81">81</xref></sup> Other costimulatory receptors such as 4-1BB (CD137) have shown promising
effects in response to intratumoral agonism in preclinical work but
have not yet been investigated for intratumoral administration in
the clinic.<sup><xref ref-type="bibr" rid="ref82">82</xref>,<xref ref-type="bibr" rid="ref83">83</xref></sup></p><p>Another interesting therapeutic
pathway that has been successfully utilized in treating hematological
malignancies and that is now increasingly being investigated for solid
tumors is bispecific T cell engagers (BiTEs), with a recent FDA approval
in uveal melanoma for tebentafusp-tebn. BiTEs are antibodies or fusion
proteins containing both a CD3-binding domain and a tumor antigen-binding
domain, such as CD19 for B cell malignancies or EpCAM for solid tumors,
that can induce T cell activation upon the engagement of both domains.<sup><xref ref-type="bibr" rid="ref84">84</xref></sup> Despite BiTEs&#8217; documented clinical success
and increasing investment into developing them for solid tumors, clinical
investigations into intratumorally administered rather than systemically
administered BiTEs remain lacking. Preclinical investigation into
intratumoral administration of oncolytic viruses encoding BiTEs, however,
has demonstrated promising results.<sup><xref ref-type="bibr" rid="ref85">85</xref>,<xref ref-type="bibr" rid="ref86">86</xref></sup> Particularly
relevant for further investigation might be the intratumoral administration
of larger BiTEs (formatted as bispecific antibodies or as fusion proteins
with Fc domains) capable of lymphatic drainage to target metastases
within LNs. In a similar vein, a recent preclinical study reported
that the intratumoral delivery of plasmid encoding agonistic anti-CD3
mAbs in combination with IL-12 drives potent antitumor immunity, lending
further credence to the idea of targeted TCR agonism via intratumoral
administration.<sup><xref ref-type="bibr" rid="ref87">87</xref></sup></p></sec><sec id="sec3.2.3"><label>3.2.3</label><title>CD40
Agonism to Activate Dendritic Cells</title><p>Agonism of CD40 on DCs,
which leads to upregulation of MHC and
costimulatory ligands, has been shown to be important for effective
antitumor T cell responses.<sup><xref ref-type="bibr" rid="ref88">88</xref></sup> The presence
of both resident and migratory DCs in the tumors presents a natural
target for CD40 agonism. Additionally, intratumoral administration
of aCD40 mAbs has been shown preclinically to result in increased
aCD40 accumulation in TDLNs and consequent stimulation of LN-resident
or recently migrated DCs to expand T cells there.<sup><xref ref-type="bibr" rid="ref89">89</xref>,<xref ref-type="bibr" rid="ref90">90</xref></sup> In light of this, there have been some early investigations of intratumoral
CD40 agonism in humans, with a recent clinical trial investigating
the mAb APX005M resulting in increases in T cell activation gene signatures
and clonal diversity in both treated and nontreated lesions, pointing
toward the possibility for this approach to generate both local and
systemic antitumor T cell responses (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02706353">NCT02706353</ext-link>).<sup><xref ref-type="bibr" rid="ref91">91</xref>,<xref ref-type="bibr" rid="ref92">92</xref></sup></p></sec><sec id="sec3.2.4"><label>3.2.4</label><title>Using Therapeutic Antibodies to Engineer
Targeted T<sub>reg</sub> Depletion</title><p>Some therapeutic antibodies
have Fc-dependent immunomodulatory effects in addition to immunomodulatory
effects resulting from targeted agonism or antagonism. In mice, treatment
with certain clones of aCTLA-4 mAbs can deplete intratumoral T<sub>reg</sub>s, enhancing the antitumor immune response. However, examination
of clinical data has revealed that neither of the two FDA-approved
aCTLA-4 mAbs (ipilimumab and tremelimumab) result in significant intratumoral
T<sub>reg</sub> depletion in humans in their current clinical context
of systemic administration, but only when administered intratumorally,
further motivating the use of intratumoral aCTLA-4.<sup><xref ref-type="bibr" rid="ref75">75</xref>,<xref ref-type="bibr" rid="ref93">93</xref></sup> At the same time, because preclinical studies have indicated that
aCTLA-4 mAbs are most effective when both their Fc-independent and
Fc-dependent functions are engaged, engineering aCTLA-4 mAbs capable
of better depleting intratumoral T<sub>reg</sub>s in humans has attracted
substantial interest. For example, gotistobart, an aCTLA-4 mAb that
is designed to enhance T<sub>reg</sub> depletion in the tumor, is
currently in phase 3 trials but is designed for systemic administration
(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05671510">NCT05671510</ext-link>). Conceivably, even next-generation aCTLA-4 antibodies
like this one could benefit from intratumoral administration in order
to increase the mAb concentration and T<sub>reg</sub> depletion in
the tumor and TDLN while seeking to minimize T<sub>reg</sub> depletion
in off-target tissues. Another example of a therapeutic antibody capable
of depleting T<sub>reg</sub>s is a OX40. Preclinical data indicate
that intratumoral aOX40 administration, in addition to its stimulatory
effects on T cells via OX40 agonism, causes activating Fc receptor-dependent
T<sub>reg</sub> depletion in the tumor, further underscoring the opportunities
available to engineer therapeutic antibodies to simultaneously stimulate
effector T cells while also depleting T<sub>reg</sub>s following intratumoral
administration.<sup><xref ref-type="bibr" rid="ref80">80</xref></sup></p></sec></sec><sec id="sec3.3"><label>3.3</label><title>Immunomodulatory Small Molecules and Oligonucleotides</title><p>Pattern recognition receptor (PRR) agonists including toll-like
receptor (TLR) agonists and stimulator of interferon genes (STING)
agonists have potent immunostimulatory effects on APCs, increasing
MHC and costimulatory ligand expression and inducing proinflammatory
cytokine production. Intratumoral administration of PRR agonists may
be critical for their success: not only do these agents see limited
tumor and LN access from systemic administration, but because many
of these modalities are nucleic acids, they are subject to rapid degradation <italic toggle="yes">in vivo</italic>. Indeed, early clinical trials of systemically administered
TLR agonists were unsuccessful in spurring significant therapeutic
responses at acceptable levels of toxicity. Intratumorally administered
PRR agonists, on the other hand, have generated promising preclinical
data indicating their ability to modulate immune responses in both
the tumor and TDLN. Recent examples of this have included TLR3 agonists,
dual TLR7/8 and RIG-I agonists, and STING agonists.<sup><xref ref-type="bibr" rid="ref94">94</xref>&#8722;<xref ref-type="bibr" rid="ref98">98</xref></sup> This in turn has prompted a degree of interest in
intratumoral administration of PRR agonists in humans, including agonists
against TLR3, TLR7/8, or TLR9, and STING agonists, with some early
reports indicating promising results such as increased T cell infiltration
and TME remodeling in treated tumors and signs of systemic T cell
response (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04695977">NCT04695977</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06343077">NCT06343077</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06022029">NCT06022029</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04799054">NCT04799054</ext-link>).<sup><xref ref-type="bibr" rid="ref99">99</xref></sup> However, it remains to be seen whether intratumoral
administration of these drugs without coupling them with an engineered
delivery system will consistently induce therapeutic responses. Despite
preclinical evidence suggesting immunostimulatory effects in the TDLN
downstream of effects in the tumor, PRR agonists themselves may be
limited in their ability to consistently access peritumoral lymphatics
and the TDLNs, for reasons discussed in later sections, at least without
undesirable systemic effects being simultaneously elicited. Given
the significant immunosuppressive effects within the tumor microenvironment,
delivery of PRR agonists to APCs within the tumor alone may be insufficient
to consistently induce potent antitumor immunity in humans and novel
drug delivery approaches may be necessary in order to achieve therapeutically
relevant delivery to both the tumor and the TDLN.</p></sec><sec id="sec3.4"><label>3.4</label><title>Immunostimulatory Cytokines</title><p>Cytokines
have been of great interest for cancer immunotherapy due to their
potent immunomodulatory effects. Indeed, some of the earliest FDA-approved
cancer immunotherapies were cytokines, with the approvals of interferon
(IFN) alpha for high-risk melanoma and high-dose interleukin (IL)
2 for metastatic renal cell carcinoma and metastatic melanoma. However,
while systemically administered cytokines can spur durable responses,
only a small fraction of patients respond and at the cost of significant
toxicities such as capillary leak syndrome.<sup><xref ref-type="bibr" rid="ref25">25</xref></sup> Intratumoral cytokine administration can potentially increase drug
accumulation in the TME and tumor-associated lymphatics to improve
therapeutic effects while also reducing systemic exposure, and consequently
has been an increasingly attractive option.<sup><xref ref-type="bibr" rid="ref100">100</xref></sup> This approach has recently seen some success in humans with the
combination neoadjuvant therapy daromun, which consists of the cytokines
IL-2 and TNF fused to tumor-targeting antibody L19 to enhance tumor
retention. Intratumoral daromun treatment induced abscopal effects
in nontreated tumors in a phase 2 trial and improved recurrence-free
survival in a phase 3 trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02938299">NCT02938299</ext-link>).<sup><xref ref-type="bibr" rid="ref69">69</xref>,<xref ref-type="bibr" rid="ref101">101</xref></sup> A variation on this approach that has also garnered significant
attention is intratumorally administering mRNA that encodes cytokines
rather than administering the cytokines themselves. Recent preclinical
work, for example, has explored the possibility of using intratumorally
administered mRNA encoding a fusion protein combining IL-12 with a
CD137 agonist and a TGF-&#946; antagonist and observed both therapeutic
effects in the treated tumor as well as abscopal effects.<sup><xref ref-type="bibr" rid="ref102">102</xref></sup> Similar approaches are currently undergoing
investigation in humans, including a trial with mRNA encoding IL-23
and IL-36&#947; along with OX40 ligand and a trial with mRNA encoding
IL-12 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03739931">NCT03739931</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05539157">NCT05539157</ext-link>). Promisingly, previous in-human data
have indicated that intratumoral cytokine treatment results in changes
in the lymphocyte compartment in the TDLNs as well as in the tumor,
highlighting the opportunities for intratumoral cytokines to modulate
immune crosstalk in the TDLN as well as the injected tumor.<sup><xref ref-type="bibr" rid="ref103">103</xref></sup></p></sec><sec id="sec3.5"><label>3.5</label><title>Opportunities for Intratumoral
Combination
Therapy</title><p>Notwithstanding the opportunities presented by various
classes of intratumoral immunotherapy in isolation, the greatest therapeutic
potential may lie in exploring combinations of these modalities in
order to provoke synergistic effects while simultaneously mitigating
the toxicities that might be seen with the same combinations administered
systemically. Possible approaches could include, for example, simultaneously
enhancing immunogenic cell death (e.g., via an oncolytic virus) and
providing T cell costimulation (aOX40) or stimulating APCs (PRR agonist)
and blocking T cell inhibition while depleting T<sub>reg</sub>s (aCTLA-4).
While there has yet to be extensive clinical investigation along these
lines, recent preclinical data have helped underscore this possibility.
One group demonstrated preclinically that combination intratumoral
administration of a TLR9 agonist and OX40 agonist substantially enhanced
the T cell response and antitumor activity in primary and metastatic
tumors as well as in TDLNs.<sup><xref ref-type="bibr" rid="ref104">104</xref></sup> Others have
shown marked tumor reduction in response to the combination of aCTLA-4,
aCD137, and aOX40 as a result of substantial antibody accumulation
in both the tumor and the TDLN, while still others have demonstrated
significant immunomodulatory effects in both the tumor and TDLN arising
following coadministration intratumorally of a TLR3 agonist and a
STING agonist.<sup><xref ref-type="bibr" rid="ref105">105</xref>,<xref ref-type="bibr" rid="ref106">106</xref></sup> Similarly, recent preclinical
work has shown that intratumoral TLR9 agonist and IL-12 with or without
aOX40 results in profound effects in the tumor and TDLN as well as
abscopal effects.<sup><xref ref-type="bibr" rid="ref107">107</xref></sup> Because of the difficulties
inherent in achieving effective drug accumulation in the tumor and
TDLN even in the context of intratumoral administration, however,
these therapeutic strategies can benefit from using engineered drug
delivery systems (DDSs) that are optimized for intratumoral immunotherapy.</p></sec></sec><sec id="sec4"><label>4</label><title>Engineering Drug Delivery Systems for Intratumoral
Immunotherapy</title><p>An important factor to consider in the design
of intratumoral immunotherapies
to modulate tumor-lymphatic crosstalk is the extent to which a drug
will reach the target tissues and target cell populations necessary
for maximum efficacy. This consideration can be seen with the radioactive
tracers typically used for lymphatic mapping, which are typically
between 10 and 200 nm in diameter to prevent rapid clearance from
the site of injection and enable lymphatic drainage and LN accumulation.<sup><xref ref-type="bibr" rid="ref108">108</xref></sup> On one hand, for modalities like oncolytic
viruses it may suffice to achieve drug delivery primarily in the injected
tumor and not in the TDLN, provided that the virus is sufficiently
engineered to drive the release of antigen and DAMPs/PAMPs that can
then drain via lymphatics. On the other hand, modalities like PRR
agonists and some cytokines have significant direct effects both in
the tumor and in the TDLN but are also relatively small in size (&lt;5
nm hydrodynamic diameter). Cargoes in this size range do not see appreciable
lymphatic exposure and are rapidly cleared from the tumor following
intratumoral administration&#8212;meaning the administration of the
drug by itself may be insufficient to achieve optimal immunomodulation
in both the tumor and the lymphatic system (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>).<sup><xref ref-type="bibr" rid="ref109">109</xref>,<xref ref-type="bibr" rid="ref110">110</xref></sup> This dilemma highlights
the opportunity to use engineered DDSs that can be tuned to achieve
drug exposure in the TDLN as well as in the tumor to maximize therapeutic
effects while also reducing systemic exposure and related toxicities.</p><fig id="fig3" position="float" orientation="portrait"><label>Figure 3</label><caption><p>Engineered
drug delivery systems improve the ability of intratumoral
immunotherapy to modulate tumor-lymphatic immune crosstalk by improving
drug access to and effects in both the tumor and the TDLN. Intratumorally
administered therapies by themselves can transiently modulate immunity
in the tumor but struggle to effectively access the lymphatics/TDLN,
with antibodies seeing some accumulation but other modalities such
as PRR agonists and cytokines seeing minimal LN access (left). Engineered
drug delivery systems such as depot-forming/hydrogel systems and nanocarrier-based
systems (right) can simultaneously enhance intratumoral immunotherapy
access to tumor lymphatics/TDLNs to amplify antitumor immunity in
those tissues as well as improve the effects in the tumor (e.g., by
reducing rates of drug clearance).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="gr3" position="float" orientation="portrait" xlink:href="mp4c00692_0003.jpg"/></fig><sec id="sec4.1"><label>4.1</label><title>Locoregional Sustained-Release and Depot-Forming
Systems</title><p>Sustained-release or depot-forming systems represent
one potential answer to the question of how to reduce systemic drug
clearance after intratumoral administration and can be further manipulated
to enhance the drug uptake by lymphatics. Many of these approaches
involve developing hydrogels from biocompatible materials such as
alginate or Pluronic that have desirable properties such as undergoing
sol&#8211;gel transitions at physiological temperatures after drug
loading and can be safely administered intratumorally. When applied
to therapeutic antibodies such as ICB mAbs, these systems not only
can enable increased antibody retention at the tumor site but also
can sustain antibody access to the TDLN, whether passively by shifting
the balance of antibody blood clearance vs lymphatic clearance in
favor of the lymphatics or actively by shedding lymph-draining antibody-containing
micelles.<sup><xref ref-type="bibr" rid="ref111">111</xref>,<xref ref-type="bibr" rid="ref112">112</xref></sup> These systems can also be engineered
to enhance the simultaneous tumor and lymphatic delivery of smaller
drugs such as PRR agonists. For example, TLR agonist-containing polyamide-based
nanocarriers capable of draining through lymphatic capillaries to
be taken up by DCs in the TDLN were released from a polyethylene glycol
(PEG)-based hydrogel that was modified to respond to reactive oxygen
species.<sup><xref ref-type="bibr" rid="ref113">113</xref></sup> Additionally, hydrogels comprised
of PEG-based microspheres to which a TLR agonist can be connected
by a degradable linker have been developed, resulting in APC activation
and T cell stimulation in both TDLNs and tumors.<sup><xref ref-type="bibr" rid="ref114">114</xref></sup> Notably, hydrogels can also be manipulated to deliver multiple
classes of drug simultaneously, such as PRR agonist and antibody or
PRR agonist and cytokine.<sup><xref ref-type="bibr" rid="ref115">115</xref>,<xref ref-type="bibr" rid="ref116">116</xref></sup> Another noteworthy
approach involves tethering the therapeutic modality of interest to
a depot-forming system to improve drug retention at the tumor site.
For example, IL-12 tethered to the depot-forming vaccine adjuvant
aluminum hydroxide enhanced immune activity in the tumor and resulted
in enhanced T cell activity in TDLNs and is currently being evaluated
in humans (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06171750">NCT06171750</ext-link>).<sup><xref ref-type="bibr" rid="ref117">117</xref></sup></p></sec><sec id="sec4.2"><label>4.2</label><title>Nanocarriers</title><p>Nanocarriers that are
optimally sized to enter peritumoral lymphatics and drain to TDLNs
are another potential solution for efficiently modulating tumor-lymphatic
immune crosstalk. A variety of approaches toward this goal have been
explored, with some additionally achieving a degree of sustained release
by balancing injection site retention and lymphatic drainage or successfully
limiting systemic exposure by constraining nanocarrier/drug accumulation
to the tumor and the TDLN. Various groups have used nanoparticles
to intratumorally administer cargoes as diverse as antibodies, STING
agonists, and TLR agonists. In doing so, they have demonstrated biodistribution
that is primarily limited to the tumor, peritumoral lymphatics, and
TDLN as well as immunomodulatory effects including DC maturation,
T cell activation, and cytokine secretion in those tissues.<sup><xref ref-type="bibr" rid="ref118">118</xref>&#8722;<xref ref-type="bibr" rid="ref122">122</xref></sup> Many of these efforts feature interesting design features to enhance
targeted drug delivery. One such effort involved the synthesis of
photosensitive and matrix metalloprotease-2-degradable PEG-based nanoparticles
loaded with aPD-L1 that improved drug accumulation following irradiation
not only in the primary TDLN but in TDLNs further downstream as well.<sup><xref ref-type="bibr" rid="ref118">118</xref></sup> Another involved the development of PEG/polyphosphoester-based
nanoparticles loaded with TLR agonist that, when injected intratumorally
after magnetic hyperthermia treatment, were capable of noncovalently
adsorbing tumor antigen on the surface of the particle before draining
to the TDLN thus in principle enabling simultaneous TLR agonist and
antigen delivery to TDLN DCs.<sup><xref ref-type="bibr" rid="ref120">120</xref></sup> In another
interesting approach, PEG- and poly lactic-<italic toggle="yes">co</italic>-glycolic
acid (PLGA)-derived nanoparticles that were functionalized with tannic
acid were formed, enabling the lymph-draining nanoparticles to enter
LN conduits and penetrate deep into the LN to target T cells and DCs
in the paracortex rather than arresting in the subcapsular sinus.<sup><xref ref-type="bibr" rid="ref121">121</xref></sup> A subset of nanocarrier work has investigated
deploying biopolymers such as glatiramer acetate or glycol chitosan
with intrinsic adjuvant properties for intratumoral immunotherapy.
Formulations of these biopolymers can form particle solutions upon
injection capable of both stimulating APCs in the TME and draining
via lymphatics to stimulate APCs in TDLNs.<sup><xref ref-type="bibr" rid="ref123">123</xref>,<xref ref-type="bibr" rid="ref124">124</xref></sup> Given the enormous wave of interest in liposomes and lipid nanoparticles
(LNPs) leading up to but especially in the wake of the SARS-CoV-2
pandemic and the successful LNP-mRNA vaccines, there have also been
recent forays into using LNPs for intratumoral administration of therapeutic
cargoes including antibodies, cytokines, and STING agonists as well
as mRNA encoding a variety of cargoes such as cytokines, costimulatory
ligands, and novel fusion proteins.<sup><xref ref-type="bibr" rid="ref102">102</xref>,<xref ref-type="bibr" rid="ref125">125</xref>&#8722;<xref ref-type="bibr" rid="ref128">128</xref></sup> Intratumorally administered mRNA LNPs are particularly interesting
for their potential to turn immune cells in both the tumor and the
TDLN into factories producing specific immunostimulatory antibodies
or cytokines, in contrast to intratumorally administered naked mRNA
which results in protein translation in the tumor but not the TDLN.<sup><xref ref-type="bibr" rid="ref127">127</xref>,<xref ref-type="bibr" rid="ref128">128</xref></sup> Particularly interesting will be in-human data indicating the extent
to which intratumorally administered LNPs are able to mitigate the
liver tropism for which LNPs are generally known.<sup><xref ref-type="bibr" rid="ref129">129</xref></sup> Another interesting development has been the functionalization
of nanocarriers, such as polymeric nanoparticles or LNPs with agonistic
aCD3 antibodies or binding domains from aCD3 antibodies. Administration
of such particles can not only stimulate T cells but can also deliver
cargoes like mRNA or small molecule drugs to those same T cells and
could enable highly specific T cell targeting in the tumor and TDLNs.<sup><xref ref-type="bibr" rid="ref130">130</xref>,<xref ref-type="bibr" rid="ref131">131</xref></sup></p></sec></sec><sec id="sec5"><label>5</label><title>Potential Future Directions for Intratumoral
Immunotherapy</title><p>Many exciting opportunities are emerging for
intratumoral immunotherapy
to modulate tumor-lymphatic immune crosstalk. Approaches using DDSs
to deliver combinations of immunomodulatory therapies (e.g., cytokine
and PRR agonist, cytokine and mAb, PRR agonist and mAb) to both the
tumor and the lymphatic system have the potential to overcome some
of the limitations of monotherapies, though a clearer understanding
of potential toxicities from intratumoral combination therapy may
be necessary before clinical success is achieved. Given the increasing
interest in developing BiTEs for solid tumors, there may also be value
in pursuing the intratumoral administration of BiTEs either in protein
form or encoded by oncolytic virus to target both the tumor and TDLN,
along with other forms of therapeutic intratumoral TCR agonism.</p><p>Beyond the approaches detailed here, there are also newfound insights
and developing therapeutic approaches that may be applied to an intratumoral
immunotherapeutic paradigm. For example, therapies that remodel the
TME and lymphatic system in order to enable increased T cell recruitment,
infiltration, and retention in the TME require further investigation.
Recent work has identified the formation of immunotherapy-inducible
tertiary lymphoid structures (TLS) within the TME that enable increased
T cell infiltration into and survival in the tumor.<sup><xref ref-type="bibr" rid="ref132">132</xref>&#8722;<xref ref-type="bibr" rid="ref134">134</xref></sup> Various chemokines and cytokines, including CCL21, CXCL13, LIGHT,
and lymphotoxin (LT) &#946;, have all been implicated in TLS formation.<sup><xref ref-type="bibr" rid="ref132">132</xref>,<xref ref-type="bibr" rid="ref135">135</xref></sup> There may be an opportunity to use DDSs to engineer enhanced TLS
formation in the TME to synergize with other immunotherapies. For
example, sustained-release or depot-forming systems could be loaded
with recombinant LIGHT or agonistic LT&#946;R mAbs to increase the
level of T cell infiltration into the TME, potentially improving the
effects of ICB. Immunomodulatory small molecules also represent a
plausible use case for DDSs. Particularly interesting are inhibitors
of the enzyme protein tyrosine phosphatase (PTP) that can enhance
TCR and cytokine signaling in T cells and demonstrate significant
antitumor potential. Inhibition of PTPN1 and PTPN2 has been shown
to enhance CD8+ T cell activation, proliferation, and cytokine secretion
in response to antigen stimulus <italic toggle="yes">ex vivo</italic> and to increase
TIL density <italic toggle="yes">in vivo</italic>.<sup><xref ref-type="bibr" rid="ref136">136</xref>&#8722;<xref ref-type="bibr" rid="ref139">139</xref></sup> Because systemic administration
of these potent inhibitors in humans raises questions around safety
and tolerability, modalities like these could also benefit from targeted
delivery to tumors and TDLNs.</p></sec><sec id="sec6"><label>6</label><title>Conclusion</title><p>The intentional
therapeutic modulation of not only the tumor but
also the tumor-associated lymphatic system offers opportunities for
augmenting antitumor immune activity to achieve curative therapeutic
efficacy in advanced disease. To aid in this goal, the development
of engineered DDSs to better enable the manipulation of tumor-lymphatic
crosstalk is critical. In an emerging practice era characterized by
less invasive LN biopsy and removal, as well as more immunotherapies
being initiated in the neoadjuvant stage, previously overlooked opportunities
in the design of intratumoral immunotherapies offer unique advantages
to define new paradigms of cancer immunotherapy. While recent late-phase
clinical trials of intratumoral immunotherapies in advanced or metastatic
cancers have succeeded in generating promising local responses, most
have yet to consistently achieve durable systemic benefit&#8212;likely
due in part to failures to generate sufficiently potent systemic antitumor
immune responses.<sup><xref ref-type="bibr" rid="ref140">140</xref></sup> Due to intratumorally
administered immunotherapies offering both therapeutic effects within
the injected tumor as well as access to LNs where systemically active
antitumor immune responses can be modulated, opportunities exist to
incorporate recent insights into tumor-lymphatic crosstalk and advances
in DDSs in order to design intratumoral immunotherapies that, in addition
to providing local control, also enhance and amplify systemic immunity.</p></sec></body><back><notes notes-type="" id="notes-1"><title>Author Contributions</title><p>The manuscript
was written through contributions of all authors. All authors have
given approval to the final version of the manuscript.</p></notes><notes notes-type="funding-statement" id="notes-2"><p>This work was
supported by US National Institutes of Health grants R01CA207619,
R01CA247484, R01HL173943 and T32GM145735.</p></notes><notes notes-type="COI-statement" id="notes-3"><p>The authors
declare no competing financial interest.</p></notes><ack><title>Acknowledgments</title><p>This work
was supported by US National Institutes of Health
grants R01CA207619, R01CA247484, R01HL173943 and T32GM145735. <xref rid="fig1" ref-type="fig">Figures <xref rid="fig1" ref-type="fig">1</xref></xref>&#8211;<xref rid="fig3" ref-type="fig">3</xref> and the graphical abstract were created with Biorender.com.</p></ack><glossary id="dl1"><def-list><title>Abbreviations</title><def-item><term>LN</term><def><p>lymph
node</p></def></def-item><def-item><term>TDLN</term><def><p>tumor-draining
lymph node</p></def></def-item><def-item><term>CLND</term><def><p>complete LN dissection</p></def></def-item><def-item><term>SLNB</term><def><p>sentinel LN biopsy</p></def></def-item><def-item><term>TME</term><def><p>tumor microenvironment</p></def></def-item><def-item><term>APC</term><def><p>antigen presenting
cell</p></def></def-item><def-item><term>DC</term><def><p>dendritic
cell</p></def></def-item><def-item><term>MDSC</term><def><p>myeloid
derived suppressor cell</p></def></def-item><def-item><term>ICB</term><def><p>immune checkpoint blockade</p></def></def-item><def-item><term>MHC</term><def><p>major histocompatibility complex</p></def></def-item><def-item><term>PD-1</term><def><p>programmed cell death protein 1</p></def></def-item><def-item><term>PD-L</term><def><p>PD-ligand</p></def></def-item><def-item><term>CTLA-4</term><def><p>cytotoxic T lymphocyte
associated protein 4</p></def></def-item><def-item><term>LAG-3</term><def><p>lymphocyte activation gene 3</p></def></def-item><def-item><term>TCR</term><def><p>T cell receptor</p></def></def-item><def-item><term>IL</term><def><p>interleukin</p></def></def-item><def-item><term>TGF&#946;</term><def><p>transforming growth factor &#946;</p></def></def-item><def-item><term>LEC</term><def><p>lymphatic endothelial
cell</p></def></def-item><def-item><term>mAb</term><def><p>monoclonal
antibody</p></def></def-item><def-item><term>BiTE</term><def><p>bispecific
T cell engager</p></def></def-item><def-item><term>PRR</term><def><p>pattern recognition receptor</p></def></def-item><def-item><term>TLR</term><def><p>toll like receptor</p></def></def-item><def-item><term>STING</term><def><p>stimulator of interferon genes</p></def></def-item><def-item><term>PEG</term><def><p>polyethylene glycol</p></def></def-item><def-item><term>LNP</term><def><p>lipid nanoparticle</p></def></def-item></def-list></glossary><ref-list><title>References</title><ref id="ref1"><mixed-citation publication-type="journal" id="cit1"><name name-style="western"><surname>Lund</surname><given-names>A. W.</given-names></name><article-title>Immune
Potential Untapped: Leveraging the Lymphatic System for Cancer Immunotherapy</article-title>. <source>Cancer Immunology Research</source><year>2022</year>, <volume>10</volume> (<issue>9</issue>), <fpage>1042</fpage>&#8211;<lpage>1046</lpage>. <pub-id pub-id-type="doi">10.1158/2326-6066.CIR-22-0266</pub-id>.<pub-id pub-id-type="pmid">35895021</pub-id><pub-id pub-id-type="pmcid">PMC9673990</pub-id></mixed-citation></ref><ref id="ref2"><mixed-citation publication-type="journal" id="cit2"><name name-style="western"><surname>Mlecnik</surname><given-names>B.</given-names></name>; <name name-style="western"><surname>Bindea</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Kirilovsky</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Angell</surname><given-names>H. K.</given-names></name>; <name name-style="western"><surname>Obenauf</surname><given-names>A. C.</given-names></name>; <name name-style="western"><surname>Tosolini</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Church</surname><given-names>S. E.</given-names></name>; <name name-style="western"><surname>Maby</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Vasaturo</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Angelova</surname><given-names>M.</given-names></name>; et al. <article-title>The tumor
microenvironment and Immunoscore
are critical determinants of dissemination to distant metastasis</article-title>. <source>Science Translational Medicine</source><year>2016</year>, <volume>8</volume> (<issue>327</issue>), <fpage>327ra326</fpage>&#8211;<lpage>327ra326</lpage>. <pub-id pub-id-type="doi">10.1126/scitranslmed.aad6352</pub-id>.<pub-id pub-id-type="pmid">26912905</pub-id></mixed-citation></ref><ref id="ref3"><mixed-citation publication-type="journal" id="cit3"><name name-style="western"><surname>Yaddanapudi</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Stamp</surname><given-names>B. F.</given-names></name>; <name name-style="western"><surname>Subrahmanyam</surname><given-names>P. B.</given-names></name>; <name name-style="western"><surname>Smolenkov</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Waigel</surname><given-names>S. J.</given-names></name>; <name name-style="western"><surname>Gosain</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Egger</surname><given-names>M. E.</given-names></name>; <name name-style="western"><surname>Martin</surname><given-names>R. C. G.</given-names></name>; <name name-style="western"><surname>Buscaglia</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Maecker</surname><given-names>H. T.</given-names></name>; et al. <article-title>Single-Cell
Immune Mapping
of Melanoma Sentinel Lymph Nodes Reveals an Actionable Immunotolerant
Microenvironment</article-title>. <source>Clin. Cancer Res.</source><year>2022</year>, <volume>28</volume> (<issue>10</issue>), <fpage>2069</fpage>&#8211;<lpage>2081</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-21-0664</pub-id>.<pub-id pub-id-type="pmid">35046061</pub-id><pub-id pub-id-type="pmcid">PMC9840851</pub-id></mixed-citation></ref><ref id="ref4"><mixed-citation publication-type="journal" id="cit4"><name name-style="western"><surname>Chen</surname><given-names>D. S.</given-names></name>; <name name-style="western"><surname>Mellman</surname><given-names>I.</given-names></name><article-title>Oncology Meets
Immunology: The Cancer-Immunity Cycle</article-title>. <source>Immunity</source><year>2013</year>, <volume>39</volume> (<issue>1</issue>), <fpage>1</fpage>&#8211;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2013.07.012</pub-id>.<pub-id pub-id-type="pmid">23890059</pub-id></mixed-citation></ref><ref id="ref5"><mixed-citation publication-type="journal" id="cit5"><name name-style="western"><surname>Kawada</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Taketo</surname><given-names>M. M.</given-names></name><article-title>Significance and Mechanism of Lymph Node Metastasis
in Cancer Progression</article-title>. <source>Cancer Res.</source><year>2011</year>, <volume>71</volume> (<issue>4</issue>), <fpage>1214</fpage>&#8211;<lpage>1218</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-3277</pub-id>.<pub-id pub-id-type="pmid">21212413</pub-id></mixed-citation></ref><ref id="ref6"><mixed-citation publication-type="journal" id="cit6"><name name-style="western"><surname>du
Bois</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Heim</surname><given-names>T. A.</given-names></name>; <name name-style="western"><surname>Lund</surname><given-names>A. W.</given-names></name><article-title>Tumor-draining lymph nodes: At the
crossroads of metastasis and immunity</article-title>. <source>Science
Immunology</source><year>2021</year>, <volume>6</volume> (<issue>63</issue>), <elocation-id>eabg3551</elocation-id><pub-id pub-id-type="doi">10.1126/sciimmunol.abg3551</pub-id>.<pub-id pub-id-type="pmid">34516744</pub-id><pub-id pub-id-type="pmcid">PMC8628268</pub-id></mixed-citation></ref><ref id="ref7"><mixed-citation publication-type="journal" id="cit7"><person-group person-group-type="allauthors"><name name-style="western"><surname>Fransen</surname><given-names>M. F.</given-names></name>; <name name-style="western"><surname>Schoonderwoerd</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Knopf</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Camps</surname><given-names>M. G.M.</given-names></name>; <name name-style="western"><surname>Hawinkels</surname><given-names>L. J.A.C.</given-names></name>; <name name-style="western"><surname>Kneilling</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>van Hall</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Ossendorp</surname><given-names>F.</given-names></name></person-group><article-title>Tumor-draining lymph nodes
are pivotal in PD-1/PD-L1 checkpoint therapy</article-title>. <source>JCI Insight</source><year>2018</year>, <volume>3</volume> ( (<issue>23</issue>), ).<pub-id pub-id-type="doi">10.1172/jci.insight.124507</pub-id>.<pub-id pub-id-type="pmcid">PMC6328025</pub-id><pub-id pub-id-type="pmid">30518694</pub-id></mixed-citation></ref><ref id="ref8"><mixed-citation publication-type="journal" id="cit8"><name name-style="western"><surname>Spitzer</surname><given-names>M. H.</given-names></name>; <name name-style="western"><surname>Carmi</surname><given-names>Y.</given-names></name>; <name name-style="western"><surname>Reticker-Flynn</surname><given-names>N. E.</given-names></name>; <name name-style="western"><surname>Kwek</surname><given-names>S. S.</given-names></name>; <name name-style="western"><surname>Madhireddy</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Martins</surname><given-names>M. M.</given-names></name>; <name name-style="western"><surname>Gherardini</surname><given-names>P. F.</given-names></name>; <name name-style="western"><surname>Prestwood</surname><given-names>T. R.</given-names></name>; <name name-style="western"><surname>Chabon</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Bendall</surname><given-names>S. C.</given-names></name>; et al. <article-title>Systemic
Immunity Is
Required for Effective Cancer Immunotherapy</article-title>. <source>Cell</source><year>2017</year>, <volume>168</volume> (<issue>3</issue>), <fpage>487</fpage>&#8211;<lpage>502.e415</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2016.12.022</pub-id>.<pub-id pub-id-type="pmid">28111070</pub-id><pub-id pub-id-type="pmcid">PMC5312823</pub-id></mixed-citation></ref><ref id="ref9"><mixed-citation publication-type="journal" id="cit9"><name name-style="western"><surname>Song</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Mao</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Dong</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Boisserand</surname><given-names>L. S. B.</given-names></name>; <name name-style="western"><surname>Antila</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Bosenberg</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Alitalo</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Thomas</surname><given-names>J.-L.</given-names></name>; <name name-style="western"><surname>Iwasaki</surname><given-names>A.</given-names></name><article-title>VEGF-C-driven lymphatic
drainage enables immunosurveillance of brain tumours</article-title>. <source>Nature</source><year>2020</year>, <volume>577</volume> (<issue>7792</issue>), <fpage>689</fpage>&#8211;<lpage>694</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-019-1912-x</pub-id>.<pub-id pub-id-type="pmid">31942068</pub-id><pub-id pub-id-type="pmcid">PMC7100608</pub-id></mixed-citation></ref><ref id="ref10"><mixed-citation publication-type="journal" id="cit10"><name name-style="western"><surname>Colombo</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Rich</surname><given-names>J. R.</given-names></name><article-title>The therapeutic
window of antibody drug conjugates:
A dogma in need of revision</article-title>. <source>Cancer Cell</source><year>2022</year>, <volume>40</volume> (<issue>11</issue>), <fpage>1255</fpage>&#8211;<lpage>1263</lpage>. <pub-id pub-id-type="doi">10.1016/j.ccell.2022.09.016</pub-id>.<pub-id pub-id-type="pmid">36240779</pub-id></mixed-citation></ref><ref id="ref11"><mixed-citation publication-type="journal" id="cit11"><person-group person-group-type="allauthors"><name name-style="western"><surname>Riccardi</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Dal Bo</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Macor</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Toffoli</surname><given-names>G.</given-names></name></person-group><article-title>A comprehensive overview on
antibody-drug conjugates: from the conceptualization to cancer therapy</article-title>. <source>Front. Pharmacol.</source><year>2023</year>, <volume>14</volume>.<pub-id pub-id-type="doi">10.3389/fphar.2023.1274088</pub-id>.<pub-id pub-id-type="pmcid">PMC10544916</pub-id><pub-id pub-id-type="pmid">37790810</pub-id></mixed-citation></ref><ref id="ref12"><mixed-citation publication-type="journal" id="cit12"><name name-style="western"><surname>Leiter</surname><given-names>U.</given-names></name>; <name name-style="western"><surname>Stadler</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Mauch</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Hohenberger</surname><given-names>W.</given-names></name>; <name name-style="western"><surname>Brockmeyer</surname><given-names>N.</given-names></name>; <name name-style="western"><surname>Berking</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Sunderk&#246;tter</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Kaatz</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Schulte</surname><given-names>K.-W.</given-names></name>; <name name-style="western"><surname>Lehmann</surname><given-names>P.</given-names></name>; et al. <article-title>Complete
lymph node dissection versus no dissection in patients with sentinel
lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised,
phase 3 trial</article-title>. <source>Lancet Oncology</source><year>2016</year>, <volume>17</volume> (<issue>6</issue>), <fpage>757</fpage>&#8211;<lpage>767</lpage>. <pub-id pub-id-type="doi">10.1016/S1470-2045(16)00141-8</pub-id>.<pub-id pub-id-type="pmid">27161539</pub-id></mixed-citation></ref><ref id="ref13"><mixed-citation publication-type="journal" id="cit13"><name name-style="western"><surname>Faries</surname><given-names>M. B.</given-names></name>; <name name-style="western"><surname>Thompson</surname><given-names>J. F.</given-names></name>; <name name-style="western"><surname>Cochran</surname><given-names>A. J.</given-names></name>; <name name-style="western"><surname>Andtbacka</surname><given-names>R. H.</given-names></name>; <name name-style="western"><surname>Mozzillo</surname><given-names>N.</given-names></name>; <name name-style="western"><surname>Zager</surname><given-names>J. S.</given-names></name>; <name name-style="western"><surname>Jahkola</surname><given-names>T</given-names></name>; <name name-style="western"><surname>Bowles</surname><given-names>T. L.</given-names></name>; <name name-style="western"><surname>Testori</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Beitsch</surname><given-names>P. D.</given-names></name>; et al. <article-title>Completion
Dissection
or Observation for Sentinel-Node Metastasis in Melanoma</article-title>. <source>New England Journal of Medicine</source><year>2017</year>, <volume>376</volume> (<issue>23</issue>), <fpage>2211</fpage>&#8211;<lpage>2222</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1613210</pub-id>.<pub-id pub-id-type="pmid">28591523</pub-id><pub-id pub-id-type="pmcid">PMC5548388</pub-id></mixed-citation></ref><ref id="ref14"><mixed-citation publication-type="journal" id="cit14"><name name-style="western"><surname>Morton</surname><given-names>D. L.</given-names></name>; <name name-style="western"><surname>Thompson</surname><given-names>J. F.</given-names></name>; <name name-style="western"><surname>Cochran</surname><given-names>A. J.</given-names></name>; <name name-style="western"><surname>Mozzillo</surname><given-names>N.</given-names></name>; <name name-style="western"><surname>Nieweg</surname><given-names>O. E.</given-names></name>; <name name-style="western"><surname>Roses</surname><given-names>D. F.</given-names></name>; <name name-style="western"><surname>Hoekstra</surname><given-names>H. J.</given-names></name>; <name name-style="western"><surname>Karakousis</surname><given-names>C. P.</given-names></name>; <name name-style="western"><surname>Puleo</surname><given-names>C. A.</given-names></name>; <name name-style="western"><surname>Coventry</surname><given-names>B. J.</given-names></name>; et al. <article-title>Final
Trial Report of
Sentinel-Node Biopsy versus Nodal Observation in Melanoma</article-title>. <source>New England Journal of Medicine</source><year>2014</year>, <volume>370</volume> (<issue>7</issue>), <fpage>599</fpage>&#8211;<lpage>609</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1310460</pub-id>.<pub-id pub-id-type="pmid">24521106</pub-id><pub-id pub-id-type="pmcid">PMC4058881</pub-id></mixed-citation></ref><ref id="ref15"><mixed-citation publication-type="journal" id="cit15"><name name-style="western"><surname>Gentilini</surname><given-names>O. D.</given-names></name>; <name name-style="western"><surname>Botteri</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Sangalli</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Galimberti</surname><given-names>V.</given-names></name>; <name name-style="western"><surname>Porpiglia</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Agresti</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Luini</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Viale</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Cassano</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Peradze</surname><given-names>N.</given-names></name>; et al. <article-title>Sentinel
Lymph Node
Biopsy vs No Axillary Surgery in Patients With Small Breast Cancer
and Negative Results on Ultrasonography of Axillary Lymph Nodes: The
SOUND Randomized Clinical Trial</article-title>. <source>JAMA Oncology</source><year>2023</year>, <volume>9</volume> (<issue>11</issue>), <fpage>1557</fpage>&#8211;<lpage>1564</lpage>. <pub-id pub-id-type="doi">10.1001/jamaoncol.2023.3759</pub-id>.<pub-id pub-id-type="pmid">37733364</pub-id><pub-id pub-id-type="pmcid">PMC10514873</pub-id></mixed-citation></ref><ref id="ref16"><mixed-citation publication-type="journal" id="cit16"><name name-style="western"><surname>Alamoodi</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Wazir</surname><given-names>U.</given-names></name>; <name name-style="western"><surname>Mokbel</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Patani</surname><given-names>N.</given-names></name>; <name name-style="western"><surname>Varghese</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Mokbel</surname><given-names>K.</given-names></name><article-title>Omitting Sentinel Lymph Node Biopsy after Neoadjuvant
Systemic Therapy for Clinically Node Negative HER2 Positive and Triple
Negative Breast Cancer: A Pooled Analysis</article-title>. <source>Cancers</source><year>2023</year>, <volume>15</volume> (<issue>13</issue>), <fpage>3325</fpage><pub-id pub-id-type="doi">10.3390/cancers15133325</pub-id>.<pub-id pub-id-type="pmid">37444434</pub-id><pub-id pub-id-type="pmcid">PMC10340379</pub-id></mixed-citation></ref><ref id="ref17"><mixed-citation publication-type="journal" id="cit17"><name name-style="western"><surname>Seth</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Agarwala</surname><given-names>S. S.</given-names></name>; <name name-style="western"><surname>Messersmith</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Alluri</surname><given-names>K. C.</given-names></name>; <name name-style="western"><surname>Ascierto</surname><given-names>P. A.</given-names></name>; <name name-style="western"><surname>Atkins</surname><given-names>M. B.</given-names></name>; <name name-style="western"><surname>Bollin</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Chacon</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Davis</surname><given-names>N.</given-names></name>; <name name-style="western"><surname>Faries</surname><given-names>M. B.</given-names></name>; et al. <article-title>Systemic
Therapy for Melanoma: ASCO Guideline
Update</article-title>. <source>JCO</source><year>2023</year>, <volume>41</volume>, <fpage>4794</fpage><pub-id pub-id-type="doi">10.1200/JCO.23.01136</pub-id>.<pub-id pub-id-type="pmid">37579248</pub-id></mixed-citation></ref><ref id="ref18"><mixed-citation publication-type="journal" id="cit18"><name name-style="western"><surname>Mittendorf</surname><given-names>E. A.</given-names></name>; <name name-style="western"><surname>Burgers</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Haanen</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Cascone</surname><given-names>T.</given-names></name><article-title>Neoadjuvant Immunotherapy:
Leveraging the Immune System to Treat Early-Stage Disease</article-title>. <source>Am. Soc. Clin Oncol Educ Book</source><year>2022</year>, (<issue>42</issue>), <fpage>189</fpage>&#8211;<lpage>203</lpage>. <pub-id pub-id-type="doi">10.1200/EDBK_349411</pub-id>.<pub-id pub-id-type="pmid">35714302</pub-id></mixed-citation></ref><ref id="ref19"><mixed-citation publication-type="journal" id="cit19"><name name-style="western"><surname>Krishnamoorthy</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Lenehan</surname><given-names>J. G.</given-names></name>; <name name-style="western"><surname>Maleki
Vareki</surname><given-names>S.</given-names></name><article-title>Neoadjuvant Immunotherapy for High-Risk,
Resectable Malignancies: Scientific Rationale and Clinical Challenges</article-title>. <source>JNCI: Journal of the National Cancer Institute</source><year>2021</year>, <volume>113</volume> (<issue>7</issue>), <fpage>823</fpage>&#8211;<lpage>832</lpage>. <pub-id pub-id-type="doi">10.1093/jnci/djaa216</pub-id>.<pub-id pub-id-type="pmid">33432320</pub-id><pub-id pub-id-type="pmcid">PMC8246900</pub-id></mixed-citation></ref><ref id="ref20"><mixed-citation publication-type="journal" id="cit20"><name name-style="western"><surname>Patel</surname><given-names>S. P.</given-names></name>; <name name-style="western"><surname>Othus</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name>; <name name-style="western"><surname>Wright</surname><given-names>G. P.</given-names></name>; <name name-style="western"><surname>Yost</surname><given-names>K. J.</given-names></name>; <name name-style="western"><surname>Hyngstrom</surname><given-names>J. R.</given-names></name>; <name name-style="western"><surname>Hu-Lieskovan</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Lao</surname><given-names>C. D.</given-names></name>; <name name-style="western"><surname>Fecher</surname><given-names>L. A.</given-names></name>; <name name-style="western"><surname>Truong</surname><given-names>T.-G.</given-names></name>; et al. <article-title>Neoadjuvant&#8211;Adjuvant or Adjuvant-Only
Pembrolizumab in Advanced Melanoma</article-title>. <source>New England
Journal of Medicine</source><year>2023</year>, <volume>388</volume> (<issue>9</issue>), <fpage>813</fpage>&#8211;<lpage>823</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa2211437</pub-id>.<pub-id pub-id-type="pmid">36856617</pub-id><pub-id pub-id-type="pmcid">PMC10410527</pub-id></mixed-citation></ref><ref id="ref21"><mixed-citation publication-type="journal" id="cit21"><name name-style="western"><surname>Blank</surname><given-names>C. U.</given-names></name>; <name name-style="western"><surname>Lucas</surname><given-names>M. W.</given-names></name>; <name name-style="western"><surname>Scolyer</surname><given-names>R. A.</given-names></name>; <name name-style="western"><surname>Van De Wiel</surname><given-names>B. A.</given-names></name>; <name name-style="western"><surname>Menzies</surname><given-names>A. M.</given-names></name>; <name name-style="western"><surname>Lopez-Yurda</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Hoeijmakers</surname><given-names>L. L.</given-names></name>; <name name-style="western"><surname>Saw</surname><given-names>R. P. M.</given-names></name>; <name name-style="western"><surname>Lijnsvelt</surname><given-names>J. M.</given-names></name>; <name name-style="western"><surname>Maher</surname><given-names>N. G.</given-names></name>; et al. <article-title>Neoadjuvant
Nivolumab and Ipilimumab in Resectable Stage III Melanoma</article-title>. <source>New England Journal of Medicine</source><year>2024</year>, <elocation-id>NEJMoa2402604</elocation-id><pub-id pub-id-type="doi">10.1056/NEJMoa2402604</pub-id>.<pub-id pub-id-type="pmid">38828984</pub-id></mixed-citation></ref><ref id="ref22"><mixed-citation publication-type="journal" id="cit22"><name name-style="western"><surname>Blank</surname><given-names>C. U.</given-names></name>; <name name-style="western"><surname>Rozeman</surname><given-names>E. A.</given-names></name>; <name name-style="western"><surname>Fanchi</surname><given-names>L. F.</given-names></name>; <name name-style="western"><surname>Sikorska</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>van de Wiel</surname><given-names>B.</given-names></name>; <name name-style="western"><surname>Kvistborg</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Krijgsman</surname><given-names>O.</given-names></name>; <name name-style="western"><surname>van den Braber</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Philips</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Broeks</surname><given-names>A.</given-names></name>; et al. <article-title>Neoadjuvant versus adjuvant
ipilimumab plus nivolumab in macroscopic stage III melanoma</article-title>. <source>Nat. Med.</source><year>2018</year>, <volume>24</volume> (<issue>11</issue>), <fpage>1655</fpage>&#8211;<lpage>1661</lpage>. <pub-id pub-id-type="doi">10.1038/s41591-018-0198-0</pub-id>.<pub-id pub-id-type="pmid">30297911</pub-id></mixed-citation></ref><ref id="ref23"><mixed-citation publication-type="journal" id="cit23"><name name-style="western"><surname>Garner</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>de Visser</surname><given-names>K. E.</given-names></name><article-title>Immune
crosstalk in cancer progression and metastatic
spread: a complex conversation</article-title>. <source>Nat. Rev. Immunol</source><year>2020</year>, <volume>20</volume> (<issue>8</issue>), <fpage>483</fpage>&#8211;<lpage>497</lpage>. <pub-id pub-id-type="doi">10.1038/s41577-019-0271-z</pub-id>.<pub-id pub-id-type="pmid">32024984</pub-id></mixed-citation></ref><ref id="ref24"><mixed-citation publication-type="journal" id="cit24"><name name-style="western"><surname>Melero</surname><given-names>I.</given-names></name>; <name name-style="western"><surname>Castanon</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Alvarez</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Champiat</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Marabelle</surname><given-names>A.</given-names></name><article-title>Intratumoural
administration and tumour tissue targeting of cancer immunotherapies</article-title>. <source>Nat. Rev. Clin Oncol</source><year>2021</year>, <volume>18</volume> (<issue>9</issue>), <fpage>558</fpage>&#8211;<lpage>576</lpage>. <pub-id pub-id-type="doi">10.1038/s41571-021-00507-y</pub-id>.<pub-id pub-id-type="pmid">34006998</pub-id><pub-id pub-id-type="pmcid">PMC8130796</pub-id></mixed-citation></ref><ref id="ref25"><mixed-citation publication-type="journal" id="cit25"><name name-style="western"><surname>Milling</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name>; <name name-style="western"><surname>Irvine</surname><given-names>D. J.</given-names></name><article-title>Delivering
safer immunotherapies
for cancer</article-title>. <source>Adv. Drug Deliv Rev.</source><year>2017</year>, <volume>114</volume>, <fpage>79</fpage>&#8211;<lpage>101</lpage>. <pub-id pub-id-type="doi">10.1016/j.addr.2017.05.011</pub-id>.<pub-id pub-id-type="pmid">28545888</pub-id><pub-id pub-id-type="pmcid">PMC5647831</pub-id></mixed-citation></ref><ref id="ref26"><mixed-citation publication-type="journal" id="cit26"><name name-style="western"><surname>Riley</surname><given-names>R. S.</given-names></name>; <name name-style="western"><surname>June</surname><given-names>C. H.</given-names></name>; <name name-style="western"><surname>Langer</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Mitchell</surname><given-names>M. J.</given-names></name><article-title>Delivery technologies
for cancer immunotherapy</article-title>. <source>Nat. Rev. Drug Discov</source><year>2019</year>, <volume>18</volume> (<issue>3</issue>), <fpage>175</fpage>&#8211;<lpage>196</lpage>. <pub-id pub-id-type="doi">10.1038/s41573-018-0006-z</pub-id>.<pub-id pub-id-type="pmid">30622344</pub-id><pub-id pub-id-type="pmcid">PMC6410566</pub-id></mixed-citation></ref><ref id="ref27"><mixed-citation publication-type="journal" id="cit27"><name name-style="western"><surname>Irvine</surname><given-names>D. J.</given-names></name>; <name name-style="western"><surname>Dane</surname><given-names>E. L.</given-names></name><article-title>Enhancing cancer immunotherapy with nanomedicine</article-title>. <source>Nat. Rev. Immunol</source><year>2020</year>, <volume>20</volume> (<issue>5</issue>), <fpage>321</fpage>&#8211;<lpage>334</lpage>. <pub-id pub-id-type="doi">10.1038/s41577-019-0269-6</pub-id>.<pub-id pub-id-type="pmid">32005979</pub-id><pub-id pub-id-type="pmcid">PMC7536618</pub-id></mixed-citation></ref><ref id="ref28"><mixed-citation publication-type="journal" id="cit28"><name name-style="western"><surname>Goldberg</surname><given-names>M. S.</given-names></name><article-title>Improving
cancer immunotherapy through nanotechnology</article-title>. <source>Nat. Rev. Cancer</source><year>2019</year>, <volume>19</volume> (<issue>10</issue>), <fpage>587</fpage>&#8211;<lpage>602</lpage>. <pub-id pub-id-type="doi">10.1038/s41568-019-0186-9</pub-id>.<pub-id pub-id-type="pmid">31492927</pub-id></mixed-citation></ref><ref id="ref29"><mixed-citation publication-type="journal" id="cit29"><name name-style="western"><surname>Martin</surname><given-names>J. D.</given-names></name>; <name name-style="western"><surname>Cabral</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Stylianopoulos</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Jain</surname><given-names>R. K.</given-names></name><article-title>Improving cancer
immunotherapy using nanomedicines: progress, opportunities and challenges</article-title>. <source>Nat. Rev. Clin Oncol</source><year>2020</year>, <volume>17</volume> (<issue>4</issue>), <fpage>251</fpage>&#8211;<lpage>266</lpage>. <pub-id pub-id-type="doi">10.1038/s41571-019-0308-z</pub-id>.<pub-id pub-id-type="pmid">32034288</pub-id><pub-id pub-id-type="pmcid">PMC8272676</pub-id></mixed-citation></ref><ref id="ref30"><mixed-citation publication-type="journal" id="cit30"><name name-style="western"><surname>Thomas</surname><given-names>S. N.</given-names></name>; <name name-style="western"><surname>Rohner</surname><given-names>N. A.</given-names></name>; <name name-style="western"><surname>Edwards</surname><given-names>E. E.</given-names></name><article-title>Implications
of Lymphatic Transport
to Lymph Nodes in Immunity and Immunotherapy</article-title>. <source>Annu. Rev. Biomed. Eng.</source><year>2016</year>, <volume>18</volume> (<issue>1</issue>), <fpage>207</fpage>&#8211;<lpage>233</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-bioeng-101515-014413</pub-id>.<pub-id pub-id-type="pmid">26928210</pub-id><pub-id pub-id-type="pmcid">PMC5518935</pub-id></mixed-citation></ref><ref id="ref31"><mixed-citation publication-type="journal" id="cit31"><name name-style="western"><surname>O&#8217;Melia</surname><given-names>M. J.</given-names></name>; <name name-style="western"><surname>Lund</surname><given-names>A. W.</given-names></name>; <name name-style="western"><surname>Thomas</surname><given-names>S. N.</given-names></name><article-title>The Biophysics
of Lymphatic Transport:
Engineering Tools and Immunological Consequences</article-title>. <source>iScience</source><year>2019</year>, <volume>22</volume>, <fpage>28</fpage>&#8211;<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1016/j.isci.2019.11.005</pub-id>.<pub-id pub-id-type="pmid">31739172</pub-id><pub-id pub-id-type="pmcid">PMC6864335</pub-id></mixed-citation></ref><ref id="ref32"><mixed-citation publication-type="journal" id="cit32"><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name>; <name name-style="western"><surname>De Koker</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>De Geest</surname><given-names>B. G.</given-names></name><article-title>Engineering Strategies for Lymph
Node Targeted Immune Activation</article-title>. <source>Acc. Chem.
Res.</source><year>2020</year>, <volume>53</volume> (<issue>10</issue>), <fpage>2055</fpage>&#8211;<lpage>2067</lpage>. <pub-id pub-id-type="doi">10.1021/acs.accounts.0c00260</pub-id>.<pub-id pub-id-type="pmid">32910636</pub-id></mixed-citation></ref><ref id="ref33"><mixed-citation publication-type="journal" id="cit33"><name name-style="western"><surname>O&#8217;Melia</surname><given-names>M. J.</given-names></name>; <name name-style="western"><surname>Manspeaker</surname><given-names>M. P.</given-names></name>; <name name-style="western"><surname>Thomas</surname><given-names>S. N.</given-names></name><article-title>Tumor-draining lymph
nodes are survival
niches that support T cell priming against lymphatic transported tumor
antigen and effects of immune checkpoint blockade in TNBC</article-title>. <source>Cancer Immunol Immunother</source><year>2021</year>, <volume>70</volume> (<issue>8</issue>), <fpage>2179</fpage>&#8211;<lpage>2195</lpage>. <pub-id pub-id-type="doi">10.1007/s00262-020-02792-5</pub-id>.<pub-id pub-id-type="pmid">33459842</pub-id><pub-id pub-id-type="pmcid">PMC8286278</pub-id></mixed-citation></ref><ref id="ref34"><mixed-citation publication-type="journal" id="cit34"><name name-style="western"><surname>Prokhnevska</surname><given-names>N.</given-names></name>; <name name-style="western"><surname>Cardenas</surname><given-names>M. A.</given-names></name>; <name name-style="western"><surname>Valanparambil</surname><given-names>R. M.</given-names></name>; <name name-style="western"><surname>Sobierajska</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Barwick</surname><given-names>B. G.</given-names></name>; <name name-style="western"><surname>Jansen</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Reyes Moon</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Gregorova</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>delBalzo</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Greenwald</surname><given-names>R.</given-names></name>; et al. <article-title>CD8+ T cell activation in cancer comprises an initial activation
phase in lymph nodes followed by effector differentiation within the
tumor</article-title>. <source>Immunity</source><year>2023</year>, <volume>56</volume> (<issue>1</issue>), <fpage>107</fpage>&#8211;<lpage>124.e105</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2022.12.002</pub-id>.<pub-id pub-id-type="pmid">36580918</pub-id><pub-id pub-id-type="pmcid">PMC10266440</pub-id></mixed-citation></ref><ref id="ref35"><mixed-citation publication-type="journal" id="cit35"><name name-style="western"><surname>Lund</surname><given-names>A. W.</given-names></name>; <name name-style="western"><surname>Wagner</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Fankhauser</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Steinskog</surname><given-names>E. S.</given-names></name>; <name name-style="western"><surname>Broggi</surname><given-names>M. A.</given-names></name>; <name name-style="western"><surname>Spranger</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Gajewski</surname><given-names>T. F.</given-names></name>; <name name-style="western"><surname>Alitalo</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Eikesdal</surname><given-names>H. P.</given-names></name>; <name name-style="western"><surname>Wiig</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Swartz</surname><given-names>M. A.</given-names></name><article-title>Lymphatic
vessels
regulate immune microenvironments in human and murine melanoma</article-title>. <source>J. Clin Invest</source><year>2016</year>, <volume>126</volume> (<issue>9</issue>), <fpage>3389</fpage>&#8211;<lpage>3402</lpage>. <pub-id pub-id-type="doi">10.1172/JCI79434</pub-id>.<pub-id pub-id-type="pmid">27525437</pub-id><pub-id pub-id-type="pmcid">PMC5004967</pub-id></mixed-citation></ref><ref id="ref36"><mixed-citation publication-type="journal" id="cit36"><name name-style="western"><surname>Im</surname><given-names>S. J.</given-names></name>; <name name-style="western"><surname>Hashimoto</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Gerner</surname><given-names>M. Y.</given-names></name>; <name name-style="western"><surname>Lee</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Kissick</surname><given-names>H. T.</given-names></name>; <name name-style="western"><surname>Burger</surname><given-names>M. C.</given-names></name>; <name name-style="western"><surname>Shan</surname><given-names>Q.</given-names></name>; <name name-style="western"><surname>Hale</surname><given-names>J. S.</given-names></name>; <name name-style="western"><surname>Lee</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Nasti</surname><given-names>T. H.</given-names></name>; et al. <article-title>Defining CD8+ T cells that provide the proliferative
burst after PD-1 therapy</article-title>. <source>Nature</source><year>2016</year>, <volume>537</volume> (<issue>7620</issue>), <fpage>417</fpage>&#8211;<lpage>421</lpage>. <pub-id pub-id-type="doi">10.1038/nature19330</pub-id>.<pub-id pub-id-type="pmid">27501248</pub-id><pub-id pub-id-type="pmcid">PMC5297183</pub-id></mixed-citation></ref><ref id="ref37"><mixed-citation publication-type="journal" id="cit37"><name name-style="western"><surname>Miller</surname><given-names>B. C.</given-names></name>; <name name-style="western"><surname>Sen</surname><given-names>D. R.</given-names></name>; <name name-style="western"><surname>Abosy</surname><given-names>R. A.</given-names></name>; <name name-style="western"><surname>Bi</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Virkud</surname><given-names>Y. V.</given-names></name>; <name name-style="western"><surname>LaFleur</surname><given-names>M. W.</given-names></name>; <name name-style="western"><surname>Yates</surname><given-names>K. B.</given-names></name>; <name name-style="western"><surname>Lako</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Felt</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Naik</surname><given-names>G. S.</given-names></name>; et al. <article-title>Subsets of exhausted CD8+ T cells differentially mediate
tumor control and respond to checkpoint blockade</article-title>. <source>Nat. Immunol</source><year>2019</year>, <volume>20</volume> (<issue>3</issue>), <fpage>326</fpage>&#8211;<lpage>336</lpage>. <pub-id pub-id-type="doi">10.1038/s41590-019-0312-6</pub-id>.<pub-id pub-id-type="pmid">30778252</pub-id><pub-id pub-id-type="pmcid">PMC6673650</pub-id></mixed-citation></ref><ref id="ref38"><mixed-citation publication-type="journal" id="cit38"><name name-style="western"><surname>Siddiqui</surname><given-names>I.</given-names></name>; <name name-style="western"><surname>Schaeuble</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Chennupati</surname><given-names>V.</given-names></name>; <name name-style="western"><surname>Fuertes Marraco</surname><given-names>S. A.</given-names></name>; <name name-style="western"><surname>Calderon-Copete</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Pais Ferreira</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Carmona</surname><given-names>S. J.</given-names></name>; <name name-style="western"><surname>Scarpellino</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Gfeller</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Pradervand</surname><given-names>S.</given-names></name>; et al. <article-title>Intratumoral Tcf1+PD-1+CD8+
T Cells with Stem-like Properties Promote Tumor Control in Response
to Vaccination and Checkpoint Blockade Immunotherapy</article-title>. <source>Immunity</source><year>2019</year>, <volume>50</volume> (<issue>1</issue>), <fpage>195</fpage>&#8211;<lpage>211.e10</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2018.12.021</pub-id>.<pub-id pub-id-type="pmid">30635237</pub-id></mixed-citation></ref><ref id="ref39"><mixed-citation publication-type="journal" id="cit39"><name name-style="western"><surname>Connolly</surname><given-names>K. A.</given-names></name>; <name name-style="western"><surname>Kuchroo</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Venkat</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Khatun</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>William</surname><given-names>I.</given-names></name>; <name name-style="western"><surname>Hornick</surname><given-names>N.</given-names></name>; <name name-style="western"><surname>Fitzgerald</surname><given-names>B.</given-names></name>; <name name-style="western"><surname>Damo</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Kasmani</surname><given-names>M. Y.</given-names></name>; et al. <article-title>A reservoir
of stem-like
CD8+ T cells in the tumor-draining lymph node preserves the ongoing
anti-tumor immune response</article-title>. <source>Science immunology</source><year>2021</year>, <volume>6</volume> (<issue>64</issue>), <elocation-id>eabg7836</elocation-id><pub-id pub-id-type="doi">10.1126/sciimmunol.abg7836</pub-id>.<pub-id pub-id-type="pmid">34597124</pub-id><pub-id pub-id-type="pmcid">PMC8593910</pub-id></mixed-citation></ref><ref id="ref40"><mixed-citation publication-type="journal" id="cit40"><name name-style="western"><surname>Schenkel</surname><given-names>J. M.</given-names></name>; <name name-style="western"><surname>Herbst</surname><given-names>R. H.</given-names></name>; <name name-style="western"><surname>Canner</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Li</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Hillman</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Shanahan</surname><given-names>S.-L.</given-names></name>; <name name-style="western"><surname>Gibbons</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Smith</surname><given-names>O. C.</given-names></name>; <name name-style="western"><surname>Kim</surname><given-names>J. Y.</given-names></name>; <name name-style="western"><surname>Westcott</surname><given-names>P.</given-names></name>; et al. <article-title>Conventional type I
dendritic cells maintain
a reservoir of proliferative tumor-antigen specific TCF-1+ CD8+ T
cells in tumor-draining lymph nodes</article-title>. <source>Immunity</source><year>2021</year>, <volume>54</volume> (<issue>10</issue>), <fpage>2338</fpage>&#8211;<lpage>2353.e6</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2021.08.026</pub-id>.<pub-id pub-id-type="pmid">34534439</pub-id><pub-id pub-id-type="pmcid">PMC8604155</pub-id></mixed-citation></ref><ref id="ref41"><mixed-citation publication-type="journal" id="cit41"><name name-style="western"><surname>Buchwald</surname><given-names>Z. S.</given-names></name>; <name name-style="western"><surname>Nasti</surname><given-names>T. H.</given-names></name>; <name name-style="western"><surname>Lee</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Eberhardt</surname><given-names>C. S.</given-names></name>; <name name-style="western"><surname>Wieland</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Im</surname><given-names>S. J.</given-names></name>; <name name-style="western"><surname>Lawson</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Curran</surname><given-names>W.</given-names></name>; <name name-style="western"><surname>Ahmed</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Khan</surname><given-names>M. K.</given-names></name><article-title>Tumor-draining lymph node is important
for a robust abscopal effect stimulated by radiotherapy</article-title>. <source>Journal for ImmunoTherapy of Cancer</source><year>2020</year>, <volume>8</volume> (<issue>2</issue>), <elocation-id>e000867</elocation-id><pub-id pub-id-type="doi">10.1136/jitc-2020-000867</pub-id>.<pub-id pub-id-type="pmid">33028691</pub-id><pub-id pub-id-type="pmcid">PMC7542667</pub-id></mixed-citation></ref><ref id="ref42"><mixed-citation publication-type="journal" id="cit42"><name name-style="western"><surname>Battaglia</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Buzzonetti</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Martinelli</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Fanelli</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Petrillo</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Ferrandina</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Scambia</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Fattorossi</surname><given-names>A.</given-names></name><article-title>Selective
changes in the immune profile of tumor-draining lymph nodes after
different neoadjuvant chemoradiation regimens for locally advanced
cervical cancer</article-title>. <source>Int. J. Radiat Oncol Biol.
Phys.</source><year>2010</year>, <volume>76</volume> (<issue>5</issue>), <fpage>1546</fpage>&#8211;<lpage>1553</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijrobp.2009.10.014</pub-id>.<pub-id pub-id-type="pmid">20338481</pub-id></mixed-citation></ref><ref id="ref43"><mixed-citation publication-type="journal" id="cit43"><name name-style="western"><surname>Scarlett</surname><given-names>U. K.</given-names></name>; <name name-style="western"><surname>Rutkowski</surname><given-names>M. R.</given-names></name>; <name name-style="western"><surname>Rauwerdink</surname><given-names>A. M.</given-names></name>; <name name-style="western"><surname>Fields</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Escovar-Fadul</surname><given-names>X.</given-names></name>; <name name-style="western"><surname>Baird</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Cubillos-Ruiz</surname><given-names>J. R.</given-names></name>; <name name-style="western"><surname>Jacobs</surname><given-names>A. C.</given-names></name>; <name name-style="western"><surname>Gonzalez</surname><given-names>J. L.</given-names></name>; <name name-style="western"><surname>Weaver</surname><given-names>J.</given-names></name>; et al. <article-title>Ovarian
cancer progression is controlled by phenotypic
changes in dendritic cells</article-title>. <source>Journal of Experimental
Medicine</source><year>2012</year>, <volume>209</volume> (<issue>3</issue>), <fpage>495</fpage>&#8211;<lpage>506</lpage>. <pub-id pub-id-type="doi">10.1084/jem.20111413</pub-id>.<pub-id pub-id-type="pmid">22351930</pub-id><pub-id pub-id-type="pmcid">PMC3302234</pub-id></mixed-citation></ref><ref id="ref44"><mixed-citation publication-type="journal" id="cit44"><name name-style="western"><surname>van
Pul</surname><given-names>K. M.</given-names></name>; <name name-style="western"><surname>Vuylsteke</surname><given-names>R. J. C. L.
M.</given-names></name>; <name name-style="western"><surname>van de Ven</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>te Velde</surname><given-names>E. A.</given-names></name>; <name name-style="western"><surname>Rutgers</surname><given-names>E. J. T.</given-names></name>; <name name-style="western"><surname>van den Tol</surname><given-names>P. M.</given-names></name>; <name name-style="western"><surname>Stockmann</surname><given-names>H. B. A. C.</given-names></name>; <name name-style="western"><surname>de Gruijl</surname><given-names>T. D.</given-names></name><article-title>Selectively hampered activation of
lymph node-resident dendritic cells precedes profound T cell suppression
and metastatic spread in the breast cancer sentinel lymph node</article-title>. <source>Journal for ImmunoTherapy of Cancer</source><year>2019</year>, <volume>7</volume> (<issue>1</issue>), <fpage>133</fpage><pub-id pub-id-type="doi">10.1186/s40425-019-0605-1</pub-id>.<pub-id pub-id-type="pmid">31118093</pub-id><pub-id pub-id-type="pmcid">PMC6530094</pub-id></mixed-citation></ref><ref id="ref45"><mixed-citation publication-type="journal" id="cit45"><name name-style="western"><surname>Munn</surname><given-names>D. H.</given-names></name>; <name name-style="western"><surname>Sharma</surname><given-names>M. D.</given-names></name>; <name name-style="western"><surname>Hou</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Baban</surname><given-names>B.</given-names></name>; <name name-style="western"><surname>Lee</surname><given-names>J. R.</given-names></name>; <name name-style="western"><surname>Antonia</surname><given-names>S. J.</given-names></name>; <name name-style="western"><surname>Messina</surname><given-names>J. L.</given-names></name>; <name name-style="western"><surname>Chandler</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Koni</surname><given-names>P. A.</given-names></name>; <name name-style="western"><surname>Mellor</surname><given-names>A. L.</given-names></name><article-title>Expression of indoleamine
2,3-dioxygenase by plasmacytoid
dendritic cells in tumor-draining lymph nodes</article-title>. <source>J. Clin Invest</source><year>2004</year>, <volume>114</volume> (<issue>2</issue>), <fpage>280</fpage>&#8211;<lpage>290</lpage>. <pub-id pub-id-type="doi">10.1172/JCI21583</pub-id>.<pub-id pub-id-type="pmid">15254595</pub-id><pub-id pub-id-type="pmcid">PMC449750</pub-id></mixed-citation></ref><ref id="ref46"><mixed-citation publication-type="journal" id="cit46"><name name-style="western"><surname>Sharma</surname><given-names>M. D.</given-names></name>; <name name-style="western"><surname>Baban</surname><given-names>B.</given-names></name>; <name name-style="western"><surname>Chandler</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Hou</surname><given-names>D.-Y.</given-names></name>; <name name-style="western"><surname>Singh</surname><given-names>N.</given-names></name>; <name name-style="western"><surname>Yagita</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Azuma</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Blazar</surname><given-names>B. R.</given-names></name>; <name name-style="western"><surname>Mellor</surname><given-names>A. L.</given-names></name>; <name name-style="western"><surname>Munn</surname><given-names>D. H.</given-names></name><article-title>Plasmacytoid dendritic cells from mouse tumor-draining
lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase</article-title>. <source>J. Clin Invest</source><year>2007</year>, <volume>117</volume> (<issue>9</issue>), <fpage>2570</fpage>&#8211;<lpage>2582</lpage>. <pub-id pub-id-type="doi">10.1172/JCI31911</pub-id>.<pub-id pub-id-type="pmid">17710230</pub-id><pub-id pub-id-type="pmcid">PMC1940240</pub-id></mixed-citation></ref><ref id="ref47"><mixed-citation publication-type="journal" id="cit47"><name name-style="western"><surname>Woo</surname><given-names>S. U.</given-names></name>; <name name-style="western"><surname>Bae</surname><given-names>J. W.</given-names></name>; <name name-style="western"><surname>Yang</surname><given-names>J.-H.</given-names></name>; <name name-style="western"><surname>Kim</surname><given-names>J. H.</given-names></name>; <name name-style="western"><surname>Nam</surname><given-names>S. J.</given-names></name>; <name name-style="western"><surname>Shin</surname><given-names>Y. K.</given-names></name><article-title>Overexpression of
Interleukin-10 in Sentinel Lymph
Node with Breast Cancer</article-title>. <source>Ann. Surg Oncol</source><year>2007</year>, <volume>14</volume> (<issue>11</issue>), <fpage>3268</fpage>&#8211;<lpage>3273</lpage>. <pub-id pub-id-type="doi">10.1245/s10434-007-9532-3</pub-id>.<pub-id pub-id-type="pmid">17762971</pub-id></mixed-citation></ref><ref id="ref48"><mixed-citation publication-type="journal" id="cit48"><name name-style="western"><surname>Li</surname><given-names>Y.-L.</given-names></name>; <name name-style="western"><surname>Hung</surname><given-names>W.-C.</given-names></name><article-title>Reprogramming
of sentinel lymph node microenvironment
during tumor metastasis</article-title>. <source>J. Biomed Sci.</source><year>2022</year>, <volume>29</volume> (<issue>1</issue>), <fpage>84</fpage><pub-id pub-id-type="doi">10.1186/s12929-022-00868-1</pub-id>.<pub-id pub-id-type="pmid">36266717</pub-id><pub-id pub-id-type="pmcid">PMC9583492</pub-id></mixed-citation></ref><ref id="ref49"><mixed-citation publication-type="journal" id="cit49"><name name-style="western"><surname>Lin</surname><given-names>J. T.</given-names></name>; <name name-style="western"><surname>Martin</surname><given-names>S. L.</given-names></name>; <name name-style="western"><surname>Xia</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Gorham</surname><given-names>J. D.</given-names></name><article-title>TGF-&#946;1 Uses
Distinct Mechanisms to Inhibit IFN-&#947; Expression in CD4+ T Cells
at Priming and at Recall: Differential Involvement of Stat4 and T-bet1</article-title>. <source>J. Immunol.</source><year>2005</year>, <volume>174</volume> (<issue>10</issue>), <fpage>5950</fpage>&#8211;<lpage>5958</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.174.10.5950</pub-id>.<pub-id pub-id-type="pmid">15879087</pub-id></mixed-citation></ref><ref id="ref50"><mixed-citation publication-type="journal" id="cit50"><name name-style="western"><surname>Chen</surname><given-names>C.-H.</given-names></name>; <name name-style="western"><surname>Seguin-Devaux</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Burke</surname><given-names>N. A.</given-names></name>; <name name-style="western"><surname>Oriss</surname><given-names>T. B.</given-names></name>; <name name-style="western"><surname>Watkins</surname><given-names>S. C.</given-names></name>; <name name-style="western"><surname>Clipstone</surname><given-names>N.</given-names></name>; <name name-style="western"><surname>Ray</surname><given-names>A.</given-names></name><article-title>Transforming Growth Factor &#946;
Blocks Tec Kinase Phosphorylation, Ca2+ Influx, and NFATc Translocation
Causing Inhibition of T Cell Differentiation</article-title>. <source>Journal of Experimental Medicine</source><year>2003</year>, <volume>197</volume> (<issue>12</issue>), <fpage>1689</fpage>&#8211;<lpage>1699</lpage>. <pub-id pub-id-type="doi">10.1084/jem.20021170</pub-id>.<pub-id pub-id-type="pmid">12810687</pub-id><pub-id pub-id-type="pmcid">PMC2193945</pub-id></mixed-citation></ref><ref id="ref51"><mixed-citation publication-type="journal" id="cit51"><name name-style="western"><surname>Alonso</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Flament</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Lemoine</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Sedlik</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Bottasso</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>P&#233;guillet</surname><given-names>I.</given-names></name>; <name name-style="western"><surname>Pr&#233;mel</surname><given-names>V.</given-names></name>; <name name-style="western"><surname>Denizeau</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Salou</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Darbois</surname><given-names>A.</given-names></name>; et al. <article-title>Induction of anergic or regulatory tumor-specific CD4+
T cells in the tumor-draining lymph node</article-title>. <source>Nat.
Commun.</source><year>2018</year>, <volume>9</volume> (<issue>1</issue>), <fpage>2113</fpage><pub-id pub-id-type="doi">10.1038/s41467-018-04524-x</pub-id>.<pub-id pub-id-type="pmid">29844317</pub-id><pub-id pub-id-type="pmcid">PMC5974295</pub-id></mixed-citation></ref><ref id="ref52"><mixed-citation publication-type="journal" id="cit52"><name name-style="western"><surname>Dammeijer</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>van Gulijk</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Mulder</surname><given-names>E. E.</given-names></name>; <name name-style="western"><surname>Lukkes</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Klaase</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>van den Bosch</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>van Nimwegen</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Lau</surname><given-names>S. P.</given-names></name>; <name name-style="western"><surname>Latupeirissa</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Schetters</surname><given-names>S.</given-names></name>; et al. <article-title>The PD-1/PD-L1-Checkpoint Restrains T cell
Immunity in Tumor-Draining Lymph Nodes</article-title>. <source>Cancer
Cell</source><year>2020</year>, <volume>38</volume> (<issue>5</issue>), <fpage>685</fpage>&#8211;<lpage>700.e8</lpage>. <pub-id pub-id-type="doi">10.1016/j.ccell.2020.09.001</pub-id>.<pub-id pub-id-type="pmid">33007259</pub-id></mixed-citation></ref><ref id="ref53"><mixed-citation publication-type="journal" id="cit53"><name name-style="western"><surname>Li</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Yuan</surname><given-names>Z.</given-names></name>; <name name-style="western"><surname>Lyu</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Ahn</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Davis</surname><given-names>S. J.</given-names></name>; <name name-style="western"><surname>Ahmed</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Zhu</surname><given-names>C.</given-names></name><article-title>PD-1 suppresses TCR-CD8 cooperativity
during T-cell antigen recognition</article-title>. <source>Nat. Commun.</source><year>2021</year>, <volume>12</volume> (<issue>1</issue>), <fpage>2746</fpage><pub-id pub-id-type="doi">10.1038/s41467-021-22965-9</pub-id>.<pub-id pub-id-type="pmid">33980853</pub-id><pub-id pub-id-type="pmcid">PMC8115078</pub-id></mixed-citation></ref><ref id="ref54"><mixed-citation publication-type="journal" id="cit54"><name name-style="western"><surname>Sun</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Mezzadra</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Schumacher</surname><given-names>T. N.</given-names></name><article-title>Regulation
and Function of the PD-L1
Checkpoint</article-title>. <source>Immunity</source><year>2018</year>, <volume>48</volume> (<issue>3</issue>), <fpage>434</fpage>&#8211;<lpage>452</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2018.03.014</pub-id>.<pub-id pub-id-type="pmid">29562194</pub-id><pub-id pub-id-type="pmcid">PMC7116507</pub-id></mixed-citation></ref><ref id="ref55"><mixed-citation publication-type="journal" id="cit55"><name name-style="western"><surname>Wei</surname><given-names>S. C.</given-names></name>; <name name-style="western"><surname>Duffy</surname><given-names>C. R.</given-names></name>; <name name-style="western"><surname>Allison</surname><given-names>J. P.</given-names></name><article-title>Fundamental
Mechanisms of Immune
Checkpoint Blockade Therapy</article-title>. <source>Cancer Discovery</source><year>2018</year>, <volume>8</volume> (<issue>9</issue>), <fpage>1069</fpage>&#8211;<lpage>1086</lpage>. <pub-id pub-id-type="doi">10.1158/2159-8290.CD-18-0367</pub-id>.<pub-id pub-id-type="pmid">30115704</pub-id></mixed-citation></ref><ref id="ref56"><mixed-citation publication-type="journal" id="cit56"><name name-style="western"><surname>Baitsch</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Baumgaertner</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Dev&#234;vre</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Raghav</surname><given-names>S. K.</given-names></name>; <name name-style="western"><surname>Legat</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Barba</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Wieckowski</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Bouzourene</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Deplancke</surname><given-names>B.</given-names></name>; <name name-style="western"><surname>Romero</surname><given-names>P.</given-names></name>; et al. <article-title>Exhaustion of tumor-specific
CD8+ T cells in metastases from melanoma patients</article-title>. <source>J. Clin Invest</source><year>2011</year>, <volume>121</volume> (<issue>6</issue>), <fpage>2350</fpage>&#8211;<lpage>2360</lpage>. <pub-id pub-id-type="doi">10.1172/JCI46102</pub-id>.<pub-id pub-id-type="pmid">21555851</pub-id><pub-id pub-id-type="pmcid">PMC3104769</pub-id></mixed-citation></ref><ref id="ref57"><mixed-citation publication-type="journal" id="cit57"><person-group person-group-type="allauthors"><name name-style="western"><surname>Dieterich</surname><given-names>L. C.</given-names></name>; <name name-style="western"><surname>Ikenberg</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Cetintas</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Kapaklikaya</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Hutmacher</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Detmar</surname><given-names>M.</given-names></name></person-group><article-title>Tumor-Associated
Lymphatic Vessels Upregulate PDL1 to Inhibit T-Cell Activation</article-title>. <source>Frontiers in Immunology</source><year>2017</year>, <volume>8</volume>.<pub-id pub-id-type="doi">10.3389/fimmu.2017.00066</pub-id><pub-id pub-id-type="pmcid">PMC5289955</pub-id><pub-id pub-id-type="pmid">28217128</pub-id></mixed-citation></ref><ref id="ref58"><mixed-citation publication-type="journal" id="cit58"><name name-style="western"><surname>Lund</surname><given-names>A. W.</given-names></name>; <name name-style="western"><surname>Duraes</surname><given-names>F. V.</given-names></name>; <name name-style="western"><surname>Hirosue</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Raghavan</surname><given-names>V. R.</given-names></name>; <name name-style="western"><surname>Nembrini</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Thomas</surname><given-names>S. N.</given-names></name>; <name name-style="western"><surname>Issa</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Hugues</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Swartz</surname><given-names>M. A.</given-names></name><article-title>VEGF-C
Promotes Immune Tolerance in B16 Melanomas and Cross-Presentation
of Tumor Antigen by Lymph Node Lymphatics</article-title>. <source>Cell
Reports</source><year>2012</year>, <volume>1</volume> (<issue>3</issue>), <fpage>191</fpage>&#8211;<lpage>199</lpage>. <pub-id pub-id-type="doi">10.1016/j.celrep.2012.01.005</pub-id>.<pub-id pub-id-type="pmid">22832193</pub-id></mixed-citation></ref><ref id="ref59"><mixed-citation publication-type="journal" id="cit59"><name name-style="western"><surname>Torcellan</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Hampton</surname><given-names>H. R.</given-names></name>; <name name-style="western"><surname>Bailey</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Tomura</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Brink</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Chtanova</surname><given-names>T.</given-names></name><article-title>In vivo photolabeling of tumor-infiltrating
cells reveals
highly regulated egress of T-cell subsets from tumors</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source><year>2017</year>, <volume>114</volume> (<issue>22</issue>), <fpage>5677</fpage>&#8211;<lpage>5682</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1618446114</pub-id>.<pub-id pub-id-type="pmid">28507145</pub-id><pub-id pub-id-type="pmcid">PMC5465915</pub-id></mixed-citation></ref><ref id="ref60"><mixed-citation publication-type="journal" id="cit60"><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name>; <name name-style="western"><surname>Tuong</surname><given-names>Z. K.</given-names></name>; <name name-style="western"><surname>Dean</surname><given-names>I.</given-names></name>; <name name-style="western"><surname>Willis</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Gaspal</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Fiancette</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Idris</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Kennedy</surname><given-names>B.</given-names></name>; <name name-style="western"><surname>Ferdinand</surname><given-names>J. R.</given-names></name>; <name name-style="western"><surname>Pe&#241;alver</surname><given-names>A.</given-names></name>; et al. <article-title>In vivo labeling reveals continuous trafficking
of TCF-1+ T cells between tumor and lymphoid tissue</article-title>. <source>Journal of Experimental Medicine</source><year>2022</year>, <volume>219</volume> (<issue>6</issue>), <elocation-id>e20210749</elocation-id><pub-id pub-id-type="doi">10.1084/jem.20210749</pub-id>.<pub-id pub-id-type="pmid">35472220</pub-id><pub-id pub-id-type="pmcid">PMC9048291</pub-id></mixed-citation></ref><ref id="ref61"><mixed-citation publication-type="journal" id="cit61"><name name-style="western"><surname>Steele</surname><given-names>M. M.</given-names></name>; <name name-style="western"><surname>Jaiswal</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Delclaux</surname><given-names>I.</given-names></name>; <name name-style="western"><surname>Dryg</surname><given-names>I. D.</given-names></name>; <name name-style="western"><surname>Murugan</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Femel</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Son</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>du Bois</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Hill</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Leachman</surname><given-names>S. A.</given-names></name>; et al. <article-title>T cell
egress via lymphatic vessels is tuned
by antigen encounter and limits tumor control</article-title>. <source>Nat. Immunol</source><year>2023</year>, <volume>24</volume>, <fpage>664</fpage><pub-id pub-id-type="doi">10.1038/s41590-023-01443-y</pub-id>.<pub-id pub-id-type="pmid">36849745</pub-id><pub-id pub-id-type="pmcid">PMC10998279</pub-id></mixed-citation></ref><ref id="ref62"><mixed-citation publication-type="journal" id="cit62"><person-group person-group-type="allauthors"><name name-style="western"><surname>Guo</surname><given-names>Z. S.</given-names></name>; <name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name>; <name name-style="western"><surname>Bartlett</surname><given-names>D. L.</given-names></name></person-group><article-title>Oncolytic Immunotherapy:
Dying the Right Way is a Key to Eliciting Potent Antitumor Immunity</article-title>. <source>Front. Oncol.</source><year>2014</year>, <volume>4</volume>.<pub-id pub-id-type="doi">10.3389/fonc.2014.00074</pub-id>.<pub-id pub-id-type="pmcid">PMC3989763</pub-id><pub-id pub-id-type="pmid">24782985</pub-id></mixed-citation></ref><ref id="ref63"><mixed-citation publication-type="journal" id="cit63"><name name-style="western"><surname>Dummer</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Gyorki</surname><given-names>D. E.</given-names></name>; <name name-style="western"><surname>Hyngstrom</surname><given-names>J. R.</given-names></name>; <name name-style="western"><surname>Ning</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Lawrence</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Ross</surname><given-names>M. I.</given-names></name><article-title>Final 5-Year Follow-Up
Results Evaluating Neoadjuvant
Talimogene Laherparepvec Plus Surgery in Advanced Melanoma: A Randomized
Clinical Trial</article-title>. <source>JAMA Oncology</source><year>2023</year>, <volume>9</volume> (<issue>10</issue>), <fpage>1457</fpage>&#8211;<lpage>1459</lpage>. <pub-id pub-id-type="doi">10.1001/jamaoncol.2023.2789</pub-id>.<pub-id pub-id-type="pmid">37561473</pub-id><pub-id pub-id-type="pmcid">PMC10416083</pub-id></mixed-citation></ref><ref id="ref64"><mixed-citation publication-type="journal" id="cit64"><name name-style="western"><surname>Palanivelu</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Liu</surname><given-names>C.-H.</given-names></name>; <name name-style="western"><surname>Lin</surname><given-names>L.-T.</given-names></name><article-title>Immunogenic cell death: The cornerstone
of oncolytic viro-immunotherapy</article-title>. <source>Frontiers in
Immunology</source><year>2023</year>, <volume>13</volume>, <elocation-id>1038226</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2022.1038226</pub-id>.<pub-id pub-id-type="pmid">36755812</pub-id><pub-id pub-id-type="pmcid">PMC9899992</pub-id></mixed-citation></ref><ref id="ref65"><mixed-citation publication-type="journal" id="cit65"><name name-style="western"><surname>Kaufman</surname><given-names>H. L.</given-names></name>; <name name-style="western"><surname>Kim</surname><given-names>D. W.</given-names></name>; <name name-style="western"><surname>DeRaffele</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Mitcham</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Coffin</surname><given-names>R. S.</given-names></name>; <name name-style="western"><surname>Kim-Schulze</surname><given-names>S.</given-names></name><article-title>Local and
Distant Immunity Induced by Intralesional
Vaccination with an Oncolytic Herpes Virus Encoding GM-CSF in Patients
with Stage IIIc and IV Melanoma</article-title>. <source>Ann. Surg Oncol</source><year>2010</year>, <volume>17</volume> (<issue>3</issue>), <fpage>718</fpage>&#8211;<lpage>730</lpage>. <pub-id pub-id-type="doi">10.1245/s10434-009-0809-6</pub-id>.<pub-id pub-id-type="pmid">19915919</pub-id></mixed-citation></ref><ref id="ref66"><mixed-citation publication-type="journal" id="cit66"><name name-style="western"><surname>Malvehy</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Samoylenko</surname><given-names>I.</given-names></name>; <name name-style="western"><surname>Schadendorf</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Gutzmer</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Grob</surname><given-names>J.-J.</given-names></name>; <name name-style="western"><surname>Sacco</surname><given-names>J. J.</given-names></name>; <name name-style="western"><surname>Gorski</surname><given-names>K. S.</given-names></name>; <name name-style="western"><surname>Anderson</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Pickett</surname><given-names>C. A.</given-names></name>; <name name-style="western"><surname>Liu</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Gogas</surname><given-names>H.</given-names></name><article-title>Talimogene laherparepvec upregulates immune-cell populations
in non-injected lesions: findings from a phase II, multicenter, open-label
study in patients with stage IIIB&#8211;IVM1c melanoma</article-title>. <source>Journal for ImmunoTherapy of Cancer</source><year>2021</year>, <volume>9</volume> (<issue>3</issue>), <elocation-id>e001621</elocation-id><pub-id pub-id-type="doi">10.1136/jitc-2020-001621</pub-id>.<pub-id pub-id-type="pmid">33785610</pub-id><pub-id pub-id-type="pmcid">PMC8011715</pub-id></mixed-citation></ref><ref id="ref67"><mixed-citation publication-type="journal" id="cit67"><name name-style="western"><surname>Andtbacka</surname><given-names>R. H. I.</given-names></name>; <name name-style="western"><surname>Collichio</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Harrington</surname><given-names>K. J.</given-names></name>; <name name-style="western"><surname>Middleton</surname><given-names>M. R.</given-names></name>; <name name-style="western"><surname>Downey</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>&#214;hrling</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Kaufman</surname><given-names>H. L.</given-names></name><article-title>Final analyses of
OPTiM: a randomized phase III trial of talimogene laherparepvec versus
granulocyte-macrophage colony-stimulating factor in unresectable stage
III&#8211;IV melanoma</article-title>. <source>Journal for ImmunoTherapy
of Cancer</source><year>2019</year>, <volume>7</volume> (<issue>1</issue>), <fpage>145</fpage><pub-id pub-id-type="doi">10.1186/s40425-019-0623-z</pub-id>.<pub-id pub-id-type="pmid">31171039</pub-id><pub-id pub-id-type="pmcid">PMC6554874</pub-id></mixed-citation></ref><ref id="ref68"><mixed-citation publication-type="journal" id="cit68"><person-group person-group-type="allauthors"><name name-style="western"><surname>Francis</surname><given-names>D. M.</given-names></name>; <name name-style="western"><surname>Manspeaker</surname><given-names>M. P.</given-names></name>; <name name-style="western"><surname>Schudel</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Sestito</surname><given-names>L. F.</given-names></name>; <name name-style="western"><surname>O&#8217;Melia</surname><given-names>M. J.</given-names></name>; <name name-style="western"><surname>Kissick</surname><given-names>H. T.</given-names></name>; <name name-style="western"><surname>Pollack</surname><given-names>B. P.</given-names></name>; <name name-style="western"><surname>Waller</surname><given-names>E. K.</given-names></name>; <name name-style="western"><surname>Thomas</surname><given-names>S. N.</given-names></name></person-group><article-title>Blockade of
immune checkpoints in lymph nodes through locoregional delivery augments
cancer immunotherapy</article-title>. <source>Science Translational
Medicine</source><year>2020</year>, <volume>12</volume> ( (<issue>563</issue>), ).<pub-id pub-id-type="doi">10.1126/scitranslmed.aay3575</pub-id>.<pub-id pub-id-type="pmcid">PMC8377700</pub-id><pub-id pub-id-type="pmid">32998971</pub-id></mixed-citation></ref><ref id="ref69"><mixed-citation publication-type="journal" id="cit69"><name name-style="western"><surname>Weide</surname><given-names>B.</given-names></name>; <name name-style="western"><surname>Eigentler</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Catania</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Ascierto</surname><given-names>P. A.</given-names></name>; <name name-style="western"><surname>Cascinu</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Becker</surname><given-names>J. C.</given-names></name>; <name name-style="western"><surname>Hauschild</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Romanini</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Danielli</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Dummer</surname><given-names>R.</given-names></name>; et al. <article-title>A phase
II study of the L19IL2 immunocytokine in combination
with dacarbazine in advanced metastatic melanoma patients</article-title>. <source>Cancer Immunol Immunother</source><year>2019</year>, <volume>68</volume> (<issue>9</issue>), <fpage>1547</fpage>&#8211;<lpage>1559</lpage>. <pub-id pub-id-type="doi">10.1007/s00262-019-02383-z</pub-id>.<pub-id pub-id-type="pmid">31482307</pub-id><pub-id pub-id-type="pmcid">PMC11028321</pub-id></mixed-citation></ref><ref id="ref70"><mixed-citation publication-type="journal" id="cit70"><name name-style="western"><surname>Burotto</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Zvirbule</surname><given-names>Z.</given-names></name>; <name name-style="western"><surname>Mochalova</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Runglodvatana</surname><given-names>Y.</given-names></name>; <name name-style="western"><surname>Herraez-Baranda</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Liu</surname><given-names>S. N.</given-names></name>; <name name-style="western"><surname>Chan</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Shearer-Kang</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name>; <name name-style="western"><surname>Tosti</surname><given-names>N.</given-names></name>; et al. <article-title>IMscin001
Part 2: a randomised phase III, open-label,
multicentre study examining the pharmacokinetics, efficacy, immunogenicity,
and safety of atezolizumab subcutaneous versus intravenous administration
in previously treated locally advanced or metastatic non-small-cell
lung cancer and pharmacokinetics comparison with other approved indications</article-title>. <source>Annals of Oncology</source><year>2023</year>, <volume>34</volume> (<issue>8</issue>), <fpage>693</fpage>&#8211;<lpage>702</lpage>. <pub-id pub-id-type="doi">10.1016/j.annonc.2023.05.009</pub-id>.<pub-id pub-id-type="pmid">37268157</pub-id></mixed-citation></ref><ref id="ref71"><mixed-citation publication-type="journal" id="cit71"><name name-style="western"><surname>George</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Bourlon</surname><given-names>M. T.</given-names></name>; <name name-style="western"><surname>Chacon</surname><given-names>M. R.</given-names></name>; <name name-style="western"><surname>Cutuli</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Lopez Chuken</surname><given-names>Y. A.</given-names></name>; <name name-style="western"><surname>Zurawski</surname><given-names>B.</given-names></name>; <name name-style="western"><surname>Mota</surname><given-names>J. M.</given-names></name>; <name name-style="western"><surname>Magri</surname><given-names>I.</given-names></name>; <name name-style="western"><surname>Burotto</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Luz</surname><given-names>M.</given-names></name>; et al. <article-title>Subcutaneous
nivolumab (NIVO SC) vs intravenous nivolumab
(NIVO IV) in patients with previously treated advanced or metastatic
clear cell renal cell carcinoma (ccRCC): Pharmacokinetics (PK), efficacy,
and safety results from CheckMate 67T</article-title>. <source>JCO</source><year>2024</year>, <volume>42</volume> (<issue>4_suppl</issue>), <fpage>LBA360</fpage>&#8211;<lpage>LBA360</lpage>. <pub-id pub-id-type="doi">10.1200/JCO.2024.42.4_suppl.LBA360</pub-id>.</mixed-citation></ref><ref id="ref72"><mixed-citation publication-type="journal" id="cit72"><name name-style="western"><surname>van
Pul</surname><given-names>K. M.</given-names></name>; <name name-style="western"><surname>Notohardjo</surname><given-names>J. C. L.</given-names></name>; <name name-style="western"><surname>Fransen</surname><given-names>M. F.</given-names></name>; <name name-style="western"><surname>Koster</surname><given-names>B. D.</given-names></name>; <name name-style="western"><surname>Stam</surname><given-names>A. G. M.</given-names></name>; <name name-style="western"><surname>Chondronasiou</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Lougheed</surname><given-names>S. M.</given-names></name>; <name name-style="western"><surname>Bakker</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Kandiah</surname><given-names>V.</given-names></name>; <name name-style="western"><surname>van den Tol</surname><given-names>M. P.</given-names></name>; et al. <article-title>Local delivery of low-dose
anti&#8211;CTLA-4 to the melanoma lymphatic basin leads to systemic
Treg reduction and effector T cell activation</article-title>. <source>Science Immunology</source><year>2022</year>, <volume>7</volume> (<issue>73</issue>), <elocation-id>eabn8097</elocation-id><pub-id pub-id-type="doi">10.1126/sciimmunol.abn8097</pub-id>.<pub-id pub-id-type="pmid">35857579</pub-id></mixed-citation></ref><ref id="ref73"><mixed-citation publication-type="journal" id="cit73"><name name-style="western"><surname>Ascierto</surname><given-names>P. A.</given-names></name>; <name name-style="western"><surname>Vecchio</surname><given-names>M. D.</given-names></name>; <name name-style="western"><surname>Robert</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Mackiewicz</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Chiarion-Sileni</surname><given-names>V.</given-names></name>; <name name-style="western"><surname>Arance</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Lebb&#233;</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Bastholt</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Hamid</surname><given-names>O.</given-names></name>; <name name-style="western"><surname>Rutkowski</surname><given-names>P.</given-names></name>; et al. <article-title>Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable
or metastatic melanoma: a randomised, double-blind, multicentre, phase
3 trial</article-title>. <source>Lancet Oncology</source><year>2017</year>, <volume>18</volume> (<issue>5</issue>), <fpage>611</fpage>&#8211;<lpage>622</lpage>. <pub-id pub-id-type="doi">10.1016/S1470-2045(17)30231-0</pub-id>.<pub-id pub-id-type="pmid">28359784</pub-id></mixed-citation></ref><ref id="ref74"><mixed-citation publication-type="journal" id="cit74"><name name-style="western"><surname>Shulgin</surname><given-names>B.</given-names></name>; <name name-style="western"><surname>Kosinsky</surname><given-names>Y.</given-names></name>; <name name-style="western"><surname>Omelchenko</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Chu</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Mugundu</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Aksenov</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Pimentel</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>DeYulia</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Kim</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Peskov</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Helmlinger</surname><given-names>G.</given-names></name><article-title>Dose dependence of treatment-related
adverse events for immune checkpoint inhibitor therapies: a model-based
meta-analysis</article-title>. <source>OncoImmunology</source><year>2020</year>, <volume>9</volume> (<issue>1</issue>), <elocation-id>1748982</elocation-id><pub-id pub-id-type="doi">10.1080/2162402X.2020.1748982</pub-id>.<pub-id pub-id-type="pmid">32934874</pub-id><pub-id pub-id-type="pmcid">PMC7466858</pub-id></mixed-citation></ref><ref id="ref75"><mixed-citation publication-type="journal" id="cit75"><name name-style="western"><surname>Tselikas</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Robert</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Dalle</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Meyer</surname><given-names>N.</given-names></name>; <name name-style="western"><surname>Lebbe</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Ammari</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Danlos</surname><given-names>F.-X.</given-names></name>; <name name-style="western"><surname>Roy</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Jannin</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Farhane</surname><given-names>S.</given-names></name>; et al. <article-title>277 Safety and efficacy
of intratumoral ipilimumab
with IV nivolumab in metastatic melanoma. The NIVIPIT trial</article-title>. <source>Journal for ImmunoTherapy of Cancer</source><year>2021</year>, <volume>9</volume> (<issue>Suppl 2</issue>), <fpage>A300</fpage>&#8211;<lpage>A300</lpage>. <pub-id pub-id-type="doi">10.1136/jitc-2021-SITC2021.277</pub-id>.</mixed-citation></ref><ref id="ref76"><mixed-citation publication-type="journal" id="cit76"><name name-style="western"><surname>Stebbings</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Poole</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Thorpe</surname><given-names>R.</given-names></name><article-title>Safety of
biologics, lessons learnt
from TGN1412</article-title>. <source>Curr. Opin. Biotechnol.</source><year>2009</year>, <volume>20</volume> (<issue>6</issue>), <fpage>673</fpage>&#8211;<lpage>677</lpage>. <pub-id pub-id-type="doi">10.1016/j.copbio.2009.10.002</pub-id>.<pub-id pub-id-type="pmid">19892543</pub-id></mixed-citation></ref><ref id="ref77"><mixed-citation publication-type="journal" id="cit77"><name name-style="western"><surname>Chester</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Sanmamed</surname><given-names>M. F.</given-names></name>; <name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Melero</surname><given-names>I.</given-names></name><article-title>Immunotherapy targeting
4&#8211;1BB: mechanistic rationale, clinical results, and future
strategies</article-title>. <source>Blood</source><year>2018</year>, <volume>131</volume> (<issue>1</issue>), <fpage>49</fpage>&#8211;<lpage>57</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2017-06-741041</pub-id>.<pub-id pub-id-type="pmid">29118009</pub-id></mixed-citation></ref><ref id="ref78"><mixed-citation publication-type="journal" id="cit78"><name name-style="western"><surname>Davis</surname><given-names>R. J.</given-names></name>; <name name-style="western"><surname>Ferris</surname><given-names>R. L.</given-names></name>; <name name-style="western"><surname>Schmitt</surname><given-names>N. C.</given-names></name><article-title>Costimulatory
and coinhibitory immune
checkpoint receptors in head and neck cancer: unleashing immune responses
through therapeutic combinations</article-title>. <source>Cancers of
the Head &amp; Neck</source><year>2016</year>, <volume>1</volume> (<issue>1</issue>), <fpage>12</fpage><pub-id pub-id-type="doi">10.1186/s41199-016-0013-x</pub-id>.<pub-id pub-id-type="pmid">31093342</pub-id><pub-id pub-id-type="pmcid">PMC6460794</pub-id></mixed-citation></ref><ref id="ref79"><mixed-citation publication-type="journal" id="cit79"><name name-style="western"><surname>Croft</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>So</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Duan</surname><given-names>W.</given-names></name>; <name name-style="western"><surname>Soroosh</surname><given-names>P.</given-names></name><article-title>The Significance
of OX40 and OX40L
to T cell Biology and Immune Disease</article-title>. <source>Immunol
Rev.</source><year>2009</year>, <volume>229</volume> (<issue>1</issue>), <fpage>173</fpage>&#8211;<lpage>191</lpage>. <pub-id pub-id-type="doi">10.1111/j.1600-065X.2009.00766.x</pub-id>.<pub-id pub-id-type="pmid">19426222</pub-id><pub-id pub-id-type="pmcid">PMC2729757</pub-id></mixed-citation></ref><ref id="ref80"><mixed-citation publication-type="journal" id="cit80"><name name-style="western"><surname>Bulliard</surname><given-names>Y.</given-names></name>; <name name-style="western"><surname>Jolicoeur</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Dranoff</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Wilson</surname><given-names>N. S.</given-names></name>; <name name-style="western"><surname>Brogdon</surname><given-names>J. L.</given-names></name><article-title>OX40 engagement
depletes intratumoral Tregs via activating
Fc&#947;Rs, leading to antitumor efficacy</article-title>. <source>Immunology &amp; Cell Biology</source><year>2014</year>, <volume>92</volume> (<issue>6</issue>), <fpage>475</fpage>&#8211;<lpage>480</lpage>. <pub-id pub-id-type="doi">10.1038/icb.2014.26</pub-id>.<pub-id pub-id-type="pmid">24732076</pub-id></mixed-citation></ref><ref id="ref81"><mixed-citation publication-type="journal" id="cit81"><name name-style="western"><surname>Duhen</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Ballesteros-Merino</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Frye</surname><given-names>A. K.</given-names></name>; <name name-style="western"><surname>Tran</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Rajamanickam</surname><given-names>V.</given-names></name>; <name name-style="western"><surname>Chang</surname><given-names>S.-C.</given-names></name>; <name name-style="western"><surname>Koguchi</surname><given-names>Y.</given-names></name>; <name name-style="western"><surname>Bifulco</surname><given-names>C. B.</given-names></name>; <name name-style="western"><surname>Bernard</surname><given-names>B.</given-names></name>; <name name-style="western"><surname>Leidner</surname><given-names>R. S.</given-names></name>; et al. <article-title>Neoadjuvant anti-OX40 (MEDI6469) therapy in
patients with head and neck squamous cell carcinoma activates and
expands antigen-specific tumor-infiltrating T cells</article-title>. <source>Nat. Commun.</source><year>2021</year>, <volume>12</volume> (<issue>1</issue>), <fpage>1047</fpage><pub-id pub-id-type="doi">10.1038/s41467-021-21383-1</pub-id>.<pub-id pub-id-type="pmid">33594075</pub-id><pub-id pub-id-type="pmcid">PMC7886909</pub-id></mixed-citation></ref><ref id="ref82"><mixed-citation publication-type="journal" id="cit82"><name name-style="western"><surname>Innamarato</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Asby</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Morse</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Mackay</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Hall</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Kidd</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Nagle</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Sarnaik</surname><given-names>A. A.</given-names></name>; <name name-style="western"><surname>Pilon-Thomas</surname><given-names>S.</given-names></name><article-title>Intratumoral
Activation of 41BB Costimulatory Signals Enhances CD8 T Cell Expansion
and Modulates Tumor-Infiltrating Myeloid Cells</article-title>. <source>J. Immunol.</source><year>2020</year>, <volume>205</volume> (<issue>10</issue>), <fpage>2893</fpage>&#8211;<lpage>2904</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.2000759</pub-id>.<pub-id pub-id-type="pmid">33020146</pub-id><pub-id pub-id-type="pmcid">PMC7741883</pub-id></mixed-citation></ref><ref id="ref83"><mixed-citation publication-type="journal" id="cit83"><name name-style="western"><surname>Palmeri</surname><given-names>J. R.</given-names></name>; <name name-style="western"><surname>Lax</surname><given-names>B. M.</given-names></name>; <name name-style="western"><surname>Peters</surname><given-names>J. M.</given-names></name>; <name name-style="western"><surname>Duhamel</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Stinson</surname><given-names>J. A.</given-names></name>; <name name-style="western"><surname>Santollani</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Lutz</surname><given-names>E. A.</given-names></name>; <name name-style="western"><surname>Pinney</surname><given-names>W.</given-names></name>; <name name-style="western"><surname>Bryson</surname><given-names>B. D.</given-names></name>; <name name-style="western"><surname>Dane Wittrup</surname><given-names>K.</given-names></name><article-title>CD8+ T cell priming that is required
for curative intratumorally
anchored anti-4&#8211;1BB immunotherapy is constrained by Tregs</article-title>. <source>Nat. Commun.</source><year>2024</year>, <volume>15</volume> (<issue>1</issue>), <fpage>1900</fpage><pub-id pub-id-type="doi">10.1038/s41467-024-45625-0</pub-id>.<pub-id pub-id-type="pmid">38429261</pub-id><pub-id pub-id-type="pmcid">PMC10907589</pub-id></mixed-citation></ref><ref id="ref84"><mixed-citation publication-type="journal" id="cit84"><name name-style="western"><surname>Arvedson</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Bailis</surname><given-names>J. M.</given-names></name>; <name name-style="western"><surname>Britten</surname><given-names>C. D.</given-names></name>; <name name-style="western"><surname>Klinger</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Nagorsen</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Coxon</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Egen</surname><given-names>J. G.</given-names></name>; <name name-style="western"><surname>Martin</surname><given-names>F.</given-names></name><article-title>Targeting
Solid Tumors
with Bispecific T Cell Engager Immune Therapy</article-title>. <source>Annual Review of Cancer Biology</source><year>2022</year>, <volume>6</volume> (<issue>1</issue>), <fpage>17</fpage>&#8211;<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-cancerbio-070620-104325</pub-id>.</mixed-citation></ref><ref id="ref85"><mixed-citation publication-type="journal" id="cit85"><name name-style="western"><surname>Fajardo</surname><given-names>C. A.</given-names></name>; <name name-style="western"><surname>Guedan</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Rojas</surname><given-names>L. A.</given-names></name>; <name name-style="western"><surname>Moreno</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Arias-Badia</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>de Sostoa</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>June</surname><given-names>C. H.</given-names></name>; <name name-style="western"><surname>Alemany</surname><given-names>R.</given-names></name><article-title>Oncolytic Adenoviral
Delivery of an EGFR-Targeting T-cell Engager Improves Antitumor Efficacy</article-title>. <source>Cancer Res.</source><year>2017</year>, <volume>77</volume> (<issue>8</issue>), <fpage>2052</fpage>&#8211;<lpage>2063</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-16-1708</pub-id>.<pub-id pub-id-type="pmid">28143835</pub-id></mixed-citation></ref><ref id="ref86"><mixed-citation publication-type="journal" id="cit86"><name name-style="western"><surname>Speck</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Heidbuechel</surname><given-names>J. P. W.</given-names></name>; <name name-style="western"><surname>Veinalde</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Jaeger</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>von Kalle</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Ball</surname><given-names>C. R.</given-names></name>; <name name-style="western"><surname>Ungerechts</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Engeland</surname><given-names>C. E.</given-names></name><article-title>Targeted BiTE Expression
by an Oncolytic Vector Augments Therapeutic Efficacy Against Solid
Tumors</article-title>. <source>Clin. Cancer Res.</source><year>2018</year>, <volume>24</volume> (<issue>9</issue>), <fpage>2128</fpage>&#8211;<lpage>2137</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-17-2651</pub-id>.<pub-id pub-id-type="pmid">29437789</pub-id></mixed-citation></ref><ref id="ref87"><mixed-citation publication-type="journal" id="cit87"><name name-style="western"><surname>Han</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Nguyen</surname><given-names>B.</given-names></name>; <name name-style="western"><surname>Lee</surname><given-names>J. Y.</given-names></name>; <name name-style="western"><surname>Browning</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Mukhopadhyay</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Gujar</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Salazar</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Hermiz</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Svenson</surname><given-names>L.</given-names></name>; et al. <article-title>Intratumoral Electroporation of Plasmid Encoded IL12
and Membrane-Anchored Anti-CD3 Increases Systemic Tumor Immunity</article-title>. <source>Molecular Cancer Research</source><year>2022</year>, <volume>20</volume> (<issue>6</issue>), <fpage>983</fpage>&#8211;<lpage>995</lpage>. <pub-id pub-id-type="doi">10.1158/1541-7786.MCR-21-0834</pub-id>.<pub-id pub-id-type="pmid">35302641</pub-id></mixed-citation></ref><ref id="ref88"><mixed-citation publication-type="journal" id="cit88"><name name-style="western"><surname>Sotomayor</surname><given-names>E. M.</given-names></name>; <name name-style="western"><surname>Borrello</surname><given-names>I.</given-names></name>; <name name-style="western"><surname>Tubb</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Rattis</surname><given-names>F.-M.</given-names></name>; <name name-style="western"><surname>Bien</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Lu</surname><given-names>Z.</given-names></name>; <name name-style="western"><surname>Fein</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Schoenberger</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Levitsky</surname><given-names>H. I.</given-names></name><article-title>Conversion of tumor-specific
CD4+ T-cell tolerance to T-cell priming through in vivo ligation of
CD40</article-title>. <source>Nat. Med.</source><year>1999</year>, <volume>5</volume> (<issue>7</issue>), <fpage>780</fpage>&#8211;<lpage>787</lpage>. <pub-id pub-id-type="doi">10.1038/10503</pub-id>.<pub-id pub-id-type="pmid">10395323</pub-id></mixed-citation></ref><ref id="ref89"><mixed-citation publication-type="journal" id="cit89"><name name-style="western"><surname>Sandin</surname><given-names>L. C.</given-names></name>; <name name-style="western"><surname>Orlova</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Gustafsson</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Ellmark</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Tolmachev</surname><given-names>V.</given-names></name>; <name name-style="western"><surname>T&#246;tterman</surname><given-names>T. H.</given-names></name>; <name name-style="western"><surname>Mangsbo</surname><given-names>S. M.</given-names></name><article-title>Locally Delivered CD40 Agonist Antibody
Accumulates in Secondary Lymphoid Organs and Eradicates Experimental
Disseminated Bladder Cancer</article-title>. <source>Cancer Immunology
Research</source><year>2014</year>, <volume>2</volume> (<issue>1</issue>), <fpage>80</fpage>&#8211;<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1158/2326-6066.CIR-13-0067</pub-id>.<pub-id pub-id-type="pmid">24778163</pub-id></mixed-citation></ref><ref id="ref90"><mixed-citation publication-type="journal" id="cit90"><name name-style="western"><surname>Jackaman</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Nelson</surname><given-names>D. J.</given-names></name><article-title>Intratumoral interleukin-2/agonist
CD40 antibody drives
CD4+-independent resolution of treated-tumors and CD4+-dependent systemic
and memory responses</article-title>. <source>Cancer Immunol Immunother</source><year>2012</year>, <volume>61</volume> (<issue>4</issue>), <fpage>549</fpage>&#8211;<lpage>560</lpage>. <pub-id pub-id-type="doi">10.1007/s00262-011-1120-5</pub-id>.<pub-id pub-id-type="pmid">22002241</pub-id><pub-id pub-id-type="pmcid">PMC11029634</pub-id></mixed-citation></ref><ref id="ref91"><mixed-citation publication-type="journal" id="cit91"><name name-style="western"><surname>Irenaeus</surname><given-names>S. M. M.</given-names></name>; <name name-style="western"><surname>Nielsen</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Ellmark</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Yachnin</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Deronic</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Nilsson</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Norl&#233;n</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Veitonm&#228;ki</surname><given-names>N.</given-names></name>; <name name-style="western"><surname>Wennersten</surname><given-names>C. S.</given-names></name>; <name name-style="western"><surname>Ullenhag</surname><given-names>G. J.</given-names></name><article-title>First-in-human study with intratumoral
administration of a CD40 agonistic antibody, ADC-1013, in advanced
solid malignancies</article-title>. <source>Int. J. Cancer</source><year>2019</year>, <volume>145</volume> (<issue>5</issue>), <fpage>1189</fpage>&#8211;<lpage>1199</lpage>. <pub-id pub-id-type="doi">10.1002/ijc.32141</pub-id>.<pub-id pub-id-type="pmid">30664811</pub-id></mixed-citation></ref><ref id="ref92"><mixed-citation publication-type="journal" id="cit92"><name name-style="western"><surname>Bentebibel</surname><given-names>S.-E.</given-names></name>; <name name-style="western"><surname>Johnson</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Pazdrak</surname><given-names>B.</given-names></name>; <name name-style="western"><surname>McGrail</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Lecagoonporn</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Haymaker</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Duose</surname><given-names>D. Y.</given-names></name>; <name name-style="western"><surname>Wani</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Sonnemann</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Safa</surname><given-names>H.</given-names></name>; et al. <article-title>782 Intratumoral sotigalimab with pembrolizumab activates
antigen-presenting cells and induces local and distant anti-tumor
responses in first-line metastatic melanoma: results of a phase I/II
study</article-title>. <source>Journal for ImmunoTherapy of Cancer</source><year>2022</year>, <volume>10</volume> (<issue>Suppl 2</issue>), <fpage>CT039</fpage><pub-id pub-id-type="doi">10.1158/1538-7445.AM2022-CT039</pub-id>.</mixed-citation></ref><ref id="ref93"><mixed-citation publication-type="journal" id="cit93"><name name-style="western"><surname>Sharma</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Subudhi</surname><given-names>S. K.</given-names></name>; <name name-style="western"><surname>Blando</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Scutti</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Vence</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Wargo</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Allison</surname><given-names>J. P.</given-names></name>; <name name-style="western"><surname>Ribas</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Sharma</surname><given-names>P.</given-names></name><article-title>Anti-CTLA-4
Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in
Human Cancers</article-title>. <source>Clin. Cancer Res.</source><year>2019</year>, <volume>25</volume> (<issue>4</issue>), <fpage>1233</fpage>&#8211;<lpage>1238</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-18-0762</pub-id>.<pub-id pub-id-type="pmid">30054281</pub-id><pub-id pub-id-type="pmcid">PMC6348141</pub-id></mixed-citation></ref><ref id="ref94"><mixed-citation publication-type="journal" id="cit94"><name name-style="western"><surname>Lee</surname><given-names>W. S.</given-names></name>; <name name-style="western"><surname>Kim</surname><given-names>D. S.</given-names></name>; <name name-style="western"><surname>Kim</surname><given-names>J. H.</given-names></name>; <name name-style="western"><surname>Heo</surname><given-names>Y.</given-names></name>; <name name-style="western"><surname>Yang</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Go</surname><given-names>E.-J.</given-names></name>; <name name-style="western"><surname>Kim</surname><given-names>J. H.</given-names></name>; <name name-style="western"><surname>Lee</surname><given-names>S. J.</given-names></name>; <name name-style="western"><surname>Ahn</surname><given-names>B. C.</given-names></name>; <name name-style="western"><surname>Yum</surname><given-names>J. S.</given-names></name>; et al. <article-title>Intratumoral immunotherapy using a TLR2/3 agonist,
L-pampo, induces robust antitumor immune responses and enhances immune
checkpoint blockade</article-title>. <source>Journal for ImmunoTherapy
of Cancer</source><year>2022</year>, <volume>10</volume> (<issue>6</issue>), <elocation-id>e004799</elocation-id><pub-id pub-id-type="doi">10.1136/jitc-2022-004799</pub-id>.<pub-id pub-id-type="pmid">35764365</pub-id><pub-id pub-id-type="pmcid">PMC9240943</pub-id></mixed-citation></ref><ref id="ref95"><mixed-citation publication-type="journal" id="cit95"><person-group person-group-type="allauthors"><name name-style="western"><surname>Roselli</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Araya</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>N&#250;&#241;ez</surname><given-names>N. G.</given-names></name>; <name name-style="western"><surname>Gatti</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Graziano</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Sedlik</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Benaroch</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Piaggio</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Maccioni</surname><given-names>M.</given-names></name></person-group><article-title>TLR3
Activation
of Intratumoral CD103+ Dendritic Cells Modifies the Tumor Infiltrate
Conferring Anti-tumor Immunity</article-title>. <source>Frontiers
in Immunology</source><year>2019</year>, <volume>10</volume>.<pub-id pub-id-type="doi">10.3389/fimmu.2019.00503</pub-id>.<pub-id pub-id-type="pmcid">PMC6435583</pub-id><pub-id pub-id-type="pmid">30949170</pub-id></mixed-citation></ref><ref id="ref96"><mixed-citation publication-type="journal" id="cit96"><name name-style="western"><surname>Heidenreich</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Jasny</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Kowalczyk</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Lutz</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Probst</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Baumhof</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Scheel</surname><given-names>B.</given-names></name>; <name name-style="western"><surname>Voss</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Kallen</surname><given-names>K.-J.</given-names></name>; <name name-style="western"><surname>Fotin-Mleczek</surname><given-names>M.</given-names></name><article-title>A novel RNA-based adjuvant combines strong immunostimulatory
capacities with a favorable safety profile</article-title>. <source>Int. J. Cancer</source><year>2015</year>, <volume>137</volume> (<issue>2</issue>), <fpage>372</fpage>&#8211;<lpage>384</lpage>. <pub-id pub-id-type="doi">10.1002/ijc.29402</pub-id>.<pub-id pub-id-type="pmid">25530186</pub-id></mixed-citation></ref><ref id="ref97"><mixed-citation publication-type="journal" id="cit97"><name name-style="western"><surname>Lutz</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Meister</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Habbeddine</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Fiedler</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Kowalczyk</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Heidenreich</surname><given-names>R.</given-names></name><article-title>Local immunotherapy with the RNA-based immune stimulator
CV8102 induces substantial anti-tumor responses and enhances checkpoint
inhibitor activity</article-title>. <source>Cancer Immunol Immunother</source><year>2023</year>, <volume>72</volume> (<issue>5</issue>), <fpage>1075</fpage>&#8211;<lpage>1087</lpage>. <pub-id pub-id-type="doi">10.1007/s00262-022-03311-4</pub-id>.<pub-id pub-id-type="pmid">36319717</pub-id><pub-id pub-id-type="pmcid">PMC10110722</pub-id></mixed-citation></ref><ref id="ref98"><mixed-citation publication-type="journal" id="cit98"><name name-style="western"><surname>Demaria</surname><given-names>O.</given-names></name>; <name name-style="western"><surname>De Gassart</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Coso</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Gestermann</surname><given-names>N.</given-names></name>; <name name-style="western"><surname>Di Domizio</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Flatz</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Gaide</surname><given-names>O.</given-names></name>; <name name-style="western"><surname>Michielin</surname><given-names>O.</given-names></name>; <name name-style="western"><surname>Hwu</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Petrova</surname><given-names>T. V.</given-names></name>; et al. <article-title>STING activation of tumor endothelial
cells initiates spontaneous and therapeutic antitumor immunity</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source><year>2015</year>, <volume>112</volume> (<issue>50</issue>), <fpage>15408</fpage>&#8211;<lpage>15413</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1512832112</pub-id>.<pub-id pub-id-type="pmid">26607445</pub-id><pub-id pub-id-type="pmcid">PMC4687570</pub-id></mixed-citation></ref><ref id="ref99"><mixed-citation publication-type="journal" id="cit99"><name name-style="western"><surname>Nair</surname><given-names>S. S.</given-names></name>; <name name-style="western"><surname>Chakravarty</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Balan</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Hakansson</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Duval</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Davicioni</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name>; <name name-style="western"><surname>Bhardwaj</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Thin</surname><given-names>T. H.</given-names></name>; <name name-style="western"><surname>Garcia-barros</surname><given-names>M.</given-names></name>; et al. <article-title>Abstract CT023: Prostate
cancer in situ autovaccination with the intratumoral viral mimic poly-ICLC:
Making a cold tumor hot</article-title>. <source>Cancer Res.</source><year>2024</year>, <volume>84</volume> (<issue>7_Supplement</issue>), <fpage>CT023</fpage><pub-id pub-id-type="doi">10.1158/1538-7445.AM2024-CT023</pub-id>.</mixed-citation></ref><ref id="ref100"><mixed-citation publication-type="journal" id="cit100"><name name-style="western"><surname>Weide</surname><given-names>B.</given-names></name>; <name name-style="western"><surname>Derhovanessian</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Pflugfelder</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Eigentler</surname><given-names>T. K.</given-names></name>; <name name-style="western"><surname>Radny</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Zelba</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Pf&#246;hler</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Pawelec</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Garbe</surname><given-names>C.</given-names></name><article-title>High response rate
after intratumoral
treatment with interleukin-2</article-title>. <source>Cancer</source><year>2010</year>, <volume>116</volume> (<issue>17</issue>), <fpage>4139</fpage>&#8211;<lpage>4146</lpage>. <pub-id pub-id-type="doi">10.1002/cncr.25156</pub-id>.<pub-id pub-id-type="pmid">20564107</pub-id></mixed-citation></ref><ref id="ref101"><mixed-citation publication-type="journal" id="cit101"><name name-style="western"><surname>Danielli</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Patuzzo</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Di Giacomo</surname><given-names>A. M.</given-names></name>; <name name-style="western"><surname>Gallino</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Maurichi</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Di Florio</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Cutaia</surname><given-names>O.</given-names></name>; <name name-style="western"><surname>Lazzeri</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Fazio</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Miracco</surname><given-names>C.</given-names></name>; et al. <article-title>Intralesional administration of L19-IL2/L19-TNF in
stage III or stage
IVM1a melanoma patients: results of a phase II study</article-title>. <source>Cancer Immunol Immunother</source><year>2015</year>, <volume>64</volume> (<issue>8</issue>), <fpage>999</fpage>&#8211;<lpage>1009</lpage>. <pub-id pub-id-type="doi">10.1007/s00262-015-1704-6</pub-id>.<pub-id pub-id-type="pmid">25971540</pub-id><pub-id pub-id-type="pmcid">PMC11028725</pub-id></mixed-citation></ref><ref id="ref102"><mixed-citation publication-type="journal" id="cit102"><name name-style="western"><surname>Cirella</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Bola&#241;os</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Luri-Rey</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Di Trani</surname><given-names>C. A.</given-names></name>; <name name-style="western"><surname>Olivera</surname><given-names>I.</given-names></name>; <name name-style="western"><surname>Gomis</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Glez-Vaz</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Pinci</surname><given-names>B.</given-names></name>; <name name-style="western"><surname>Garasa</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>S&#225;nchez-Gregorio</surname><given-names>S.</given-names></name>; et al. <article-title>Intratumoral
immunotherapy with mRNAs encoding chimeric protein constructs encompassing
IL-12, CD137 agonists, and TGF-&#946; antagonists</article-title>. <source>Molecular Therapy - Nucleic Acids</source><year>2023</year>, <volume>33</volume>, <fpage>668</fpage>&#8211;<lpage>682</lpage>. <pub-id pub-id-type="doi">10.1016/j.omtn.2023.07.026</pub-id>.<pub-id pub-id-type="pmid">37650116</pub-id><pub-id pub-id-type="pmcid">PMC10462790</pub-id></mixed-citation></ref><ref id="ref103"><mixed-citation publication-type="journal" id="cit103"><name name-style="western"><surname>van Herpen</surname><given-names>C. M.</given-names></name>; <name name-style="western"><surname>Looman</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Zonneveld</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Scharenborg</surname><given-names>N.</given-names></name>; <name name-style="western"><surname>de Wilde</surname><given-names>P. C.</given-names></name>; <name name-style="western"><surname>van de Locht</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Merkx</surname><given-names>M. A. W.</given-names></name>; <name name-style="western"><surname>Adema</surname><given-names>G. J.</given-names></name>; <name name-style="western"><surname>De Mulder</surname><given-names>P. H.</given-names></name><article-title>Intratumoral
Administration of Recombinant Human Interleukin 12 in Head and Neck
Squamous Cell Carcinoma Patients Elicits a T-Helper 1 Profile in the
Locoregional Lymph Nodes</article-title>. <source>Clin. Cancer Res.</source><year>2004</year>, <volume>10</volume> (<issue>8</issue>), <fpage>2626</fpage>&#8211;<lpage>2635</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-03-0304</pub-id>.<pub-id pub-id-type="pmid">15102664</pub-id></mixed-citation></ref><ref id="ref104"><mixed-citation publication-type="journal" id="cit104"><name name-style="western"><surname>Hong</surname><given-names>W. X.</given-names></name>; <name name-style="western"><surname>Sagiv-Barfi</surname><given-names>I.</given-names></name>; <name name-style="western"><surname>Czerwinski</surname><given-names>D. K.</given-names></name>; <name name-style="western"><surname>Sallets</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Levy</surname><given-names>R.</given-names></name><article-title>Neoadjuvant
Intratumoral Immunotherapy
with TLR9 Activation and Anti-OX40 Antibody Eradicates Metastatic
Cancer</article-title>. <source>Cancer Res.</source><year>2022</year>, <volume>82</volume> (<issue>7</issue>), <fpage>1396</fpage>&#8211;<lpage>1408</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-21-1382</pub-id>.<pub-id pub-id-type="pmid">35135810</pub-id><pub-id pub-id-type="pmcid">PMC8983569</pub-id></mixed-citation></ref><ref id="ref105"><mixed-citation publication-type="journal" id="cit105"><name name-style="western"><surname>Hebb</surname><given-names>J. P. O.</given-names></name>; <name name-style="western"><surname>Mosley</surname><given-names>A. R.</given-names></name>; <name name-style="western"><surname>Vences-Catal&#225;n</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Rajasekaran</surname><given-names>N.</given-names></name>; <name name-style="western"><surname>Ros&#233;n</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Ellmark</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Felsher</surname><given-names>D. W.</given-names></name><article-title>Administration
of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into
murine tumor or proximal to the tumor draining lymph node induces
systemic tumor regression</article-title>. <source>Cancer Immunol Immunother</source><year>2018</year>, <volume>67</volume> (<issue>1</issue>), <fpage>47</fpage>&#8211;<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1007/s00262-017-2059-y</pub-id>.<pub-id pub-id-type="pmid">28905118</pub-id><pub-id pub-id-type="pmcid">PMC7446289</pub-id></mixed-citation></ref><ref id="ref106"><mixed-citation publication-type="journal" id="cit106"><name name-style="western"><surname>Alvarez</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Molina</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>De Andrea</surname><given-names>C. E.</given-names></name>; <name name-style="western"><surname>Fernandez-Sendin</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Villalba</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Gonzalez-Gomariz</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Ochoa</surname><given-names>M. C.</given-names></name>; <name name-style="western"><surname>Teijeira</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Glez-Vaz</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Aranda</surname><given-names>F.</given-names></name>; et al. <article-title>Intratumoral co-injection
of the poly I:C-derivative BO-112 and a
STING agonist synergize to achieve local and distant anti-tumor efficacy</article-title>. <source>Journal for ImmunoTherapy of Cancer</source><year>2021</year>, <volume>9</volume> (<issue>11</issue>), <elocation-id>e002953</elocation-id><pub-id pub-id-type="doi">10.1136/jitc-2021-002953</pub-id>.<pub-id pub-id-type="pmid">34824158</pub-id><pub-id pub-id-type="pmcid">PMC8627419</pub-id></mixed-citation></ref><ref id="ref107"><mixed-citation publication-type="journal" id="cit107"><name name-style="western"><surname>Sagiv-Barfi</surname><given-names>I.</given-names></name>; <name name-style="western"><surname>Czerwinski</surname><given-names>D. K.</given-names></name>; <name name-style="western"><surname>Shree</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Lohmeyer</surname><given-names>J. J. K.</given-names></name>; <name name-style="western"><surname>Levy</surname><given-names>R.</given-names></name><article-title>Intratumoral immunotherapy
relies on B and T cell collaboration</article-title>. <source>Science
Immunology</source><year>2022</year>, <volume>7</volume> (<issue>71</issue>), <elocation-id>eabn5859</elocation-id><pub-id pub-id-type="doi">10.1126/sciimmunol.abn5859</pub-id>.<pub-id pub-id-type="pmid">35622903</pub-id><pub-id pub-id-type="pmcid">PMC9254330</pub-id></mixed-citation></ref><ref id="ref108"><mixed-citation publication-type="book" id="cit108"><person-group person-group-type="allauthors"><name name-style="western"><surname>Grant</surname><given-names>F. D.</given-names></name>; <name name-style="western"><surname>Maclellan</surname><given-names>R. A.</given-names></name>; <name name-style="western"><surname>Greene</surname><given-names>A. K.</given-names></name></person-group><article-title>Lymphoscintigraphy</article-title>. In <source>Pediatric Nuclear
Medicine and Molecular Imaging</source>; <person-group person-group-type="editor"><name name-style="western"><surname>Treves</surname><given-names>S. T.</given-names></name></person-group>, Ed.; <publisher-name>Springer</publisher-name>, <year>2014</year>; pp <fpage>189</fpage>&#8211;<lpage>202</lpage>.</mixed-citation></ref><ref id="ref109"><mixed-citation publication-type="journal" id="cit109"><name name-style="western"><surname>Yousefpour</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Ni</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Irvine</surname><given-names>D. J.</given-names></name><article-title>Targeted
modulation
of immune cells and tissues using engineered biomaterials</article-title>. <source>Nat. Rev. Bioeng</source><year>2023</year>, <volume>1</volume> (<issue>2</issue>), <fpage>107</fpage>&#8211;<lpage>124</lpage>. <pub-id pub-id-type="doi">10.1038/s44222-022-00016-2</pub-id>.<pub-id pub-id-type="pmid">37772035</pub-id><pub-id pub-id-type="pmcid">PMC10538251</pub-id></mixed-citation></ref><ref id="ref110"><mixed-citation publication-type="journal" id="cit110"><name name-style="western"><surname>Rohner</surname><given-names>N. A.</given-names></name>; <name name-style="western"><surname>Thomas</surname><given-names>S. N.</given-names></name><article-title>Melanoma growth
effects on molecular
clearance from tumors and biodistribution into systemic tissues versus
draining lymph nodes</article-title>. <source>J. Controlled Release</source><year>2016</year>, <volume>223</volume>, <fpage>99</fpage>&#8211;<lpage>108</lpage>. <pub-id pub-id-type="doi">10.1016/j.jconrel.2015.12.027</pub-id>.<pub-id pub-id-type="pmcid">PMC4724472</pub-id><pub-id pub-id-type="pmid">26721446</pub-id></mixed-citation></ref><ref id="ref111"><mixed-citation publication-type="journal" id="cit111"><name name-style="western"><surname>Kim</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Francis</surname><given-names>D. M.</given-names></name>; <name name-style="western"><surname>Sestito</surname><given-names>L. F.</given-names></name>; <name name-style="western"><surname>Archer</surname><given-names>P. A.</given-names></name>; <name name-style="western"><surname>Manspeaker</surname><given-names>M. P.</given-names></name>; <name name-style="western"><surname>O&#8217;Melia</surname><given-names>M. J.</given-names></name>; <name name-style="western"><surname>Thomas</surname><given-names>S. N.</given-names></name><article-title>Thermosensitive hydrogel releasing
nitric oxide donor and anti-CTLA-4 micelles for anti-tumor immunotherapy</article-title>. <source>Nat. Commun.</source><year>2022</year>, <volume>13</volume> (<issue>1</issue>), <fpage>1479</fpage><pub-id pub-id-type="doi">10.1038/s41467-022-29121-x</pub-id>.<pub-id pub-id-type="pmid">35304456</pub-id><pub-id pub-id-type="pmcid">PMC8933465</pub-id></mixed-citation></ref><ref id="ref112"><mixed-citation publication-type="journal" id="cit112"><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name>; <name name-style="western"><surname>Fang</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Song</surname><given-names>Y.</given-names></name>; <name name-style="western"><surname>Shi</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Li</surname><given-names>W.</given-names></name>; <name name-style="western"><surname>Wu</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Ren</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name>; et al. <article-title>Hydrogel dual delivered celecoxib and anti-PD-1
synergistically improve
antitumor immunity</article-title>. <source>OncoImmunology</source><year>2016</year>, <volume>5</volume> (<issue>2</issue>), <elocation-id>e1074374</elocation-id><pub-id pub-id-type="doi">10.1080/2162402X.2015.1074374</pub-id>.<pub-id pub-id-type="pmid">27057439</pub-id><pub-id pub-id-type="pmcid">PMC4801446</pub-id></mixed-citation></ref><ref id="ref113"><mixed-citation publication-type="journal" id="cit113"><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name>; <name name-style="western"><surname>Hu</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Yang</surname><given-names>W.</given-names></name>; <name name-style="western"><surname>Xia</surname><given-names>X.</given-names></name>; <name name-style="western"><surname>Lei</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Lin</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Li</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name>; <name name-style="western"><surname>Gao</surname><given-names>H.</given-names></name><article-title>In Situ Tumor Vaccine for Lymph Nodes
Delivery and Cancer Therapy
Based on Small Size Nanoadjuvant</article-title>. <source>Small</source><year>2023</year>, <volume>19</volume> (<issue>33</issue>), <elocation-id>2301041</elocation-id><pub-id pub-id-type="doi">10.1002/smll.202301041</pub-id>.<pub-id pub-id-type="pmid">37078903</pub-id></mixed-citation></ref><ref id="ref114"><mixed-citation publication-type="journal" id="cit114"><name name-style="western"><surname>Z&#250;&#241;iga</surname><given-names>L. A.</given-names></name>; <name name-style="western"><surname>Le&#223;mann</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Uppal</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Bisek</surname><given-names>N.</given-names></name>; <name name-style="western"><surname>Hong</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Rasmussen</surname><given-names>C. E.</given-names></name>; <name name-style="western"><surname>Karlsson</surname><given-names>J.-J.</given-names></name>; <name name-style="western"><surname>Zettler</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Holten-Andersen</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Bang</surname><given-names>K.</given-names></name>; et al. <article-title>Intratumoral delivery of TransCon TLR7/8 Agonist promotes
sustained anti-tumor activity and local immune cell activation while
minimizing systemic cytokine induction</article-title>. <source>Cancer
Cell Int.</source><year>2022</year>, <volume>22</volume> (<issue>1</issue>), <fpage>286</fpage><pub-id pub-id-type="doi">10.1186/s12935-022-02708-6</pub-id>.<pub-id pub-id-type="pmid">36123697</pub-id><pub-id pub-id-type="pmcid">PMC9484246</pub-id></mixed-citation></ref><ref id="ref115"><mixed-citation publication-type="journal" id="cit115"><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Najibi</surname><given-names>A. J.</given-names></name>; <name name-style="western"><surname>Sobral</surname><given-names>M. C.</given-names></name>; <name name-style="western"><surname>Seo</surname><given-names>B. R.</given-names></name>; <name name-style="western"><surname>Lee</surname><given-names>J. Y.</given-names></name>; <name name-style="western"><surname>Wu</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Li</surname><given-names>A. W.</given-names></name>; <name name-style="western"><surname>Verbeke</surname><given-names>C. S.</given-names></name>; <name name-style="western"><surname>Mooney</surname><given-names>D. J.</given-names></name><article-title>Biomaterial-based
scaffold for in situ chemo-immunotherapy
to treat poorly immunogenic tumors</article-title>. <source>Nat. Commun.</source><year>2020</year>, <volume>11</volume> (<issue>1</issue>), <fpage>5696</fpage><pub-id pub-id-type="doi">10.1038/s41467-020-19540-z</pub-id>.<pub-id pub-id-type="pmid">33173046</pub-id><pub-id pub-id-type="pmcid">PMC7655953</pub-id></mixed-citation></ref><ref id="ref116"><mixed-citation publication-type="journal" id="cit116"><name name-style="western"><surname>Cheng</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Su</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Zhou</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name>; <name name-style="western"><surname>Yang</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Lin</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Guo</surname><given-names>W.</given-names></name>; <name name-style="western"><surname>Zhu</surname><given-names>G.</given-names></name><article-title>Single-dose
injectable nanovaccine-in-hydrogel for robust immunotherapy of large
tumors with abscopal effect</article-title>. <source>Science Advances</source><year>2023</year>, <volume>9</volume> (<issue>28</issue>), <elocation-id>eade6257</elocation-id><pub-id pub-id-type="doi">10.1126/sciadv.ade6257</pub-id>.<pub-id pub-id-type="pmid">37450588</pub-id><pub-id pub-id-type="pmcid">PMC10348685</pub-id></mixed-citation></ref><ref id="ref117"><mixed-citation publication-type="journal" id="cit117"><name name-style="western"><surname>Agarwal</surname><given-names>Y.</given-names></name>; <name name-style="western"><surname>Milling</surname><given-names>L. E.</given-names></name>; <name name-style="western"><surname>Chang</surname><given-names>J. Y. H.</given-names></name>; <name name-style="western"><surname>Santollani</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Sheen</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Lutz</surname><given-names>E. A.</given-names></name>; <name name-style="western"><surname>Tabet</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Stinson</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Ni</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Rodrigues</surname><given-names>K. A.</given-names></name>; et al. <article-title>Intratumourally injected alum-tethered
cytokines elicit potent and safer local and systemic anticancer immunity</article-title>. <source>Nat. Biomed Eng.</source><year>2022</year>, <volume>6</volume> (<issue>2</issue>), <fpage>129</fpage>&#8211;<lpage>143</lpage>. <pub-id pub-id-type="doi">10.1038/s41551-021-00831-9</pub-id>.<pub-id pub-id-type="pmid">35013574</pub-id><pub-id pub-id-type="pmcid">PMC9681025</pub-id></mixed-citation></ref><ref id="ref118"><mixed-citation publication-type="journal" id="cit118"><name name-style="western"><surname>Wang</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Wang</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Yu</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Feng</surname><given-names>B.</given-names></name>; <name name-style="western"><surname>Zhou</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Zhou</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Hou</surname><given-names>B.</given-names></name>; <name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Luo</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><article-title>Engineering nanoparticles
to locally activate T cells
in the tumor microenvironment</article-title>. <source>Science Immunology</source><year>2019</year>, <volume>4</volume> (<issue>37</issue>), <elocation-id>eaau6584</elocation-id><pub-id pub-id-type="doi">10.1126/sciimmunol.aau6584</pub-id>.<pub-id pub-id-type="pmid">31300478</pub-id></mixed-citation></ref><ref id="ref119"><mixed-citation publication-type="journal" id="cit119"><name name-style="western"><surname>Shae</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Becker</surname><given-names>K. W.</given-names></name>; <name name-style="western"><surname>Christov</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Yun</surname><given-names>D. S.</given-names></name>; <name name-style="western"><surname>Lytton-Jean</surname><given-names>A. K. R.</given-names></name>; <name name-style="western"><surname>Sevimli</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Ascano</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Kelley</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Johnson</surname><given-names>D. B.</given-names></name>; <name name-style="western"><surname>Balko</surname><given-names>J. M.</given-names></name>; <name name-style="western"><surname>Wilson</surname><given-names>J. T.</given-names></name><article-title>Endosomolytic polymersomes
increase the activity of cyclic dinucleotide STING agonists to enhance
cancer immunotherapy</article-title>. <source>Nat. Nanotechnol.</source><year>2019</year>, <volume>14</volume> (<issue>3</issue>), <fpage>269</fpage>&#8211;<lpage>278</lpage>. <pub-id pub-id-type="doi">10.1038/s41565-018-0342-5</pub-id>.<pub-id pub-id-type="pmid">30664751</pub-id><pub-id pub-id-type="pmcid">PMC6402974</pub-id></mixed-citation></ref><ref id="ref120"><mixed-citation publication-type="journal" id="cit120"><name name-style="western"><surname>Jin</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Yang</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Song</surname><given-names>Y.</given-names></name>; <name name-style="western"><surname>Li</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Xu</surname><given-names>W.</given-names></name>; <name name-style="western"><surname>Zhu</surname><given-names>Y.</given-names></name>; <name name-style="western"><surname>Xu</surname><given-names>C.-F.</given-names></name>; <name name-style="western"><surname>Lu</surname><given-names>Y.</given-names></name>; <name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name><article-title>In Situ Programming
of Nanovaccines for Lymph Node-Targeted Delivery and Cancer Immunotherapy</article-title>. <source>ACS Nano</source><year>2022</year>, <volume>16</volume> (<issue>9</issue>), <fpage>15226</fpage>&#8211;<lpage>15236</lpage>. <pub-id pub-id-type="doi">10.1021/acsnano.2c06560</pub-id>.<pub-id pub-id-type="pmid">36018240</pub-id></mixed-citation></ref><ref id="ref121"><mixed-citation publication-type="journal" id="cit121"><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Wen</surname><given-names>Z.</given-names></name>; <name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Yang</surname><given-names>Z.</given-names></name>; <name name-style="western"><surname>Le</surname><given-names>Z.</given-names></name>; <name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name>; <name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name>; <name name-style="western"><surname>Liu</surname><given-names>L.</given-names></name><article-title>Nanoadjuvants Actively targeting
lymph node conduits and blocking tumor invasion in lymphatic vessels</article-title>. <source>J. Controlled Release</source><year>2022</year>, <volume>352</volume>, <fpage>497</fpage>&#8211;<lpage>506</lpage>. <pub-id pub-id-type="doi">10.1016/j.jconrel.2022.10.053</pub-id>.<pub-id pub-id-type="pmid">36341931</pub-id></mixed-citation></ref><ref id="ref122"><mixed-citation publication-type="journal" id="cit122"><name name-style="western"><surname>Nuhn</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>De Koker</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Van Lint</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Zhong</surname><given-names>Z.</given-names></name>; <name name-style="western"><surname>Catani</surname><given-names>J. P.</given-names></name>; <name name-style="western"><surname>Combes</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Deswarte</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name>; <name name-style="western"><surname>Lambrecht</surname><given-names>B. N.</given-names></name>; <name name-style="western"><surname>Lienenklaus</surname><given-names>S.</given-names></name>; et al. <article-title>Nanoparticle-Conjugate
TLR7/8 Agonist Localized Immunotherapy Provokes Safe Antitumoral Responses</article-title>. <source>Adv. Mater.</source><year>2018</year>, <volume>30</volume> (<issue>45</issue>), <elocation-id>1803397</elocation-id><pub-id pub-id-type="doi">10.1002/adma.201803397</pub-id>.<pub-id pub-id-type="pmid">30276880</pub-id></mixed-citation></ref><ref id="ref123"><mixed-citation publication-type="journal" id="cit123"><name name-style="western"><surname>Song</surname><given-names>J. Y.</given-names></name>; <name name-style="western"><surname>Larson</surname><given-names>N. R.</given-names></name>; <name name-style="western"><surname>Thati</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Torres-Vazquez</surname><given-names>I.</given-names></name>; <name name-style="western"><surname>Martinez-Rivera</surname><given-names>N.</given-names></name>; <name name-style="western"><surname>Subelzu</surname><given-names>N. J.</given-names></name>; <name name-style="western"><surname>Leon</surname><given-names>M. A.</given-names></name>; <name name-style="western"><surname>Rosa-Molinar</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Sch&#246;neich</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Forrest</surname><given-names>M. L.</given-names></name>; et al. <article-title>Glatiramer
acetate persists
at the injection site and draining lymph nodes via electrostatically-induced
aggregation</article-title>. <source>J. Controlled Release</source><year>2019</year>, <volume>293</volume>, <fpage>36</fpage>&#8211;<lpage>47</lpage>. <pub-id pub-id-type="doi">10.1016/j.jconrel.2018.11.007</pub-id>.<pub-id pub-id-type="pmcid">PMC6372117</pub-id><pub-id pub-id-type="pmid">30414463</pub-id></mixed-citation></ref><ref id="ref124"><mixed-citation publication-type="journal" id="cit124"><person-group person-group-type="allauthors"><name name-style="western"><surname>Mahmudi</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Adili-Aghdam</surname><given-names>M. A.</given-names></name>; <name name-style="western"><surname>Shahpouri</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Jaymand</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Amoozgar</surname><given-names>Z.</given-names></name>; <name name-style="western"><surname>Jahanban-Esfahlan</surname><given-names>R.</given-names></name></person-group><article-title>Tumor microenvironment
penetrating chitosan nanoparticles for elimination of cancer relapse
and minimal residual disease</article-title>. <source>Front. Oncol.</source><year>2022</year>, <volume>12</volume>.<pub-id pub-id-type="doi">10.3389/fonc.2022.1054029</pub-id>.<pub-id pub-id-type="pmcid">PMC9751059</pub-id><pub-id pub-id-type="pmid">36531004</pub-id></mixed-citation></ref><ref id="ref125"><mixed-citation publication-type="journal" id="cit125"><name name-style="western"><surname>Kwong</surname><given-names>B.</given-names></name>; <name name-style="western"><surname>Gai</surname><given-names>S. A.</given-names></name>; <name name-style="western"><surname>Elkhader</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Wittrup</surname><given-names>K. D.</given-names></name>; <name name-style="western"><surname>Irvine</surname><given-names>D. J.</given-names></name><article-title>Localized
Immunotherapy via Liposome-Anchored Anti-CD137
+ IL-2 Prevents Lethal Toxicity and Elicits Local and Systemic Antitumor
Immunity</article-title>. <source>Cancer Res.</source><year>2013</year>, <volume>73</volume> (<issue>5</issue>), <fpage>1547</fpage>&#8211;<lpage>1558</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-12-3343</pub-id>.<pub-id pub-id-type="pmid">23436794</pub-id><pub-id pub-id-type="pmcid">PMC3594475</pub-id></mixed-citation></ref><ref id="ref126"><mixed-citation publication-type="journal" id="cit126"><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name>; <name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Song</surname><given-names>Q.</given-names></name>; <name name-style="western"><surname>Ali</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Crowe</surname><given-names>W. N.</given-names></name>; <name name-style="western"><surname>Kucera</surname><given-names>G. L.</given-names></name>; <name name-style="western"><surname>Hawkins</surname><given-names>G. A.</given-names></name>; <name name-style="western"><surname>Soker</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Thomas</surname><given-names>K. W.</given-names></name>; <name name-style="western"><surname>Miller</surname><given-names>L. D.</given-names></name>; et al. <article-title>Intrapleural nano-immunotherapy
promotes innate
and adaptive immune responses to enhance anti-PD-L1 therapy for malignant
pleural effusion</article-title>. <source>Nat. Nanotechnol.</source><year>2022</year>, <volume>17</volume> (<issue>2</issue>), <fpage>206</fpage>&#8211;<lpage>216</lpage>. <pub-id pub-id-type="doi">10.1038/s41565-021-01032-w</pub-id>.<pub-id pub-id-type="pmid">34916656</pub-id><pub-id pub-id-type="pmcid">PMC9074399</pub-id></mixed-citation></ref><ref id="ref127"><mixed-citation publication-type="journal" id="cit127"><name name-style="western"><surname>Hewitt</surname><given-names>S. L.</given-names></name>; <name name-style="western"><surname>Bai</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Bailey</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Ichikawa</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Zielinski</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Karp</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Apte</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Arnold</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Zacharek</surname><given-names>S. J.</given-names></name>; <name name-style="western"><surname>Iliou</surname><given-names>M. S.</given-names></name>; et al. <article-title>Durable
anticancer immunity
from intratumoral administration of IL-23, IL-36&#947;, and OX40L
mRNAs</article-title>. <source>Science Translational Medicine</source><year>2019</year>, <volume>11</volume> (<issue>477</issue>), <elocation-id>eaat9143</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.aat9143</pub-id>.<pub-id pub-id-type="pmid">30700577</pub-id></mixed-citation></ref><ref id="ref128"><mixed-citation publication-type="journal" id="cit128"><name name-style="western"><surname>Hotz</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Wagenaar</surname><given-names>T. R.</given-names></name>; <name name-style="western"><surname>Gieseke</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Bangari</surname><given-names>D. S.</given-names></name>; <name name-style="western"><surname>Callahan</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Cao</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Diekmann</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Diken</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Grunwitz</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Hebert</surname><given-names>A.</given-names></name>; et al. <article-title>Local delivery of mRNA-encoded
cytokines promotes antitumor immunity and tumor eradication across
multiple preclinical tumor models</article-title>. <source>Science Translational
Medicine</source><year>2021</year>, <volume>13</volume> (<issue>610</issue>), <elocation-id>eabc7804</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.abc7804</pub-id>.<pub-id pub-id-type="pmid">34516826</pub-id></mixed-citation></ref><ref id="ref129"><mixed-citation publication-type="journal" id="cit129"><name name-style="western"><surname>Huayamares</surname><given-names>S. G.</given-names></name>; <name name-style="western"><surname>Loughrey</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Kim</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Dahlman</surname><given-names>J. E.</given-names></name>; <name name-style="western"><surname>Sorscher</surname><given-names>E. J.</given-names></name><article-title>Nucleic acid-based drugs for patients
with solid tumours</article-title>. <source>Nat. Rev. Clin Oncol</source><year>2024</year>, <volume>21</volume> (<issue>6</issue>), <fpage>407</fpage>&#8211;<lpage>427</lpage>. <pub-id pub-id-type="doi">10.1038/s41571-024-00883-1</pub-id>.<pub-id pub-id-type="pmid">38589512</pub-id></mixed-citation></ref><ref id="ref130"><mixed-citation publication-type="journal" id="cit130"><name name-style="western"><surname>Francis</surname><given-names>D. M.</given-names></name>; <name name-style="western"><surname>Manspeaker</surname><given-names>M. P.</given-names></name>; <name name-style="western"><surname>Archer</surname><given-names>P. A.</given-names></name>; <name name-style="western"><surname>Sestito</surname><given-names>L. F.</given-names></name>; <name name-style="western"><surname>Heiler</surname><given-names>A. J.</given-names></name>; <name name-style="western"><surname>Schudel</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Thomas</surname><given-names>S. N.</given-names></name><article-title>Drug-eluting immune
checkpoint blockade antibody-nanoparticle conjugate enhances locoregional
and systemic combination cancer immunotherapy through T lymphocyte
targeting</article-title>. <source>Biomaterials</source><year>2021</year>, <volume>279</volume>, <elocation-id>121184</elocation-id><pub-id pub-id-type="doi">10.1016/j.biomaterials.2021.121184</pub-id>.<pub-id pub-id-type="pmid">34678650</pub-id><pub-id pub-id-type="pmcid">PMC8639654</pub-id></mixed-citation></ref><ref id="ref131"><mixed-citation publication-type="journal" id="cit131"><name name-style="western"><surname>Kheirolomoom</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Kare</surname><given-names>A. J.</given-names></name>; <name name-style="western"><surname>Ingham</surname><given-names>E. S.</given-names></name>; <name name-style="western"><surname>Paulmurugan</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Robinson</surname><given-names>E. R.</given-names></name>; <name name-style="western"><surname>Baikoghli</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Inayathullah</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Seo</surname><given-names>J. W.</given-names></name>; <name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Fite</surname><given-names>B. Z.</given-names></name>; et al. <article-title>In
situ T-cell transfection by anti-CD3-conjugated lipid nanoparticles
leads to T-cell activation, migration, and phenotypic shift</article-title>. <source>Biomaterials</source><year>2022</year>, <volume>281</volume>, <elocation-id>121339</elocation-id><pub-id pub-id-type="doi">10.1016/j.biomaterials.2021.121339</pub-id>.<pub-id pub-id-type="pmid">35078042</pub-id><pub-id pub-id-type="pmcid">PMC8892572</pub-id></mixed-citation></ref><ref id="ref132"><mixed-citation publication-type="journal" id="cit132"><name name-style="western"><surname>Saut&#232;s-Fridman</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Petitprez</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Calderaro</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Fridman</surname><given-names>W. H.</given-names></name><article-title>Tertiary lymphoid structures in the
era of cancer immunotherapy</article-title>. <source>Nat. Rev. Cancer</source><year>2019</year>, <volume>19</volume>, <fpage>307</fpage><pub-id pub-id-type="doi">10.1038/s41568-019-0144-6</pub-id>.<pub-id pub-id-type="pmid">31092904</pub-id></mixed-citation></ref><ref id="ref133"><mixed-citation publication-type="journal" id="cit133"><name name-style="western"><surname>Hua</surname><given-names>Y.</given-names></name>; <name name-style="western"><surname>Vella</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Rambow</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Allen</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Antoranz
Martinez</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Duhamel</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Takeda</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Jalkanen</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Junius</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Smeets</surname><given-names>A.</given-names></name>; et al. <article-title>Cancer immunotherapies
transition endothelial cells into HEVs that generate TCF1+ T lymphocyte
niches through a feed-forward loop</article-title>. <source>Cancer Cell</source><year>2022</year>, <volume>40</volume> (<issue>12</issue>), <fpage>1600</fpage>&#8211;<lpage>1618.e1610</lpage>. <pub-id pub-id-type="doi">10.1016/j.ccell.2022.11.002</pub-id>.<pub-id pub-id-type="pmid">36423635</pub-id><pub-id pub-id-type="pmcid">PMC9899876</pub-id></mixed-citation></ref><ref id="ref134"><mixed-citation publication-type="journal" id="cit134"><name name-style="western"><surname>Asrir</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Tardiveau</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Coudert</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Laffont</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Blanchard</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Bellard</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Veerman</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Bettini</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Lafouresse</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Vina</surname><given-names>E.</given-names></name>; et al. <article-title>Tumor-associated high
endothelial venules mediate lymphocyte entry into tumors and predict
response to PD-1 plus CTLA-4 combination immunotherapy</article-title>. <source>Cancer Cell</source><year>2022</year>, <volume>40</volume> (<issue>3</issue>), <fpage>318</fpage>&#8211;<lpage>334.e9</lpage>. <pub-id pub-id-type="doi">10.1016/j.ccell.2022.01.002</pub-id>.<pub-id pub-id-type="pmid">35120598</pub-id></mixed-citation></ref><ref id="ref135"><mixed-citation publication-type="journal" id="cit135"><name name-style="western"><surname>Najibi</surname><given-names>A. J.</given-names></name>; <name name-style="western"><surname>Mooney</surname><given-names>D. J.</given-names></name><article-title>Cell and tissue
engineering in lymph
nodes for cancer immunotherapy</article-title>. <source>Adv. Drug Deliv
Rev.</source><year>2020</year>, <volume>161&#8211;162</volume>, <fpage>42</fpage>&#8211;<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1016/j.addr.2020.07.023</pub-id>.<pub-id pub-id-type="pmcid">PMC7736208</pub-id><pub-id pub-id-type="pmid">32750376</pub-id></mixed-citation></ref><ref id="ref136"><mixed-citation publication-type="journal" id="cit136"><name name-style="western"><surname>Baumgartner</surname><given-names>C. K.</given-names></name>; <name name-style="western"><surname>Ebrahimi-Nik</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Iracheta-Vellve</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Hamel</surname><given-names>K. M.</given-names></name>; <name name-style="western"><surname>Olander</surname><given-names>K. E.</given-names></name>; <name name-style="western"><surname>Davis</surname><given-names>T. G. R.</given-names></name>; <name name-style="western"><surname>McGuire</surname><given-names>K. A.</given-names></name>; <name name-style="western"><surname>Halvorsen</surname><given-names>G. T.</given-names></name>; <name name-style="western"><surname>Avila</surname><given-names>O. I.</given-names></name>; <name name-style="western"><surname>Patel</surname><given-names>C. H.</given-names></name>; et al. <article-title>The
PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity</article-title>. <source>Nature</source><year>2023</year>, <volume>622</volume> (<issue>7984</issue>), <fpage>850</fpage>&#8211;<lpage>862</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-023-06575-7</pub-id>.<pub-id pub-id-type="pmid">37794185</pub-id><pub-id pub-id-type="pmcid">PMC10599993</pub-id></mixed-citation></ref><ref id="ref137"><mixed-citation publication-type="journal" id="cit137"><name name-style="western"><surname>Liang</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Tran</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Du</surname><given-names>X.</given-names></name>; <name name-style="western"><surname>Dong</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Sudholz</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Qu</surname><given-names>Z.</given-names></name>; <name name-style="western"><surname>Huntington</surname><given-names>N. D.</given-names></name>; <name name-style="western"><surname>Babon</surname><given-names>J. J.</given-names></name>; <name name-style="western"><surname>Kershaw</surname><given-names>N. J.</given-names></name>; et al. <article-title>A small
molecule inhibitor
of PTP1B and PTPN2 enhances T cell anti-tumor immunity</article-title>. <source>Nat. Commun.</source><year>2023</year>, <volume>14</volume> (<issue>1</issue>), <fpage>4524</fpage><pub-id pub-id-type="doi">10.1038/s41467-023-40170-8</pub-id>.<pub-id pub-id-type="pmid">37500611</pub-id><pub-id pub-id-type="pmcid">PMC10374545</pub-id></mixed-citation></ref><ref id="ref138"><mixed-citation publication-type="journal" id="cit138"><name name-style="western"><surname>Wiede</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Lu</surname><given-names>K.-H.</given-names></name>; <name name-style="western"><surname>Du</surname><given-names>X.</given-names></name>; <name name-style="western"><surname>Zeissig</surname><given-names>M. N.</given-names></name>; <name name-style="western"><surname>Xu</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Goh</surname><given-names>P. K.</given-names></name>; <name name-style="western"><surname>Xirouchaki</surname><given-names>C. E.</given-names></name>; <name name-style="western"><surname>Hogarth</surname><given-names>S. J.</given-names></name>; <name name-style="western"><surname>Greatorex</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Sek</surname><given-names>K.</given-names></name>; et al. <article-title>PTP1B Is an Intracellular Checkpoint that Limits T-cell
and CAR T-cell Antitumor Immunity</article-title>. <source>Cancer Discovery</source><year>2022</year>, <volume>12</volume> (<issue>3</issue>), <fpage>752</fpage>&#8211;<lpage>773</lpage>. <pub-id pub-id-type="doi">10.1158/2159-8290.CD-21-0694</pub-id>.<pub-id pub-id-type="pmid">34794959</pub-id><pub-id pub-id-type="pmcid">PMC8904293</pub-id></mixed-citation></ref><ref id="ref139"><mixed-citation publication-type="journal" id="cit139"><name name-style="western"><surname>Wiede</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Lu</surname><given-names>K. H.</given-names></name>; <name name-style="western"><surname>Du</surname><given-names>X.</given-names></name>; <name name-style="western"><surname>Liang</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Hochheiser</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Dodd</surname><given-names>G. T.</given-names></name>; <name name-style="western"><surname>Goh</surname><given-names>P. K.</given-names></name>; <name name-style="western"><surname>Kearney</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Meyran</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Beavis</surname><given-names>P. A.</given-names></name>; et al. <article-title>PTPN2 phosphatase deletion
in T cells promotes anti-tumour immunity and CAR T-cell efficacy in
solid tumours</article-title>. <source>EMBO Journal</source><year>2020</year>, <volume>39</volume> (<issue>2</issue>), <elocation-id>e103637</elocation-id><pub-id pub-id-type="doi">10.15252/embj.2019103637</pub-id>.<pub-id pub-id-type="pmid">31803974</pub-id><pub-id pub-id-type="pmcid">PMC6960448</pub-id></mixed-citation></ref><ref id="ref140"><mixed-citation publication-type="journal" id="cit140"><name name-style="western"><surname>Luke</surname><given-names>J. J.</given-names></name>; <name name-style="western"><surname>Davar</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Andtbacka</surname><given-names>R. H.</given-names></name>; <name name-style="western"><surname>Bhardwaj</surname><given-names>N.</given-names></name>; <name name-style="western"><surname>Brody</surname><given-names>J. D.</given-names></name>; <name name-style="western"><surname>Chesney</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Coffin</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>de Baere</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>de Gruijl</surname><given-names>T. D.</given-names></name>; <name name-style="western"><surname>Fury</surname><given-names>M.</given-names></name>; et al. <article-title>Society
for Immunotherapy of Cancer (SITC) recommendations on intratumoral
immunotherapy clinical trials (IICT): from premalignant to metastatic
disease</article-title>. <source>Journal for ImmunoTherapy of Cancer</source><year>2024</year>, <volume>12</volume> (<issue>4</issue>), <elocation-id>e008378</elocation-id><pub-id pub-id-type="doi">10.1136/jitc-2023-008378</pub-id>.<pub-id pub-id-type="pmid">38641350</pub-id><pub-id pub-id-type="pmcid">PMC11029323</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>